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Abstract
Antimicrobial photodynamic therapy (aPDT) uses photosensitiser (PS) molecules in
combination with visible light to generate reactive oxygen species (ROS; e.g. 1O2 and
•OH) that kill bacteria. The approach is highly suited to skin and other body surface
infections, where photosensitisers and light can easily be applied directly to infection
sites. As examples, the phenothiazinium PS methylene blue (MB) has been used in
aPDT for the sterilisation of blood products, and aPDT with a related compound
toluidine blue O (TBO) has been used for oral disinfection of dental cavities and for
treating periodontitis.
It has been shown that membrane efflux pumps can limit bacterial cell killing
during aPDT with MB, probably by lowering the levels of intracellular ROS produced.
This observation suggests that combination approaches, where MB is used alongside
small molecule efflux pump inhibitors (EPIs), might potentiate the aPDT effects of MB,
allowing its use to be extended to multi-drug resistant (MDR) skin and soft-tissue
infections, such as those mediated by methicillin-resistant Staphylococcus aureus
(MRSA). Studies have confirmed that combinations of EPIs with MB do indeed show
increased aPDT potency relative to MB.
This thesis explored a novel approach where MB was covalently linked to EPIs
to create MB-EPI hybrid molecules. The rationale for the approach (Chapter 1) was
based on prior studies showing that conjugation of the weak antibacterial berberine to
the MDR inhibitor INF55 produced berberine-INF55 hybrids that show increased
potency over berberine alone and berberine/INF55 combinations. The similarities
iv

between berberine and MB (both planar, aromatic, hydrophobic cations) suggested a
similar MB-EPI approach might be successfully adapted for use in aPDT. To explore
this hypothesis, a 16 member MB-EPI hybrid library was conceived (compounds 4762), where members incorporated one of four known inhibitors of the NorA efflux
pump in S. aureus; reserpine (47-50), pterostilbene (51-54), INF55 (55-58) or INF271
(59-62). The library contained four examples of each MB-EPI type that carried
variations in the linker group between the EPI and MB. Two principal linker groups
were employed; piperazine and N,N’-dimethylethylenediamine, and these were linked
directly to the C7 position of MB and to EPIs through either N-alkyl (2 compounds) or
N-acyl (2 compounds) linkages. It was rationalised that production of a library of this
type, which scanned photophysical, EPI, physicochemical and other properties of
hybrids, would maximise the chances of identifying one or more effective compounds.
Synthesis of the hybrids (Chapter 2) employed a convergent strategy that made
use of a phenothiazinium salt common intermediate 63, which had previously been used
for the synthesis of asymmetric MB derivatives. The approach required that advanced
secondary amine intermediates containing pre-assembled EPI and linker portions be
synthesised first, before submitting these individually to reactions with common
intermediate 63, giving the target hybrids in the final step. The approach was used
successfully to produce all 16 hybrids in pure form and in quantities suitable for the
study.
In Chapter 3, the hybrids were first studied using UV/Vis spectroscopy for the
effects of attaching the EPI-linker groups to MB on the absorption properties of their
constituent MB chromophores. The wavelength maxima and extinction coefficients of
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the MB absorption bands in all hybrids were found to change very little from those in
MB, indicating that the structural changes introduced had not significantly impacted the
chromophore. Chapter 3 also explored production of ROS 1O2 and •OH from the
hybrids upon illumination with 652 nm red light. All hybrids were observed to produce
1

O2 and •OH, albeit at lower levels than MB. Levels of 1O2 were in general higher than

•OH. As a class, the INF55-containing hybrids showed the strongest production of 1O2.
All hybrids were next screened for aPDT activity using the test organism MRSA
USA300 (Chapter 3). Pterostilbene-containing compounds 51-54 were found to be
devoid of activity and only one reserpine-containing compound, 50, showed slight
activity at the highest concentration tested (20 M). Three of the four INF271containing hybrids 59, 60 and 62, on the other hand, showed enhanced aPDT activity
relative to MB, as did two of the INF55-containing hybrids (56 and 58). Compound 58
was the most potent compound identified, producing an impressive 6-log reduction in
MRSA USA300 cells at 20 M (fluence = 6 J/cm2) in this assay.
Based on the preliminary screening results, four hybrids (56 and 58 from the
INF55-containing compounds and 59 and 60 from the INF271 series) were advanced to
further in vitro studies. The four leads were next studied for their aPDT effects against
S. aureus strains expressing reduced (NorA-), basal (wild-type, WT) and high
(NorA++) levels of the NorA efflux pump (Chapter 3). MB (20 M) showed aPDT
activity against these cells in the following order: NorA- > WT > NorA++, consistent
with it being a substrate for the NorA pump, where pump activity removes the
compound from cells resulting in lower intracellular ROS upon illumination. Hybrids
56, 58, 59 and 60 at 20 M all showed enhanced aPDT effects against the WT and
vi

NorA++ strains relative to MB, whilst showing similar effects to MB against the NorAstrain. This was consistent with the compounds functioning as designed; i.e. with their
attached EPIs serving to reduce NorA-mediated efflux of the appended MB moiety,
leading to increased intracellular ROS upon illumination and greater cell killing.
Subsequent dose-response aPDT experiments with three of these hybrids (56, 58 and
60, Chapter 3) revealed very high potency for the INF55-containing compounds 56 and
58, which produced total eradication of NorA- and NorA++ cells at 40-80 M.
Uptake of 56, 58 and 60 into NorA-, WT and NorA++ S. aureus cells (Chapter
3) was found to be virtually unchanged across the three compounds and strains,
consistent with these hybrids being poor substrates for NorA, and possibly acting to
block the pumps. In comparison, MB showed high uptake into NorA- cells, which
reduced in WT cells and was very low in NorA++ cells, consistent with it being a NorA
substrate.
The question of whether active hybrids were (a) blocking the NorA pump in S.
aureus cells or (b) simply evading its action, was addressed in two experiments. In the
first of these, a series of synthetic intermediates containing INF55 or INF271 attached
to the various linker types used in hybrids, while lacking the terminal MB moiety, were
examined for their abilities to potentiate aPDT effects of co-administered MB in
NorA++ cells. In all cases, the intermediates produced similar potentiation effects to the
parent EPIs INF55 and INF271, suggesting that the structural changes introduced
through attachment of linkers did not abrogate their pump-blocking activities. In the
second type of experiments, the antibacterial activity of ciprofloxacin, a known
substrate for NorA, was examined in the dark against a bioluminescent S. aureus strain,
vii

both alone and in the presence of hybrids 56, 58 and 60. Each hybrid was found to
potentiate the activity of ciprofloxacin, consistent with the hybrids inhibiting its efflux
by blocking NorA activity.
The final part of the thesis (Chapter 4) explored the aPDT activity of lead hybrid
58 in a murine MRSA wound infection model. The primary goal of this study was to
demonstrate superior efficacy of 58 over MB. Infections were established by inoculating
bioluminescent MRSA into 1 cm2 scratch wounds on the shaved dorsal surfaces of
BALB/c female mice and monitored using real time bioluminescence imaging.
Infections were studied in the presence/absence of MB and 58, both with and without
application of 652 nm light. aPDT treatment with 58 produced dramatically enhanced
effects relative to MB. At very low fluence (12 J/cm2), 58 reduced the bacterial load by
~ 98%, whereas a much higher fluence (~ 96 J/cm2) was required to effect similar
reductions with MB. Furthermore, a rebound in bacterial load was observed 1 day after
treatment in the MB/aPDT group that was not observed in the group treated with 58.
Moreover, total clearance of the infection took only 4 days with 58 (7 days for MB) and
the wounds healed faster (~ 4 days for 58; ~ 7 days for MB).
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Chapter 1
Introduction
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1.1 Bacterial Resistance - A Global Health Threat
In today’s world, no nation’s health is secure due to the increasing threat posed
by drug-resistant pathogens. Antimicrobial resistance arises when pathogens, including
bacteria, fungi, viruses and parasites, no longer respond to drugs to which they were
formerly sensitive.1 For example, the Gram-positive bacteria Staphylococcus aureus and
Gram-negatives like Staphylococcus epidermis and Staphylococcus hemolyticus have
demonstrated an ability to develop resistance to each new generation of antibiotics.
Methicillin-resistant S. aureus (MRSA) and vancomycin-resistant Enterococcus
faecium (VRE) are two examples that are causing great clinical concern.2 In some
settings, as many as 90% of S. aureus infections are reported to arise from MRSA
leading to ineffective treatments with standard antibiotics. This hospital-derived
(nosocomial) ‘superbug’ has been estimated to increase the likelihood of patient death
by 64%.3 Of over two million people who contract antibiotic-resistant infections
annually, at least 23,000 die directly from the infection and another 100,000 die from
related complications.3 According to the U.S. Centers for Diseases Control and
Prevention (CDC), antibiotic-resistant pathogens cost the U.S. health care system
between $21-34 billion each year.4
The glycopeptide antibiotic vancomycin is considered the last line of defense
antibiotic against Gram-positives resistant to all β-lactams. These days, however,
vancomycin-resistant S. aureus (VRSA) is recognised as a “concerning threat” by the
CDC.5 Many countries are also reporting high rates of resistance to third-generation
cephalosporins, carbapenems and fluoroquinolones in Escherichia coli and Klebsiella
pneumoniae, which are responsible for pneumonia and bloodstream infections.3 Social
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factors contributing to the problem include unnecessary prescribing of antibiotics,
addition of antibiotics to feedstuffs, transmission of infections via international
travellers and the rise in poverty in some countries. These factors in combination with
cellular bacteria resistance mechanisms have created the worrying scenario we face
today.6
A great concern is that we will enter a post-antibiotic era where standard
antibiotic treatments no longer work and infections become more and more difficult or
impossible to control. To counter this threat there is a continuing and urgent need to
discover new antibiotics and antimicrobial strategies, preferably acting via novel
mechanisms.
1.2 Bacterial Resistance Mechanisms
Existence on earth for more than three billion years7 has allowed bacteria to
evolve multiple mechanisms for surviving in diverse and challenging environments.
They have learned how to detoxify harmful substances, like naturally occurring toxins
and, in more recent times, antibiotics developed by humans. When we create new
antibiotics, mankind encourages resistance development and expands the survival
mechanisms available to bacteria.8 Thus, while effective new antimicrobials are clearly
needed it is imperative that they be developed in parallel with new tactics that address
the problem of resistance.9
Three of the major cellular mechanisms that bacteria use to resist antimicrobials
are summarized in Figure 1.1. Firstly, enzymatic inactivation of antibiotics can occur
when bacteria express enzymes to detoxify compounds before they reach their
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target(s).10

β-lactamases, for examples, serve to deactivate β-lactam antibiotics by

hydrolysing their essential β-lactam ring.10-11 Both Gram-positive (e.g. S. aureus and
Bacillus cereus) and Gram-negative (e.g. Pseudomonas sp and Acinetobacter sp)
species produce β-lactamases.12

Figure 1.1 Three major bacterial antibiotic resistance mechanisms: (A) enzymatic
inactivation, (B) drug target alteration and (C) expression of efflux pumps. Figure
modified from Nordmann et al.13

A second mechanism that bacteria use to resist antimicrobials is to alter their
drug targets through mutation. By modifying their targets, bacteria render antibiotics
ineffective by reducing their target affinity, which nullifies their ability to inhibit
microbial cell functions. As an example, when the peptidoglycan precursors used by
4

enterococci for cell wall synthesis are mutated from D-Ala-D-Ala to D-Ala-D-Lac, the
binding of vancomycin is impaired.14
Expression of efflux pumps is a third major resistance mechanism and the focus
of this PhD project. The role of efflux pumps in preventing molecules, including those
produced by the host organism (e.g. bile) from accumulating in bacterial cells, was first
described in 1980.15 It is now accepted that efflux pumps are responsible for importing
essential nutrients into cells and exporting a wide variety of toxic agents, such as dyes,
drugs, cationic agents and metabolites.16 Efflux pumps essentially serve as gatekeepers
that shuttle molecules between the cell cytoplasm and the extracellular environment.17
1.3 Efflux Pumps - General
Membrane-bound efflux transporter proteins (pumps) are found in both
prokaryotic and eukaryotic organisms.16 The term Multi-Drug Resistance (MDR)
pumps is used to differentiate pumps that are capable of transporting a wide variety of
structurally diverse compounds from those that selectively extrude specific molecules.
Based on sequence similarity and structural homology, efflux systems have been
classified into six super-families. These include the ATP-binding cassettes (ABC),
major facilitators (MFS), resistance-nodulation cell division (RND), small multidrugresistance family (SMR), multi-antimicrobial extrusion protein family (MATE) and
multidrug endosomal transporters (MET). The first five families are found in
microorganisms, while the MET family appears to be restricted to higher eukaryotes.
Representatives of all families are found in mammalian cells.18
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1.4 Bacterial Efflux Pumps
Evidence that MDR pumps contribute to antibiotic resistance in bacteria comes
from experiments showing that there is an increase in the minimum inhibitory
concentration (MIC) of multiple antibiotics against a particular bacterium, compared to
the MICs of the same antibiotics against non-MDR expressing parent strains.19 It is well
accepted that the ‘intrinsic resistance’ of Gram-negative bacteria to certain antibiotics is
a result of efflux systems.20
A summary of bacterial efflux systems that illustrates their biological
complexity, overlapping specificity and evolutionary adaptability to antimicrobials, is
provided in Figure 1.2.

Figure 1.2 Summary of efflux systems found in Gram-positive and Gram-negative
bacteria. Examples of individual proteins that comprise each class are shown, along
with their typical substrates. MDRs expressed by Gram-negatives contain several
components, with the outer membrane protein normally being TolC. Figure modified
from Piddock et al.21

Both Gram-positive and Gram-negative bacteria can produce a variety of efflux
systems that contribute to multidrug resistance, virulence and pathogenesis.22
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Mechanisms that induce upregulation of efflux pumps include: (1) mutations in
promoter regions or insertion elements located upstream from efflux pump genes, (2)
mutations in local repressor genes and (3) mutations in global regulatory genes.
Substrates for individual efflux pumps vary depending on the pump and the
bacteria. A typical substrate profile of an MDR pump might include chloramphenicol,
quinolones (e.g. nalidixic acid, ciprofloxacin and norfloxacin), polycyclic dyes (e.g.
acriflavine and ethidium bromide), some detergents (e.g. sodium dodecyl sulfate and
Triton X-100) and biocides (e.g. cetrimide and triclosan).23
1.4.1 Efflux Pumps in Clinically Important Gram-Positive Bacteria
The major efflux systems implicated in Gram-positive bacterial drug resistance
are comprised of six chromosomally encoded transporters, including MFS members
NorA, NorB, NorC and MdeA, the MATE multidrug export protein mepRAB24 and the
SMR member SepA.25 Three plasmid encoded pumps QacA, QacB,26 and Tet(K) are
also important.27 These systems have broad and overlapping substrate specificities,
extruding quinolones, tetracyclines, monovalent and divalent antimicrobial cations (i.e.
intercalating dyes, quaternary ammonium compounds, diamidines, biguanidines) and
plant secondary metabolites.28
Pumps belonging to the MFS superfamily in S. aureus are NorA, NorB, NorC,
SdrM and Tet38. One study showed that 50% of 232 blood-borne S. aureus isolates
were able to efflux more than two substrates. Overexpressed genes identified were
mepA 4%, mdeA 11%, norA 23%, norB 25% and norC 17%. Another 20% of strains
over-expressed two or more efflux genes.29 Other genes, such as mepA (belonging to the
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MATE family) and sepA (belonging to the SMR family), are also present in the S.
aureus genome. Sav1866 is an ATP-binding cassette protein from the pathogen S.
aureus which is frequently used to homology model human and microbial ABC
multidrug transporters. The structure of the Sav1866 ABC pump from S. aureus is
shown in Figure 1.3.

Figure 1.3 Ribbon representation of the Sav1866 ABC pump in S. aureus. Two of six
transmembrane helical domains and two intracellular nucleotide-binding domains are
shown. Figure modified from Dawson and Locher.30

The clinical relevance of efflux pumps in S. aureus is best understood for NorA.
The NorA pump confers resistance to fluoroquinolone antibiotics, as well as dyes and
biocides.31 While nafcillin, ciprofloxacin, vancomycin and linezolid are typically used
for treatment of methicillin-susceptible S. aureus (MSSA) and MRSA infections, the
MICs of these agents are generally not affected by NorA, except for ciprofloxacin.

8

Enterococcus faecium is a commensal (innocuous, coexisting) organism in the
human intestine that can cause diseases such as neonatal meningitis. Analysis of foodborne infections revealed that Tet(L), Tet(M) and Tet(K) pumps are present in E.
faecium. MsrC pumps (belonging to the ABC transporters) have been shown to confer
resistance to macrolides and quinupristin in E. faecium, while EfmA pumps (MFS
family) have been shown to confer intrinsic resistance to many fluoroquinolones and
tetraphenylphosphonium ions. EmeA (a NorA homologue) has also been identified in E.
faecalis.32
S. pneumonia infections can lead to fatal pneumonia, bronchitis and meningitis,
particularly in the young and elderly. The MFS pumps in S. pneumonia MefA, MefE
and PmrA, have been implicated in macrolide and fluoroquinolone resistance.33 The
PmrA (MFS family) pump in S. pneumonia shares 42% identity with NorA and 43%
with Bmr pumps. It can export ciprofloxacin and norfloxacin, as well as the dyes
acriflavine and ethidium bromide.29,34 Overexpression of pmrA is not exclusively
associated with norfloxacin-resistant S. pneumonia as it is also found in norfloxacinsusceptible isolates.35
The mef (MFS pump Mef) and mel (ABC pump Mel) genes, which are located
on a conjugative transposon-related element in the genome of S. pneumonia, confer
resistance to macrolides and are responsible for increasing resistance problems
worldwide.36
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1.4.2 Efflux Pumps in Clinically Important Gram-Negative Bacteria
The most clinically significant efflux systems in Gram-negative bacteria are the
RND tripartite transporters, which show exceptionally broad substrate recognition
profiles. These proton-driven pumps are highly conserved across representative
proteobacteria and a representative example, AcrAB-TolC from E. coli, is shown in
Figure 1.4. Several members of the RND superfamily encoded in the human genome are
homologues of bacterial RND pumps (16% identity).37

Figure 1.4 Model of the TolC-MexA-AcrB pump in E. coli. The pump comprises the αhelical domain of a nonameric MexA complex that accommodates the periplasmic end
of the TolC efflux channel (pale orange), α/β barrel domain (blue), a “lipoyl” domain
(red), an extended α-helical domain (green) and the AcrB pump (grey). Figure modified
from Cuthbertson et al.38
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Pseudomonas aeruginosa, E. coli, Salmonella enterica, Campylobacter jejuni
and Neisseria gonorrhoeae are clinically relevant Gram-negative bacteria known to
express MDR pumps. P. aeruginosa can cause pneumonia and other opportunistic
infections (e.g. skin and soft-tissue infections in burns patients). Several antibiotics,
including chloramphenicol, fluoroquinolones and tetracycline, as well as other
substances like acriflavine, ethidium bromide and even some organic solvents, are
exported by P. aeruginosa pumps. The clinically relevant pumps in P. aeruginosa are
MexAB-OprM, MexCD-OprJ, MexEF-OprN and MexXY-OprM. These are expressed
at basal levels in wild-type cells and can confer intrinsic resistance to many
antimicrobials.39 Expression of MexCD-OprJ and MexEF-OprN has only been observed
in

multi-drug

resistant

strains

and

is

induced

by

pump

substrates.40

P.

aeruginosa carries twelve related Mex efflux systems but only the above four have
been shown to be clinically significant for resistance.41
Overexpression of pumps can occur as a result of mutations in operons within
transcriptional regulatory regions.42 For example, overexpression of mexAB-OprM in
nalB strains due to mutations in the mexR gene confers multi-drug resistance in P.
aeruginosa.43 Other genes involved in the overexpression of MexAB-OprM include
nalC and nalD. Hyperexpression of MexCD-OprJ in nfxB mutants of P. aeruginosa
contributes resistance to fluoroquinolones and fourth generation cephems (e.g.
cefpriome and cefozopran).44
Decisions on which antibiotics to use when treating P. aeruginosa infections
depends on whether the compounds are Mex pump substrates.45 For instance, the
MexXY-OprM system exports aminoglycosides, the MexAB-OprM system certain β-
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lactams and the MexCD-OprJ system novobiocin and cefsulodin. Another RND
transporter, MexGHI-OpM, has been shown to facilitate quorum sensing and antibiotic
susceptibility in P. aeruginosa, and to promote virulence and contribute to persistence.45
Although E. coli is a commensal organism found in the human gut it is often
responsible for urinary-tract infections. Enteropathogenic E. coli (EPEC) and
enterotoxigenic E. coli (ETEC) can cause severe diarrhoea.21 Pumps in E. coli include
EmrB, MdfA, TetA and Acr. Acr (i.e. AcrB) functions as a multi-subunit complex in
association with the outer membrane channel TolC and the membrane fusion protein
AcrA.21 Figure 1.5 shows the structure of the AcrAB-TolC pump in E. coli.

Figure 1.5 Example of an MDR efflux pump in E. coli. The pump is an AcrAB-TolC
complex. The TolC trimer (orange, red, and yellow subunits with grey equatorial
domains and membrane regions) was docked onto the AcrA (green) and AcrB trimer
(blue/light blue subunits with grey membrane regions). Figure modified from Symmons
et al.46
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AcrAB-TolC from the RND family is remarkably polyspecific47 and can be
overexpressed in some clinical isolates.48 Overexpression of AcrAB-TolC does not
generally confer clinical resistance on its own. As with RND pumps in P. aeruginosa,
AcrAB-TolC in E. coli is a tripartite complex formed between the RND pump AcrB, the
membrane fusion protein AcrA and the low permeability outer membrane protein
TolC.37a While a crystal structure has been reported and a model of the pump
assembled46 the exact role of each component during efflux remains largely unknown.
The AcrAB-TolC complex is capable of extruding a very broad range of
substances that differ in both structure and charge. Examples include antibiotics like
chloramphenicol, lipophillic β-lactams, tetracycline, rifamipicin, novabicin, fusidic acid
and nalidixic acid.47 Non-antibiotic substrates include disinfectants and detergents, bile
salts, cationic dyes, ethidium bromide and some solvents.49
Treatment of E. coli infections usually involves administration of cotrimoxazole (trimethoprim-sulfamethoxazole), a nitrofurantoin or a fluoroquinolone.
Ceftriaxone, a third-generation cephalosporin, is used for invasive or life-threatening E.
coli infections.50
Salmonella enterica serovar Typhimurium and Salmonella enterica serovar
Enteritidis can cause gastroenteritis, with invasive salmonellosis occurring in 1-4% of
human infections.51 When treatment is required the antibiotics most commonly used are
fluoroquinolones (e.g. ciprofloxacin) or the cephalosporin ceftriaxone. The AcrABTolC system of S. Typhimurium is similar to that of E. coli. It has been shown that
overexpression of AcrB in human and veterinary isolates and laboratory mutants of S.
Typhimurium are associated with MDR.52
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C. jejuni contains RND-family members and is the most common cause of
bacterial gastroenteritis in developed countries. Overexpression of CmeB confers
resistance to ciprofloxacin, erythromycin, ampicillin, chloramphenicol and tetracycline
and decreases susceptibility to bile salts, SDS, Triton X-100 and triclosan.53 Both
human and veterinary isolates of C. jejuni have been found to overexpress cmeB.54
Resistance of N. gonorrhoeae to some antibiotics (i.e. erythromycin, penicillin
and tetracycline) due to multiple transferable resistance (mtr) was first identified in the
1970s.55 The mtr property is due to the action of the MtrC-MtrD-MtrE pump, which
expels structurally diverse hydrophobic antimicrobial agents by an energy-dependent
process.56 Recently, overexpression of MtrC-MtrD-MtrE pumps due to an mtrR
mutation was shown to confer chromosomally mediated penicillin resistance in N.
gonorrhoeae.57 N. gonorrhoeae is responsible for the sexually transmitted infection
gonorrhoea but can also cause conjunctivitis, pharyngitis, prostatitis and orchitis.58
1.5 Strategies for Inhibiting Microbial Efflux Pumps
Strategies that have been investigated to date for overcoming efflux-mediated
bacterial resistance are of three types: (1) biological inhibition of efflux pumps using
neutralizing antibodies or antisense approaches. For example, use of small interfering
RNAs (siRNAs) have been used for inhibition of the AcrAB efflux pump in E. coli;59
(2) evasion of efflux systems, where the structure of antimicrobials is modified such
that they are no longer substrates for pumps. For instance, newer antibiotics like
sparfloxacin and trovafloxacin were purposely engineered to be less susceptible to
efflux than their parent compounds, nalidixic acid and norfloxacin;60 (3)
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pharmacological inhibition of pumps, where small molecule inhibitors are used to
selectively block pumps and restore potency of co-administered antibacterials.
1.6 Small Molecule Efflux Pump Inhibitors
Many of the small molecule inhibitors identified to date have been natural
products, and it has been proposed that these compounds may have evolved to protect
plants from infections by acting synergistically with other plant antibacterial
compounds.61 A potential clinical strategy that mimics this approach from nature is to
use small molecule MDR pump inhibitors in combination with antibacterial agents.
Whilst an attractive strategy, only a small numbers of lead chemotypes have been
advanced to preclinical and clinical studies to date. Lack of broad activity and selective
action against bacterial pumps over mammalian pumps appear to be key challenges for
adopting the approach in the clinic.
Phenotypic assays with efflux systems have been used extensively in microbial
efflux pump inhibitor (EPI) discovery. These functional assays typically employ a
fluorescent dye pump substrate to report on efflux activity and have been successfully
established in low- and mid-throughput formats.62 Fluorescence microscopy and highresolution multi-parametric flow cytometry are gradually superseding fluorimeters and
plate readers in these assays because of their capacity for increased throughput and
sensitivity.62b
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1.6.1 EPIs against Gram-Negative Bacteria
The number of EPI chemotypes targeting Gram-negatives identified to date is
much smaller than the number against Gram-positives. Phenyl-arginine-betanaphthylamide (PaβN), also called MC-207 110 1 (Figure 1.6), was the first EPI
identified against Gram-negatives.63 It was discovered by testing an array of synthetic
and natural compounds against P. aeruginosa strains over-expressing the three intrinsic
efflux systems (i.e. MexAB-OprM, MexCD-OprJ, MexEF-OprN) in the presence of
levofloxacin.64 Results of various microbiological assays suggested that MC-207 110
promoted a competition-like process during the recognition/transport of antibiotic
molecules.65 A derivative of PaβN, MC-04 124 2, showed improved EPI activity,
pharmacokinetic properties and increased stability.66 Both inhibitors were studied in
preclinical work by Mpex Pharmaceuticals.67 Recent investigations suggested the
compounds show toxicity due to effects on membrane function.68 PaβN/MC-207 110
remains as a valuable probe for exploring bacterial efflux systems.

Figure 1.6 Examples of EPIs against Gram-negative bacteria.
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EPI activity against RND pumps can be assessed using a microfluidic channel
device

and

fluorescence

microscope.69

In

these

assays,

fluorescein-di-β-D-

galactopyranoside (FDG) is hydrolyzed by β-galactosidase in the cytoplasm of E. coli to
produce the fluorescent dye fluorescein. Both FDG and fluorescein are effluxed in E.
coli, allowing the effects of EPIs to be measured. This assay was used to validate the
activity of MexB-specific tert-butyl thiazolyl aminocarboxyl pyridopyrimidine (ABIPP) 3 and PaβN 1.70 Pyridopyrimidine-based EPIs carrying acrylic acid (e.g. 4) were
shown to be more soluble than 3 and showed acceptable safety profiles but they
displayed only moderate activity in vivo.71 Recently, co-crystallization of the MexB
pump with PaβN and ABI-PP revealed tighter binding for the latter, leading the authors
to propose a set of physicochemical parameters for development of EPIs.72
1.6.2 Natural Product EPIs
Numerous phytochemicals have been shown to act as EPIs in combination with
antimicrobials against Gram-positive bacteria.73 A selection of phenolic natural product
EPIs is shown in Figure 1.7.
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Figure 1.7 Examples of phenolic EPIs discovered from natural sources. Reserpine 8
and pterostilbene 10 were important compounds in this PhD project.

Epigallocatechin gallate (EGCG) 5, a major polyphenol extracted from green
tea,74 shows resistance-modifying activities when used with norfloxacin and tetracycline
at low concentrations.75 At less than half its MIC (100 μg/mL) EGCG was able to
reverse tetracycline resistance in staphylococcal isolates.75 EGCG was also identified as
a resistance-modifying agent in Campylobacter spp.76
The flavonolignan 5’-methoxyhydnocarpin (5’-MHC 6) and its 5-desmethoxy
analogue 7 (Figure 1.7) were isolated from Hydnocarpus wightiana.77 Both compounds
were shown to be MDR inhibitors without showing antibacterial activity on their own.78
The compounds were evaluated against 20 clinical isolates of MRSA in combination
with ampicillin or oxacillin, where they reduced MICs more than 4-fold.79 Subinhibitory
concentrations of the weak antibacterial alkaloid berberine with 1.2 µg/mL of 6
completely inhibited growth of S. aureus growth.78a
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1.6.2.1 Reserpine
Reserpine 8 (Figure 1.7) is an anti-hypertensive alkaloid that was first extracted
from the roots of Rauwolfia vomitoria in 1954.80 The compound was originally shown
to be a potent inhibitor of mammalian P-glycoprotein81 but later investigations revealed
its MDR inhibitory properties in the Gram-positive bacterium Bacillus subtilis,82 where
it was shown to inhibit tetracycline efflux by the Bmr pump. The study revealed that
reserpine interacts directly with the Bmr protein at a hydrophobic site formed around
Phe143, Val286 and Phe306.82
Reserpine reversal of NorA-mediated efflux in S. aureus was shown to enhance
the potency of fluoroquinolones,83 where it lowered MICs by up to 4-fold when present
at 20 µg/mL.84 In a study by Schmitz et al. MICs and LC50 values were measured
against 102 clonally non-related S. aureus strains from eight different countries for
ciprofloxacin, sparfloxacin and moxifloxacin in the presence and absence of reserpine.84
The potentiation effect of reserpine on the hydrophilic variants (e.g. ciprofloxacin) was
greater than for the hydrophobic compounds (e.g. moxifloxacin and sparfloxacin).
Fluoroquinolone resistance mediated by the PmrA pump in S. pneumoniae (43%
amino acid similarity to NorA) was shown to decrease in the presence of reserpine.85 In
an investigation by Markham et al, a single-step mutant of S. pneumoniae resistant to 34 fold MICs of ciprofloxacin was studied in vitro in the presence and absence of
reserpine.85b A pronounced inhibition of selection of S. pneumoniae ATCC 49619
mutants resistant to ciprofloxacin was noted when reserpine (20 μg/mL) was present. In
the absence of reserpine, 135 colonies of S. pneumoniae showed 3 x baseline MIC and
19 colonies showed 4 x baseline MIC. In the presence of reserpine only 3 colonies were
19

resistant to 3 x MIC (45-fold reduction) and no colonies were resistant to 4 x MIC
(complete suppression). In these experiments reserpine affected neither the colony size
nor the colony-forming ability of S. pneumoniae when plated in the absence of
ciprofloxacin.85b
A significant problem with many natural product EPIs is their toxicity, which
hinders their potential for clinical applications.67,86 Reserpine is neurotoxic at the
concentrations required to inhibit MDR pumps (20 µg/mL) and is thus not suitable as an
antibacterial adjuvant in humans.67 It remains, however, a widely used tool for
evaluating bacterial efflux mechanisms.87
1.6.2.2 Pterostilbene 10
Organic extracts of Dalea versicolor in the presence of berberine showed strong
potentiation effects against S. aureus.88 Two pterostilbene derivatives 9 and 10 (Figure
1.7) were contained in the extract fractions and co-extracted with berberine. It was
hypothesized that the MDR inhibitory properties of these molecules was being exploited
by the plant to potentiate the antibacterial effects of berberine; that is, the compound
combination was acting as the plant’s antibacterial defence mechanism.88-89 Both 9 and
10 showed only weak activity alone (MICs 250 and 500 µg/mL, respectively)90 but 10
caused complete growth inhibition at low concentrations (~ 3.3 µg/mL) in combination
with berberine. Compound 10 was also tested alone and in combination with berberine
against the opportunistic pathogen Bacillus cereus and was shown to increase the
activity of berberine 16-fold.90
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1.6.3 Synthetic EPIs
An investigation aimed at exploring the effects of NorA inhibition in S. aureus
studied the activities of fluoroquinolones (i.e. levofloxacin, ciprofloxacin and
norfloxacin) in the presence and absence of various synthetic NorA inhibitors.91 The
H+/K+ ATPase pump inhibitor omeprazole 11 (Figure 1.8) was found to have moderate
activity (less than reserpine) but significantly greater activity than verapamil. The
compound decreased the frequency of ciprofloxacin resistance almost 100-fold.92
When the mammalian MDR inhibitor timcodar (VX-853) 12 was evaluated for
EPI activity in a variety of bacteria,93 it was found to potentiate the activity of ethidium
bromide against S. aureus94 and to decrease the MIC of fluoroquinolones. Against a
NorA-overproducing strain (SA-1199B), VX-853 12 reduced the MIC of norfloxacin
32-fold and 8-fold for ciprofloxacin.93a
A new generation of MDR modulators that included tariquidar 13 and elacridar
14 (Figure 1.8) was identified during screening for inhibitors of mammalian ABC-type
transporters and breast cancer resistance proteins (BCRP, ABCG2).95 Elacridar 14 had
previously shown equipotent activity with reserpine in ciprofloxacin/norfloxacin
combinations against S. aureus strains in vitro.96 The potency of tariquidar 13 was also
investigated in combination with ciprofloxacin and showed potent inhibitory effects
against some efflux pumps.97 The compound produced 10-fold reductions in the
ciprofloxacin MIC against S. aureus while no effect was observed with P. aeruginosa.
An investigation by Influx Inc. aimed at discovering inhibitors of the NorA
pump in S. aureus saw the screening of over 9,600 structurally distinct synthetic
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compounds in the late 1990s.98 The compounds were screened at 20 µg/mL and those
that reversed NorA-mediated efflux of ethidium bromide whilst being nontoxic to
bacteria on their own were considered hits. Initial efforts identified 399 compounds
showing activity above threshold. Twenty-eight of the hits were at least as potent as
reserpine, with eleven showing higher potency (effective at 5 µg/mL or less). Thirty of
the compounds contained an indole moiety, while a significant number contained the
toxic trichloromethylaminal group. However, seven compounds were relatively nontoxic nitroindoles. Out of 32 bisaryl ureas in the library eleven compounds were found
to be active. Two of the most active EPIs from the investigation were the 5-nitroindole
derivative INF55 15 and bis-aryl urea INF271 16 (Figure 1.8). Both compounds have
since been studied further for their EPI effects in Gram-positive bacteria.99

Figure 1.8 Representative synthetic EPIs identified to date. INF55 15 and INF271 16
were important compounds in this PhD project.
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1.6.3.1 5-Nitro-2-phenylindole (INF55) 15
Markham et al described several indole-based inhibitors of multidrug transport
proteins that showed potential for use in combination with existing antibacterial or
antifungal agents.100 The compounds were identified as inhibitors in bacteria expressing
the NorA pump and fungi expressing another multidrug transport protein. A theoretical
structure-activity study using COMFA (3D-QSAR) analysis suggested that replacement
of the indole 5-nitro group of INF55 15 with other electron-withdrawing substituents
should be favourable for EPI inhibitory activity.99b A separate study identified a series
of 2-arylbenzo[b]thiophenes related to INF55 as NorA inhibitors, suggesting that the
indole NH group is not essential for activity.101 Most of the compounds exhibited no
antibiotic activity alone and several were shown to be inhibitors of the NorA pump in S.
aureus.
An SAR study by Samosorn et al showed that various substituents around the 2aryl ring of INF55 can affect NorA inhibitory potency.102 For example, the INF55
analogue 5’-benzyloxy-2’-hydroxymethyl-5-nitroindole 17 (Figure 1.9) potentiated the
activity of berberine (a known substrate of NorA) more than 15-fold against the NorA
overexpressing S. aureus strain K2361 at a concentration of 0.8 µg/mL.102 In later work
the same group reported more SAR explorations around the 2-aryl ring of INF55 as well
as the effects of substituting the indole 5-nitro group.103 The study identified three new
potent indole-based NorA EPIs, 18, 19, and 20 (Figure 1.9), along with a new indole
derivative 21 that showed direct antibacterial activity against S. aureus.
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Figure 1.9 2-Arylindole-based inhibitors of the NorA pump in S. aureus related to
INF55 15.

1.6.2.2 INF271
The bis-aryl urea INF271 16 (Figure 1.8) inhibits the NorA pump in S. aureus at
concentrations less than 1.5 µg/mL. It was shown to potentiate the action of
ciprofloxacin,98 where it decreased the IC50 2.5-fold at an 8-fold lower concentration
than reserpine. A decrease in cell viability recorded during these experiments using
OD600 measurements showed that viability in the presence of 0.13 µg/mL
ciprofloxacin alone was 3 x 107 CFU/mL. In the presence of reserpine (20 µg/mL) the
number was reduced to 5 x 104 CFU/mL and to 1.2 x 105 CFU/mL with INF 271 (2.5
µg/mL) present.
Isoflavones 22-28 (Figure 1.10) isolated from Lupinus argenteus potentiate the
activity of berberine and norfloxacin.104 In one report INF271 16 was studied alongside
isoflavones to compare their EPI activities and berberine potentiation effects.105
Accumulation of berberine in S. aureus cells alone and in the presence of the
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isoflavones and INF271 16 showed that INF271 was more potent. The results also
suggested that there may be MDR pumps in S. aureus other than NorA that are inhibited
by INF271.105

Figure 1.10 Examples of isoflavone-based EPIs.105

Studies have shown that INF271 and some plant-based EPIs strongly increase
the penetration rate and accumulation of berberine in S. aureus cells.98,106 This synergy
has also been observed in some Gram-negative bacteria.107 A study by Lewis et al
examined the effects of INF271 16 and MC-207 110 1 on berberine accumulation in S.
enterica, S. typhimurium, Pseudomonas syringae, Xanthomonas campestris, E.
carotovora and Sinorhizobium meliloti.107 Strongly elevated rates of accumulation of
berberine were observed with MC-207 110, INF271 and both compounds together, and
similar results were observed with other weak antibacterial compounds. For instance,
coumestrol alone showed very little antibacterial activity against Agrobacterium

25

tumefaciens (MIC 500 µg/mL) but in the presence of INF271 and MC-207 110 its MIC
decreased to 125 µg/mL. Greater increases in coumestrol activity were observed with
other bacteria. For example, p. aeruginosa strains (MIC 500 µg/mL) expressing the
MexAB pump showed 300-fold increases in sensitivity when INF271 and MC-207 110
were present.107
German et al have described hybrid compounds containing fluoroquinolone
antibacterials covalently linked to various EPIs, including INF271-based hybrids 29 and
30, as well as dipeptide-based hybrids 31 and 32 (Figure 1.11).108 One of the conjugates
significantly inhibited MexAB-mediated ethidium bromide efflux in P. aeruginosa and
dipeptide-based conjugates 31 and 32 showed no inhibition of ethidium efflux in either
NorA or MepA expressing S. aureus and P. aeruginosa strains. In contrast, the
ofloxacin-based conjugate 29 was a potent inhibitor of NorA and MepA-mediated
efflux in S. aureus. One conclusion from this study was that inhibition of NorA by
conjugates 29 and 30 was not simply due to the attached INF271, but was probably a
consequence of the entire structure of the molecules.

Figure 1.11 Fluoroquinolone-EPI hybrids reported by German et al.108
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1.7 Photodynamic Therapy
Photodynamic therapy (PDT) uses the combined action of visible light of
specific wavelengths and a dye or photosensitizer (PS) to generate cytotoxic reactive
oxygen species (ROS), including singlet oxygen (1O2) and free radicals, to kill cells. In
this approach, the administered photosensitizing compound is allowed to accumulate in
and around target cells and visible light is applied109 (Figure 1.12). The majority of PDT
investigations to date have focused on its use in treating of solid tumours.
The mechanisms involved in obtaining selectivity against tumour cells during
PDT are not well understood. Some characteristics of tumour cells that may play a role
include high expression of low-density protein (LDL) receptors, involvement of
macrophages, greater cellular proliferative rates and leaky vasculature.110 Low pH and a
high level of newly synthesized collagen in tumours have also been implicated.111

Figure 1.12 In PDT for cancer a photosensitizing compound is applied locally to
lesions or injected intravenously. Healthy cells shed the drug allowing the agent to
concentrate in and around cancer cells. The tumour is illuminated with an appropriate
wavelength of visible light and the resulting ROS destroy tumour cells.

Lipson and Schwartz originally developed PDT at the Mayo Clinic (USA) in the
1960’s to treat tumours during surgery.112 When using a fluorescent tumour localizing
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hematoporphyrin derivative they found that injecting crude preparations of the
compound led to fluorescence of neoplasms upon illumination. Schwartz later treated
the hematoporphyrin preparations with acetic acid and sulphuric acid to create a
porphyrin mixture with improved tumour-localizing properties.113 The mixture, termed
hematoporphyrin derivative (HPD), was less active,114 however, as it contained
porphyrin monomers, dimers and oligomers. Partial purification to remove the less
active porphyrins led to Photofrin®,115 which remains the most widely used 1stgeneration PS for clinical PDT.
One shortcoming of

Photofrin® is

that it

causes

long-lasting skin

phototoxicity.116 Another issue is that it absorbs light only up to about 640 nm, which
cannot penetrate well through tissues. Second generation PSs were thus created to
absorb light of longer wavelengths (650-850 nm). Examples include porphyrin
derivatives and other compounds made after the late 1980’s.114 Third generation agents
for anti-tumour PDT are showing increasing complexity, where PSs have been
conjugated to tumour targeting monoclonal antibodies and other biologicals.117
The therapeutic uses of PDT continue to expand into various non-oncological
indications, which include macular degeneration, autoimmune disorders and dermal
pathologies.118 A more recent area of research is antimicrobial photodynamic therapy
(aPDT), where PDT is used to treat localized bacterial, fungal, viral and yeast
infections.119 A key driver of efforts to create effective aPDT treatments as alternative to
antibiotics has been the global emergence of antibiotic resistance.120
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1.8 Antimicrobial Photodynamic Therapy (aPDT)
The concept of aPDT was first described in 1900 by Oskar Raab in Munich.121
Very little further work was done in the early 20th century, however, due to the
discovery of antibiotics, starting with penicillin in 1929.122 The Golden Age of
antibiotics followed when over half of today’s commonly used drugs were discovered.
Concerns about antibiotic resistance have catalysed research into novel approaches for
managing bacterial infections leading to a resurgence in interest in PDT.123
A major advantage of aPDT is that antibiotic-resistant bacteria are as susceptible
to aPDT as their non-resistant counterparts.124 The non-specific nature of cell killing
through ROS-mediated photooxidative damage means there is little possibility for
resistant strains to survive during aPDT.125
Other advantages of aPDT that have been identified include: (1) efficacy
independent of antibiotic resistance patterns, (2) extensive pathogen reduction with
limited damage to host tissues, (3) removal of photoresistant strains after multiple
treatments, (4) absence of microorganism recovery following treatment, (5) direct
application of PSs to infected areas, (6) low cost light sources and (7) more rapid
inactivation of bacterial cells compared to traditional antimicrobials.124c,126
While aPDT shows promise as an alternative to antibiotics for treating localized
infections, key issues still need to be addressed. These are: (1) ensuring that the
treatment destroys sufficient numbers of disease-causing pathogens, (2) selectivity of
PSs for bacterial cells over mammalian cells and (3) preventing recurrence of infections
due to regrowth of small numbers of cells that survive treatment.127
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In aPDT for localized infections, the PSs can be directly applied to the infected
area via topical application, instillation, interstitial injection or through use of
aerosols.127 For a PS to be effective it should selectively accumulate around (or even
better inside) target cells. Selective localization is facilitated by the net charge on PSs
and the surface charges present on targeted cells. Gram-positive bacteria have a thick
cell wall composed largely of peptidoglycan (~ 90%, c.f. 20% for Gram-negatives),
along with teichoic acids, polysaccharides and peptidoglycolipids. The net negative
charge of bacterial cell walls thus enables favourable electrostatic interactions with
cationic PSs.118 Indeed cationic PSs have been shown to be more effective at lower
concentrations than neutral or anionic compounds in aPDT.118,128
Ideally, aPDT produces selective killing of pathogens whilst leaving host cells
unharmed. Techniques for achieving selective killing include short incubation times,
low PS concentrations and soft irradiation.118 The external structures of bacteria targeted
by ROS lead to cell death, so the PSs don’t actually need to penetrate into bacteria.
However, if the compounds could be concentrated inside bacterial cells it is predicted
that the aPDT would become more effective due to increased potency and selectivity.129
1.9 Mechanisms of aPDT
The basic premise of aPDT is to use photoactive dyes that upon irradiation with
visible light are able to generate toxic ROS to kill bacterial cells. When the dye absorbs
light it is excited from the ground state to an excited singlet state that subsequently loses
energy via three pathways: (1) non-radiative processes, where the excited state species
release excess energy as heat through vibrational relaxation, internal conversion and
intersystem crossing; (2) radiative processes, where excess energy is lost through
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fluorescence and/or phosphorescence and (3) other processes, where the excited
molecules undergo photochemical or photophysical reactions (i.e. photosensitization).
When molecular oxygen is involved in the photosensitisation event such processes are
called photodynamic action. Two different mechanisms of photodynamic action are
possible and are termed Type I and Type II processes (Figure 1.13).
In Type I processes, the PS in its singlet or triplet excited state reacts with a
substrate through electron transfer or via a hydrogen abstraction to yield unstable and
reactive radicals (i.e. hydroxyl radicals and superoxide), which can further react with
molecular O2 to form peroxyl radicals. In Type II processes, the PS in its triplet excited
state transfers energy to ground-state molecular oxygen and produces highly reactive
singlet oxygen (1O2).

Figure 1.13 Type I and Type II processes in aPDT. PS = photosensitizer.

In bacterial cells both mechanisms lead to photooxidation of amino acids,
nucleobases and lipids, leading to damaged proteins, DNA and membranes. Reactions
based on Type I mechanisms have been shown to effect membrane permeability through
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lipid peroxidation, causing loss of fluidity and increased ion permeability.130 It has been
suggested that Type I processes could potentially be employed in aPDT against
anaerobic gut pathogens (e.g. Clostridium difficile) where O2 is absent.131 In Type II
reactions, the resulting 1O2 targets cell wall and membrane components (i.e. lipids,
sterols and peptides). The individual reaction products from the two mechanisms can
vary considerably. For instance, during Type I reactions, cholesterol is converted to
cholesterol-7α and 7β-hydroperoxide but is converted to the 5α-isomer by 1O2 in Type
II reactions.132
Nucleic acids are targeted by both Type I and Type II processes. Hydroxyl
radicals formed in Type I mechanisms can attack the sugar moiety of nucleic acids,
while 1O2 from Type II reactions targets guanine bases. These genotoxic events can
cause base substitutions, strand cleavage, mutations and inhibition of replication.130,133
The types of mechanisms at play during aPDT depend on the PS used. Most
photosensitizers are highly conjugated aromatic molecules capable of forming longlived triplet states. The amount of energy required for production of ROS depends on
the individual structures.124a
1.10 Photosensitizers in aPDT
Photosensitizers are defined as molecules that when activated by radiation or
light cause nearby molecules to undergo chemical reactions.119a PSs for use in aPDT
ideally display the following properties:118,134
(1) Efficacy against several classes of microorganisms at relatively low
concentrations and low light fluence.
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(2) Low toxicity in the absence of light (i.e. low dark toxicity).
(3) Selectivity for microbial cells over human cells.
(4) Hydrophilic character and net positive charges to allow better interactions
with microbial cell walls.
(5) High extinction coefficients that allow efficient absorption of blue or red
light.
(6) High superoxide and/or singlet oxygen quantum yields.
Over 400 compounds are known to exhibit photosensitizing properties, including
dyes, drugs, cosmetics and many natural substances. The majority of PSs can be divided
into three structural classes; the tricyclic dyes, tetrapyrroles and furocoumarins.119a The
class relevant to this PhD project was the tricyclic phenothiazinium dyes.
1.10.1 Phenothiazinium Dyes as Photosensitizers
Phenothiazinium dyes have been reported as effective photosensitisers that
inactivate a wide range of microorganisms upon illumination with red light. An
important property of aPDT with these dyes is that bacteria that show resistance to
frontline antibiotics like methicillin and vancomycin are easily inactivated.135
Importantly, members of the class are also known to be relatively nontoxic to humans136
and are currently used for aPDT disinfection of blood products.137
Phenothiazinium dyes are hydrophobic cationic salts that show limited
permeability across cell membranes. They exhibit strong reactivity towards proteins,
lipoproteins and nucleic acids upon illumination. Methylene blue (MB) 33 (Figure 1.14)
is the parent member of the class. Various substituents around the phenothiazinium core
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can have a pronounced effect on photochemical properties, e.g. maximum absorption
wavelength and lipophilicity.138 Variations in these properties can affect the type and
cellular location of photodamage. Cellular uptake is also affected by a combination of
charge type/distribution and lipophilicity, which vary with substituents patterns.139

Figure 1.14 Methylene blue (MB) and related phenothiazinium photosensitizers.

Phenothiazinium PSs related to MB include toluidine blue O (TBO) 34, thionin
35, azure A 36, azure B 37, azure C 38, new methylene blue (NMB) 39, dimethyl
methylene blue (DMMB) 40 and methylene orange (MO) 41 (Figure 1.14). The
compounds are all planar, tricyclic, aromatic molecules with an intrinsic positive charge
and they all show an intense absorption band between 600 - 680 nm. MB and TBO are
used clinically in aPDT.137a
1.10.1.1 aPDT with Methylene Blue (MB)
aPDT with MB is used to sterilize blood products, where it serves to inactivate
HIV, hepatitis B and C and other viruses.137e MB has also been used to treat
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methemoglobinemia in humans and has been investigated clinically as a PDT
photosensitizer in the treatment of bladder cancers, adenocarcinomas, inoperable
esophageal tumours and psoriasis.140 TBO is predominantly used in aPDT as an oral
disinfectant for sterilizing dental cavities and root canals and for treating periodontitis141
aPDT with intravenously administrated MB has been examined against various
Gram-positive and Gram-negative bacteria.142 Wainwright et al have demonstrated the
photobactericidal activity of MB during aPDT against VRE and MRSA.143 The
hydrophilicity of MB along with its low molecular weight and positive charge are
thought to facilitate its passage across porin channels in the outer membrane of Gramnegative bacteria. Studies have demonstrated the promising photodynamic action of MB
on E. coli.144
Inactivation of bacteria by MB during aPDT can occur via both Type I and/or
Type II processes, depending on the cell type being studied and the experimental
conditions. For example, Type I processes occur when the photodynamic action of MB
is coupled to reduction of the photoexcited dye by nicotinamide adenine dinucleotide
(NADH).145
The photochemical properties of MB (and its analogues) make it highly suitable
for aPDT. It exhibits 1O2 quantum yield upwards of 0.5, it has a low reduction potential
and shows an intense absorption maximum around 664 nm in water.146
The absorption spectrum of MB is concentration-dependent due to dimerisation,
with the equilibrium constant for dimerization in water being 3.8×103 M−1.146c MB
monomers and dimers show different absorbtion spectra, with monomers showing a
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maximum at 664 nm that shifts to 590 nm for dimers. Monomers and dimers can be
involved in different kinds of photochemical reactions and can affect the mechanisms
and efficiency of cell killing.146c,147 Use of MB to treat a patient with an arm tumour
revealed that in 20 µM aqueous solutions only MB monomers were present, while after
local injections of a 2% MB solution the absorption maximum shifted to 580 nm,
indicating the presence of dimers.146c
Singlet oxygen is produced in Type II processes from MB where its triplet state
energy is transferred to oxygen. Singlet oxygen is also formed from MB in Type I
processes when reducing agents donate an electron to triplet MB to form semi-reduced
radicals.146c Different concentrations of MB can influence which mechanisms
predominate. At high MB concentrations, where the compound exists mostly as dimers,
Type I reactions are limited.146c In homogeneous monomer solutions MB produces a
high quantum yield of singlet oxygen.148 The pH of solutions can also influence whether
MB undergoes Type I or Type II processes. MB has been shown to be less active at
lower pHs due to lower 1O2 quantum yields.149
MB can distribute into subcellular compartments like lysosomes and
mitochondria. As a cation, MB is attracted to the negative electrochemical environment
of the mitochondrial matrix.150 Once localized in mitochondria, the optical density of
MB at the excitation wavelength changes, as does its 1O2 quantum yield.151 It is thought
that decreases in 1O2 as MB accumulates in and around mitochondria is due to
formation of MB dimers. MB is sometimes referred to as a mitochondrial sensitizer as it
is the only PS that can selectively oxidize mitochondrial NAD(P)H.152
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Upon irradiation with visible light MB has been shown to liberate lysosomal
enzymes from human fibroblast cells. One interesting study showed that MB localized
in lysosomes can actually migrate to the nucleus, but only after light activation. The cell
nucleus is also a known site of localization of MB153 and it has been suggested that
when the compound enters cells it increases the effectiveness of aPDT.154
1.12 Microbial Resistance in aPDT
In section 1.6 it was discussed how plants appear to use synergistic
combinations of weak antibacterials and EPIs as a defence against bacterial
pathogens.155 A study by Lewis et al showed that the alkaloid berberine 42 (Figure
1.15), widely found in Barberry (Berberis) plants, co-extracts with 5-methoxyhydnocarpin (5’-MHC). Berberine is a hydrophobic cation that exhibits weak
antibacterial effects by increasing membrane permeability and via interactions with
DNA.156 Due to its positive charge it could conceivably accumulate in bacterial cells
due to the electrochemical gradient across the membrane. However, hydrophobic
cations are the preferred substrates of many classes of MDR pumps,157 which is
probably why its antibacterial activity is weak. Lewis & Stermitz showed that 5’-MHC,
which has no antimicrobial activity on its own, strongly potentiates the antibacterial
activity of berberine against S. aureus through inhibition of efflux,158 indicating that it is
the berberine/5’-MHC combination that provides plants with antibacterial defence
(Figure 1.15).
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Figure 1.15 Structures of berberine (antibacterial) and 5’-MHC (EPI).

Like berberine, MB 33 is a planar, aromatic hydrophobic cation, which suggests
it too might be a preferred substrate for microbial efflux systems. A comprehensive
study by Tegos et al revealed that the three cationic phenothiazinium photosensitizers
MB 33, TBO 34, and DMMB 40 are indeed all susceptible to efflux, whereas the
neutral PS Rose Bengal is not.154 The study demonstrated that MB 33 shows different
uptake levels in three S. aureus strains varying in expression of the NorA MDR pump:
i.e. NorA knockout, wild-type and NorA-overexpressing. The NorA knockout strain
took up 1.22 ± 0.22 × 109 molecules/cell of MB, compared to 0.06 ± 0.01 × 109 for the
wild type and 0.021 ± 0.003 × 109 for the NorA-overexpressing strain.154 Other nonphenothiazinium PSs showed equivalent uptake across all three NorA phenotypes,
demonstrating that these non-phenothiaziniums are not NorA substrates. It was
suggested that efflux of phenothiazinium PSs from cells by MDRs reduces their
phototoxicity upon illumination.154
1.13 Combination aPDT with MB and EPIs
The discovery that bacterial MDRs contribute to aPDT resistance through efflux
of MB, combined with studies showing that plants use the hydrophobic cation berberine
in combination with 5’-MHC to provide antibacterial defence, suggested that
combinations of MB with an MDR inhibitor might increase aPDT activity.
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Tegos et al demonstrated that the effectiveness of photodynamic inactivation
mediated by MB in S. aureus was inversely proportional to the level of NorA
expression using three S. aureus strains; wild-type 8325-4, NorA knockout K1758 and
NorA overexpresser K2378.154 The same strains were then used to test whether the
NorA inhibitors INF271 16, reserpine 8 and INF55 15 potentiate the aPDT activity of
MB.
Wild-type cells incubated with MB in the presence of INF271 and illuminated at
635 nm showed light-dependent cell killing increases 2-5 log units above levels
observed when INF271 was absent. No significant killing in the presence of INF271
alone was observed in the light or dark. Reserpine showed slightly better activity while
similar results were obtained with INF55.154
Tegos et al showed that Gram-positive bacteria tend to show better potentiation
effects in aPDT than Gram-negatives when using combinations of phenothiazinium
salts and EPIs.99a An interesting observation was that pre-incubation of strains with EPIs
produced a stronger aPDT effect than when EPIs and PSs are added together.99a It was
suggested that this may be because of competition between EPIs and PSs for pump
binding sites.
The simplest application of a combination therapy aPDT approach would be in
localized dermal infections, where both the PS and light could easily be delivered to the
infection site. Although some work has been done towards discovering and optimizing
EPI structures for use in combination with PSs, no clinical studies have been reported.
This may be because some EPIs show unacceptable toxicity when tested in rodent
infection models, possibly due to the multitude of normal physiological roles of related
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pumps in eukaryotic cells (e.g. p-glycoprotein).159 Clinical development of drug
combinations also presents higher regulatory barriers due to the need to prove efficacy
and safety in not one, but two active agents.
1.14 MB-EPI Hybrids for use in aPDT
One strategy being explored to address the clinical challenges associated with
co-administering antibacterials with EPIs is to covalently link the EPI and antibacterial
components together into a single (non-cleavable) hybrid molecule.160 Such hybrids
carry the potential advantage of delivering equimolar quantities of the two agents to
infection sites whilst avoiding some of the complications arising through multi-agent
co-dosing.161
Bremner et al described the first such hybrid, termed SS14-O 43 in 2006 (Figure
1.16), consisting of berberine substituted at its 13-position via a methylene linkage to
INF55 15.162 In designing the hybrid it was reasoned that the berberine portion could
show enhanced antibacterial effects due to higher intracellular concentrations arising
through inhibition of NorA-mediated efflux by the appended INF55 15 component. The
hybrid was shown to accumulate in wild-type, norA-knockout and NorA overexpressing
strains of S. aureus and showed higher antibacterial potency than berberine alone or in
combination with INF55.
A follow-up study investigated the effects of varying the relative orientations of
the berberine and INF55 components by comparing the activities of isomers SS14-O 43,
SS14-M 44 and SS14-P 45 (Figure 1.16).99e The isomers showed surprisingly similar
MICs given their structural differences, which remained almost unchanged across wild-
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type, norA-knockout, and NorA overexpressing S. aureus cells. A important conclusion
from these studies was that berberine-INF55 hybrids are not substrates for NorA,
although ethidium bromide uptake experiments suggested that they might also block the
NorA pump.99e In another study, an SS14 analogue bearing an extended methylene ether
linkage (46, Figure 1.16) was shown to have similar antibacterial properties to the other
hybrids against the S. aureus panel.99d

Figure 1.16 Berberine-INF55 hybrid antibacterials 43-46.99d,e,160a

As mentioned previously, berberine 42 and methylene blue 33 are both
amphipatic cations and thus share similar physicochemical properties. Evidence has
revealed that both are also substrates for NorA efflux pumps in S. aureus, hinting that
an MB-EPI hybrid strategy analogues to the berberine-INF55 approach might be
successfully adapted in aPDT.99a Hybrids formed by linking MB to EPIs may decrease
efflux of the PS, leading to increased intracellular concentrations and therefore
increased microbial cell killing upon illumination. This idea is summarized in Figure
1.17.
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Figure 1.17 Adapting the berberine-INF55 hybrid antibacterial concept to MB-EPI
hybrids for use in aPDT.

1.15 Thesis Aims
This PhD project aimed to synthesise a 16 compound library of MB-EPI hybrids
and explore their potential as agents for use in aPDT. Methylene blue 33 was chosen as
the PS for inclusion in the hybrids, along with the NorA pump inhibitors reserpine 8
(Section 1.6.2.1), pterostilbene 10 (Section 1.6.2.2), INF55 15 (Section 1.6.3.1) and
INF271 16 (Section 1.6.3.2). Four different linkages between the MB and EPI portions
were also incorporated into the target structures, which are shown in Figure 1.18.
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Figure 1.18 Structures of target MB-EPI hybrids. EPI portions are coloured red, linker
regions black and the MB moiety blue.

We hypothesized that MB-EPI conjugates 47-62 might show enhanced aPDT
activity (relative to MB) against S. aureus, which carries the NorA pump. In designing
the hybrids, it was considered important that only minimal modifications be made to the
phenothiazinium core to retain the photochemical properties of MB. In this way hybrids
would be more likely to elicit similar spectral properties to MB and be able to undergo
analogous Type I and Type II aPDT processes. Substituting the N-(CH3)2 group at the
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C-7 position of MB with alkyl linkages appeared to be the best way to maintain these
properties.
At the outset of the project it was not known what effect substituting EPIs with
linker moieties to MB so that they could be attached would have on their NorA
inhibitory activity. It was therefore considered important to prepare a library of MB-EPI
hybrids with different EPIs and linkages to maximise the chances of identifying active
hybrid compounds. The effects of attaching large groups to MB on its photochemical
properties were also unknown, further justifying the need for a library of hybrids.
Additionally, it was considered vital to explore hybrids with a range of physicochemical
properties.
Four classes of hybrids carrying four different EPIs were designed giving a total
of 16 target hybrids. Two examples from each EPI class were tethered to MB via N,N’dimethylethylenediamine linkages. These two differed from each other by incorporating
either alkyl or acyl attachments to the EPI. The other two examples from each EPI class
carried a piperazine linker, one with an alkyl and one with an acyl attachment to the
EPI.

Comparing

piperazine-

versus

ethylenediamine-linked

hybrids

allowed

examination of the effects of rigidifying the linker, while exploring alkyl versus acyl
attachments allowed modulation of physiochemical properties, especially polarity.
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Chapter 2
Synthesis of MB-EPI Hybrids
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2.1 General Synthetic Strategy
The synthetic strategy towards MB-EPI hybrids 47-62 made use of chemistry
reported by Strekowski et al for the preparation of asymmetric MB derivatives.163
Strekowski discovered that reactions of secondary amines with the triiodide salt of N,Ndimethylaminophenothiazinium 63 installed the amine at the 7-position (Scheme 2.1
(a)). Adapting this chemistry to the synthesis of MB-EPI hybrids required that the
requisite

EPI-alkyl/acyl-piperazine

and

EPI-alkyl/acyl-ethylenediamine-based

precursors be independently prepared and then reacted with the triiodide salt 63 in the
final step (Scheme 2.1 (b)).

Scheme 2.1 (a) Strekowski’s chemistry for the synthesis of asymmetric MB derivatives.
(b) Adapting Strekowski’s chemistry to the synthesis of MB-EPI hybrids containing
piperazine and N,N’-dimethylethylenediamine-based linkers.
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2.2 Synthesis of 3-(dimethylamino)phenothiazine-5-ium triiodide 63
Key intermediate 63 was synthesized via an adaptation of Strekowski’s
method.163 In the first step, commercially available phenothiazine 64 was stirred with I2
in wet chloroform at 5 oC for 4 h before being allowed to warm to room temperature.
The resulting dark precipitate was washed with large volume of chloroform until no
yellow washings were obtained. The tetraiodide salt 65 was obtained in 83% yield after
overnight air drying (Scheme 2.2).
The salt 65 was then reacted using Strekowski’s procedure with 2 eq of
dimethylamine to provide 63 in 24% yield. This method involved stirring 65 for 3 h in
MeOH at room temperature.163 Strekowski reported a 24% yield for this reaction while
New and Dolphin reported a 48% yield under the same conditions.164 It was found that
the yield of 63 could be improved to 60% simply by changing the reaction solvent from
MeOH to 15% MeOH in CHCl3. This change also yielded the pure product after simple
filtration.

Scheme 2.2 Synthesis of intermediate 63.
Reagents and Conditions: (a) I2, CHCl3, rt, 4 h, 83%; (b) (CH3)2NH, MeOH/CHCl3, rt, 4
h, 60%.
Carrying out this reaction required preparation of a methanolic solution of
NH(CH3)2 of known concentration. This was achieved by bubbling the gas into MeOH
over several minutes and determining the exact molar ratio of NH(CH3)2 to MeOH by
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1

H NMR. The required volume was then gradually added to a stirring solution of 65 in

15% MeOH in CHCl3 over 4 h at 23 oC. Stirring for a further 1 h at room temperature
gave the desired product as a dark solid. Reaction progress was monitored by thin layer
chromatography (TLC) using a solution containing 3% aqueous NH4OAc(aq) in MeOH
(15:85) as eluent. Under these conditions, the product 63 appeared as a dark spot with Rf
=

0.43. A clear and sharp NMR spectrum was obtained for 63 in DMSO-d6, whereas a

poorer spectrum was obtained in D2O, the NMR solvent reported by Strekowski.
2.3 Synthesis of Reserpine-Containing Intermediates 66, 67, 68 and 69
Selective demethylation of the central methyl ether in the gallic acid portion of
reserpine had been reported previously using Lewis acids (BBr3, AlCl3 and pyridinium
chloride Py-HCl) in a variety of solvents, including petroleum ether and EtOAc/HCl.165
Availability of this phenolic reserpine derivative 70 indicated that MB-EPI hybrids
incorporating reserpine should be obtainable by attaching linker moieties via Oalkylation.
After testing several reported conditions it was observed that AlCl3 in CH2Cl2
provided the best yield of the demethylated reserpine 70. Adding an excess (~ 50 mol
eq) of finely ground AlCl3 in one portion to a stirring solution of reserpine 8 in CH2Cl2
and then stirring for an additional 2 h at room temperature afforded 70 in 95% (lit. yield
47%).165 The structure of 70 was confirmed by 1H NMR and mass spectrometry. The
1

H spectrum showed the central phenolic methyl ether at 3.92 ppm had been lost and a

peak at m/z 595.2671 was observed in the high resolution electrospray mass spectrum
(HRESI-MS) corresponding to the expected C32H38N2O9 [M+H]+ ion for 70.
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Scheme 2.3 Synthesis of reserpine-containing intermediates 66, 67, 68 and 69
Reagents and Conditions: (a) AlCl3, CH2Cl2, rt, 2 h, 95%; (b) 2-bromoethanol, K2CO3,
DMF, 80 oC,16 h, 96%; (c) CBr4/PPh3, THF, rt, 3 h, 91%; (d) 73, Et3N, THF, reflux, 24
h, 80%; (e) Boc2O, Et3N/MeOH, 16 h, 45%; (f) 75, Et3N, THF, reflux, 48 h, 75%; (g)
Bromoacetyl chloride, N,N-diethylaniline, acetone, 0 oC → rt, 16 h, 35%; (h) 76,
K2CO3, DMF, 80 oC, 16 h, 64%; (i) Bromoacetyl chloride, N,N-diethylaniline, acetone,
0 oC → rt, 48 h, 40%; (j) 77, Cs2CO3, DMF, 80 oC, 24 h 70%.
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O-alkylation of 70 with 2-bromoethanol was carried out in the presence of
K2CO3 in DMF with stirring at 80 oC overnight. The desired alcohol 71 was isolated as
a yellowish solid after silica gel column chromatography in 96% yield. The structure of
71 was confirmed by 1H NMR spectroscopy, where two new coupled triplets were
observed at 4.25 and 3.73 ppm (J = 10.0 Hz), corresponding to the new CH2 groups. A
peak at m/z 639.2844 was observed in the HRESI-MS corresponding to the expected
C34H42N2O10 [M+H]+ ion for 71.
Bromination of alcohol 71 was achieved using standard Appel conditions166 with
CBr4/PPh3 in dry THF. Stirring for 3 h at room temperature gave 72 in 91% yield. The
compound showed 99% purity by 1H NMR and the HRESI-MS revealed a peak at m/z
701.2645 corresponding to the expected C34H41BrN2O9 [M]+ ion for 72.
N-Alkylation of N-Boc-piperazine 73 with bromide 72 in dry THF with Et3N at
reflux provided analytically pure 66 in 80% yield after 24 h. The structure of 66 was
confirmed by 1H NMR spectroscopy, where piperazine CH2 peaks were observed as
doublets at 3.41 and 2.56 ppm (J = 8.5 Hz). A peak at m/z 807.4188 was observed in the
HRESI-MS corresponding to the expected C43H58N4O11 [M+H]+ ion for 66.
Analogous chemistry was used to prepare reserpine-containing intermediate 67
bearing

an

N-alkyl-N,N’-dimethylethylenediamine

linker.

N-Boc-N,N’-

dimethylethylenediamine 75 was synthesized from the commercially available N,N’dimethylethylenediamine 74 using literature procedure.167 Briefly, 74 was reacted with
Boc2O in MeOH in the presence of Et3N and after overnight stirring (monitored by
TLC; EtOAc:MeOH:Et3N, 87:10:3; stained with ninhydrin) the product 75 was isolated
in 45% yield after silica gel column chromatography (Scheme 2.3). Reaction of 75 with
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bromide 72 in dry THF in the presence of Et3N at reflux afforded intermediate 67 in
75% (Scheme 2.3). The structure of 67 was confirmed by 1H NMR spectroscopy, where
N-methyl peaks were observed at 2.94 and 2.92 ppm as singlets and CH2 peaks as
triplets at 3.22 and 2.55 ppm (J = 10 Hz). A peak at m/z 809.4369 was observed in the
HRESI-MS corresponding to the expected C43H60N4O11 [M+H]+ ion for 67.
Similar strategies were applied in the synthesis of intermediates 68 and 69,
which carried amide linkages from the piperazine and N,N’-dimethylethylenediamine
groups to the EPIs. Commercially available N-Boc-piperazine 73 and the synthesized NBoc-N,N’-dimethylethylenediamine 75 were coupled to bromoacetyl chloride in the
presence of N,N-diethylaniline to give 76 and 77 in 35% and 40% yields, respectively.
The reactions were carried out by stirring in acetone (0 oC to room temperature) for 16 h
for 76 and 48 h for 77.
Intermediates 68 and 69 were synthesized from phenolic reserpine derivative 70
by O-alkylation with 76 and 77, respectively. The reactions were carried out using
K2CO3 or Cs2CO3 in DMF at 80 oC and provided respective yields of 64% and 70%. A
peak at m/z 821.3987 observed in the HRESI-MS corresponded to the expected
C43H56N4O12 [M+H]+ ion for 68. A peak was similarly observed at m/z 823.4135
corresponding to the expected C43H58N4O12 [M+H]+ ion for 69.
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2.4 Synthesis of Pterostilbene-Containing Intermediates 78, 79, 80 and 81
Intermediates 80 and 81 were synthesized from the commercially available
phenolic pterostilbene derivative 9 by O-alkylation reactions using N-bromoacetyl-N’Boc-piperazine 76 and N-bromoacetyl-N’-Boc-N,N’-dimethylethylenediamine 77,
respectively (Scheme 2.4). The reactions were carried out using K2CO3 in DMF at 80
o

C and gave identical yields of 77%. Intermediate 80 showed a peak at m/z 505.2331 in

the HRESI-MS, corresponding to the expected C27H34N2O6 [M+Na]+ ion. A peak at m/z
507.2486 was observed for 81, corresponding to the expected C27H36N2O6 [M+Na]+ ion.
O-Alkylation of 9 with 2-bromoethanol in the presence of K2CO3 afforded the
phenoxyethyl alcohol 82 in 90% yield after overnight stirring in DMF at 80 oC. The 1H
spectrum of 82 showed two characteristic triplets for the new ethyl group at 4.31 and
3.65 ppm (J = 12 Hz). The Appel reaction was used for bromination of alcohol 82,
where stirring with CBr4/PPh3 in THF for 3 h at room temperature afforded bromide 83
in 94% yield. A peak at m/z 362.0524 observed in the HRESI-MS corresponded to the
expected C18H19BrO3 [M]+ ion for 83 (Scheme 2.4).

53

Scheme 2.4 Synthesis of pterostilbene-containing intermediates 78, 79, 80 and 81
Reagents and Conditions: (a) N-bromoacetyl-N’-Boc-piperazine 76, K2CO3, DMF, 100
o
C, 48 h, 77%; (b) N-bromoacetyl-N’-Boc-N,N’-dimethylethylenediamine 77, K2CO3,
DMF, 80 oC, 24 h, 77%; (c) 2-bromoethanol, K2CO3, DMF, 80 oC, 16 h, 90%; (d)
CBr4/PPh3, THF, rt, 3 h, 94%; (e) N-Boc-piperazine, KI (40 mol %), THF, reflux, 48 h,
87%; (f) N-Boc-N,N’-dimethylethylenediamine, K2CO3, CH2Cl2, reflux, 48 h, 81%.

N-alkylation of N-Boc-piperazine and N-Boc-N,N’-dimethylethylenediamine
with bromide 83 afforded 78 and 79 in 87% and 81% yields, respectively. The 1H
spectrum of 78 showed characteristic CH2 signals for piperazine at 3.43 and 2.65 ppm
and the Boc CH3 group at 1.46 ppm. A peak at m/z 491.4487 observed in the HRESIMS corresponded to the expected C27H36N2O5 [M+Na]+ ion for 78. For compound 79,
the 1H spectrum showed characteristic signals for N-CH3 protons at 2.57 and 2.19 ppm
and Boc CH3 protons at 1.45 ppm. Ethyl CH2 signals were also observed at 3.13 and
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2.43 ppm. A peak at m/z 493.2364 in the HRESI-MS corresponded to the expected
C27H38N2O5 [M+Na]+ ion for 79.
2.5 Synthesis of INF55-Containing Intermediates 84, 85, 86 and 87
INF55 methyl ester derivative 88 was synthesized by Naveen Dolla (PhD
student in the Kelso Group) using the reported method.168 Ester 88 was quantitatively
reduced to the benzylic alcohol 89 using NaBH4 in THF and bromination of 89 using
CBr4/PPh3 in Et2O/THF afforded 90 in 85% yield. The bromination reaction was carried
out by stirring at room temperature for 3 h. Purification was achieved by silica gel
column chromatography (Scheme 2.5).

Scheme 2.5 Synthesis of INF55-containing intermediates 84, 85, 86 and 87.
Reagents and Conditions: (a) NaBH4, THF, rt, 24 h, quant.; (b) CBr4/PPh3, Et2O/THF,
rt, 3 h, 85%; (c) N-Boc-piperazine, KI (45 mol%), THF, reflux, 48 h, 96%; (d) N-BocN,N’-dimethylethylenediamine, KI (50 mol%), THF, reflux, 48 h, 78%; (e) NaOH,
MeOH/CH2Cl2, rt, 30 min, then reflux, overnight, 96% (f) N-Boc-piperazine, HATU,
DIEA, THF, rt, 5 h, 85%; (g) N-Boc-N,N’-dimethylethylenediamine, HATU, DIEA,
THF, rt, 7 h, 78%.
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Bromide 90 was reacted separately with commercial N-Boc-piperazine and NBoc-N,N’-dimethylethylenediamine 75 in anhydrous THF in the presence of KI. After
48 h at reflux the alkylated products 84 and 85 were isolated in 96% and 78% yields,
respectively, after silica gel column chromatography. The 1H spectrum of 84 showed
characteristic CH2 signals for piperazine at 3.30 and 2.33 ppm and a peak at m/z
435.2043 observed in the HRESI-MS corresponded to the expected C24H28N4O4 [M-H]ion. For intermediate 85, the 1H spectrum showed characteristic signals for the ethyl
group at 3.37 and N-CH3 groups at 2.66 ppm and 1.96 ppm. A peak at m/z 437.2180 in
the HRESI-MS corresponded to the expected C24H30N4O4 [M-H]- ion for 85.
Similar strategies were applied in the synthesis of INF55-containing intermediates
86 and 87 containing amide linkages between the piperazine and N,N’dimethylethylenediamine groups and the EPI. INF55 acid derivative 91 was obtained by
hydrolysing 90 with NaOH. The crude acid 91 was coupled to N-Boc-piperazine and NBoc-N,N’-dimethylethylenediamine using HATU with diisopropylethylamine (DIPEA)
as base. Stirring at room temperature in THF for 5 h and 7 h gave the Boc-protected
intermediates 86 and 87 in 85% and 78% yields, respectively. The 1H spectrum of 86
showed characteristic CH2 signals for piperazine at 3.35 and 2.13 ppm and the

13

C

spectrum showed a carbonyl signal at 171.1 ppm. A peak at m/z 449.1826 observed in
the HRESI-MS corresponded to the expected C24H26N4O5 [M-H]- ion for 86. For 87, the
1

H spectrum showed characteristic CH2 signals for the ethyl group at 3.76-3.32 ppm and

N-CH3 signals at 2.76 ppm and 1.67 ppm. The

13

C spectrum showed a characteristic

signal for the amide carbonyl at 174.0 ppm and a peak at m/z 451.1988 observed in the
HRESI-MS corresponded to the expected C24H28N4O5 [M-H]- ion for 87.
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2.6 Synthesis of INF271-Containing Intermediates 92, 93, 94 and 95
Synthesis of INF271-containing intermediates 92, 93, 94 and 95 commenced
with the chlorination of 2-naphthoic acid 96 using thionyl chloride (Scheme 2.6).

Scheme 2.6 Synthesis of INF271-containing intermediates 92, 93, 94 and 95.
Reagents and Conditions: (a) SOCl2, C6H6, reflux, 16 h, 95%; (b) NaN3, 5% HCl, N,Ndiethylaniline, C6H6/H2O, rt, 16 h, 76%; (c) C6H6, reflux, 4 h, quant.; (d) Oaminophenol, CH2Cl2, rt, 48 h, 80%; (e) 3-bromopropanol, K2CO3, DMF, rt, 16 h, 75%;
(f) CBr4/PPh3, THF, 40 oC, 16 h, 85%; (g) N-Boc-piperazine 73, K2CO3, KI (25 mol%),
THF, reflux, 16 h, 85%; (h) N-Boc-N,N’-dimethylethylenediamine 75, K2CO3 KI (30
mol%), THF, 80 oC, 48 h, 85%; (i) N-bromoacetyl-N’-Boc-piperazine 76, K2CO3, DMF,
80 oC, overnight, 66%; (j) N-bromoacetyl-N’-Boc-N,N’-dimethylethylenediamine 77,
K2CO3, DMF, 80 oC, overnight, 80%.
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Thionyl chloride was gradually added to the solution of 2-naphthoic acid in
benzene before stirring the reaction at reflux overnight. Upon consumption of the
starting material (TLC; Pet. Spirit:EtOAc, 50:50) the solvent was evaporated and the
residue used without further purification. The crude acyl chloride was reacted with
NaN3/HCl in a two phase solvent system (C6H6/H2O) using the phase transfer catalyst
N,N’-diethylaniline. After stirring overnight at room temperature the desired acyl azide
was obtained in 76% yield. Quantitative conversion to isocyanate 97 was then achieved
by heating the acyl azide at reflux in benzene for 4 h (Scheme 2.6). These procedures
were based on the method reported by Rineh et al.169
Reaction of 2-naphthylisocyanate 97 with O-aminophenol in anhydrous CH2Cl2
at room temperature for 48 h afforded the substituted urea 98 in 80% yield. Urea 98
formed as a white precipitate that was filtered, dried under reduced pressure and used
without further purification. In cases where O-aminophenol starting material was
observed in the 1H NMR spectrum of the product the mixture was washed with 1 M
HCl. The 1H NMR spectrum of 98 showed characteristic urea NH signals at 9.50 and
8.24 ppm and a peak at m/z 277.0973 observed in the HRESI-MS corresponded to the
expected C17H14N2O2 [M-H]- ion.
O-Alkylation of 98 with 3-bromopropanol was achieved by stirring overnight at
room temperature with K2CO3 in DMF, affording 99 in 75% yield. The 1H NMR
spectrum confirmed alkylation with the appearance of new CH2 signals at 4.27, 3.65
and 1.97 ppm. A peak at m/z 335.1396 observed in the HRESI-MS corresponding to the
molecular formula C20H20N2O3 [M-H]- supported formation of 99. Bromination of 99
under Appel conditions using CBr4/PPh3 in dry THF at 40 oC gave the desired halide
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100 in 85% yield after silica gel column chromatography. The 1H NMR spectrum
confirmed loss of the OH signal at 4.70 ppm and downfield shifting of the CH2OH
signal from 3.65 to 3.80 ppm, consistent with a CH2Br signals. A peak at m/z 397.0552
observed in the HRESI-MS corresponded to the expected C20H19BrN2O2 [M]- ion for
100.
Reaction of N-Boc-piperazine 73 with bromide 100 in the presence of K2CO3
and KI (25 mol%) in anhydrous THF afforded 92 in 85% yield after overnight heating
at reflux (Scheme 2.6). A peak at m/z 505.2834 observed in the HRESI-MS
corresponding to the molecular formula C29H36N4O4 [M+H]+ supported formation of 92.
Intermediate 93 was synthesized by reacting N-Boc-N,N’-dimethylethylenediamine 75
with bromide 100 in the presence of K2CO3 and KI (30 mol%) in dry THF. A yield of
85% was obtained after heating overnight at reflux (Scheme 2.6). A peak at m/z
507.2971 observed in the HRESI-MS corresponded to the molecular formula
C29H38N4O4 [M+H]+ for 93.
Alkylation of N-bromoacetyl-N’-Boc-piperazine 76 and N-bromoacetyl-N’-BocN,N’-dimethylethylenediamine 77 with the phenolic urea derivative 98 in DMF at 80 oC
in the presence of Cs2CO3 gave 94 and 95 in 66% and 80% yields, respectively, after
silica gel column chromatography. The 1H NMR spectra for both compounds showed
the presence of a Boc CH3 group at 1.41 ppm. The 13C NMR spectra showed signals for
the amide carbonyl groups at 166.0 and 168.2 ppm, consistent with formation of 94 and
95, respectively. Additional confirmation of the structures was obtained by HRESI-MS,
which showed peaks at m/z 505.2827 corresponding to the C28H32N4O5 [M+H]+ ion for
94, and m/z 507.2598, corresponding to the C28H34N4O5 [M+H]+ ion for 95.
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2.7 Synthesis of MB-EPI Hybrids
Completion of the synthesis of hybrids 47, 49, 51, 53, 55, 57, 59 and 61 with
piperazine-based linkers and hybrids 48, 50, 52, 54, 56, 58, 60 and 62 with N,N’dimethylethylenediamine-based linkers was achieved using Strekowski’s chemistry.163
The Boc group was quantitatively removed from intermediates 66-69, 78-81, 84-87 and
92-95 using TFA in CH2Cl2 and the crude products were subsequently reacted with
phenothiazinium intermediate 63. Stirring the deprotected amine with 63 at room
temperature for 48-96 h in anhydrous CH2Cl2 provided the target hybrids as dark blue
powders in modest yields (11-30%). Adequate quantities (25-95 mg) were obtained in
all cases for photochemical and biological studies (Chapters 3-4). The quantities of
hybrids produced (mg) and yield’s for the Strekowski reactions are provided in Tables
2.1 and 2.2.
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Table 2.1 Synthesis of hybrids with piperazine-based linkers.
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Table 2.2 Synthesis of hybrids with N,N’-dimethylethylenediamine-based linkers.
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2.7.1 Hybrids with Piperazine-Based Linkers
Synthesis of reserpine-containing hybrids 47 and 49 with piperazine-based
linkers was carried out by deprotecting the Boc groups of intermediates 66 and 68 and
coupling the resulting amine trifluoroacetate salts to the C-7 position of
phenothiazinium precursor 63. Stirring for 72 h and 96 h, respectively, at room
temperature in dry CH2Cl2 gave hybrids 47 and 49 as dark blue powders in 18% and
14% yields after preparative TLC and anion exchange to the chloride salt (Table 2.1,
Entries 1 and 2). Structures of the hybrids were confirmed by HRESI-MS, which
showed a peak at m/z 946.4276 corresponding to the C52H61N6O9S [M]+ ion for hybrid
47 and a peak at m/z 960.4063 corresponding to the C52H59N6O10S [M]+ for hybrid 49.
1

H and 13C NMR spectra for 47 and 49 were of poor quality. At this point it was

noted that other papers describing related asymmetric phenothiazinium salts failed to
report NMR spectra.170 Y. Lu et al reported that changing the counter ion of
phenothiazinium gave better NMR spectra, while J. Jahnchen used a mixture of normal
and deuterium solvent to reduce peak broadening in the phenothiazinium.170a,b The 1H
NMR spectrum of 3-(dimethylamino)phenothiazine-5-ium triiodide 63 was found to be
as expected in DMSO-d6 solution (Figure 2.1A). However, the aromatic region of 47
and 49 showed only broadened phenothiazinium signals in all solvents. The same effect
was noted for all other hybrids, except 51. Figure 2.1B highlights this for a model
compound, which contains only phenothiazine aryl protons for clarity, where the
phenothiazinium peaks were noticeably broadened. Due to this effect, all hybrids except
51 were unable to be completely characterized by NMR spectroscopy. Nevertheless, all
synthesized hybrids showed clean ESI mass spectra that supported their structure and
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purity, as exemplified by the ESI-MS of 50 and 57 shown in Figure 2.2. LRESI-MS for
some selected hybrids are provided in Appendix 2.1.
A

B

Phenothiazinium signals
broadened

Figure 2.1 (A) 1H NMR spectrum of 3-(dimethylamino)phenothiazine-5-ium triiodide
63 in DMSO-d6; (B) 1H NMR spectrum of model asymmetric substituted
phenothiazinium highlighting the broadened aryl signals. Similar spectra with
broadened phenothiazinium signals were observed for all hybrids, except 51.
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A

B

Figure 2.2 LRESI-MS of hybrids 50 and 57
For unknown reasons the 1H NMR spectrum of hybrid 51 was an exception,
clearly showing the phenothiazinium signals in CD2Cl2 (Figure 2.3A). The structure of
this hybrid was supported by its correct in the LRESI-MS (Figure 2.3B).
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A

B

Figure 2.3 (A) 1H NMR spectrum of 51 in CD2Cl2 clearly showing the presence of
phenothiazinium signals (B) LRESI-MS of 51.
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Pterostilbene-containing intermediates 78 and 80 with piperazine-based linkers
were quantitatively deprotected with TFA in dry CH2Cl2 by stirring for 3 h at room
temperature. The crude residues were submitted to reactions with 63. After 72 h stirring
at room temperature in the presence of K2CO3 (0.3 eq and 0.2 eq, respectively) the
hybrids 51 and 53 were isolated in 26% and 30% yields after preparative TLC and anion
exchange (Table 2.1, Entries 3 and 4). A peak at m/z 607.2764 observed in HRESI-MS
corresponding to the molecular formula C36H39N4O3S [M]+ supported formation of 51.
Hybrid 53 was also confirmed using HRESI-MS, where a peak at m/z 621.2546
corresponding to the expected C36H37N4O4S [M]+ ion was observed. 1H NMR spectra
lacking phenothiazine peaks were observed for these hybrids.
Synthesis of INF55-containing hybrids with piperazine-based linkers was initiated
by quantitatively removing the Boc group from intermediates 84 and 86 by stirring with
TFA in dry CH2Cl2 at room temperature for 3 h. The resulting amines were reacted with
63 in the standard way to afford hybrids 55 and 57 in 23% and 22% yields, respectively,
after preparative TLC and anion exchange (Table 2.1, Entries 5 and 6). The structures
were confirmed by HRESI-MS, where a peak at m/z 575.2229 corresponding to the
C33H31N6O2S [M]+ ion for hybrid 55 was observed. A peak at m/z 589.2048
corresponding to the C33H29N6O3S [M]+ ion was observed for 57. The 1H NMR spectra
lacked phenothiazine signals for these hybrids.
Synthesis of INF271-containing hybrids with piperazine-based linkers was
carried out as above to provide 92 and 94 in 25% and 17% yields, respectively, after
preparative TLC and anion exchange resin. A peak at m/z 643.2870 observed in the
HRESI-MS corresponding to the molecular formula C38H39N6O2S [M]+ supported
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formation of 92. Hybrid 94 showed a peak at m/z 643.2508 corresponding to the
expected C37H35N6O3S [M]+ ion. 1H NMR spectra lacking phenothiazine peaks were
observed for these hybrids.
2.7.2 Hybrids with N,N’-Dimethylethylenediamine-Based Linkers
Synthesis of reserpine-containing hybrids 48 and 50 was initiated by removing
the Boc group from intermediates 67 and 69. The secondary amines were then coupled
to the C-7 position of 63 by stirring in the presence of K2CO3 (0.4 eq) at room
temperature for 72 h and 96 h, respectively, giving 48 and 50 in 18% and 11% yields
after preparative TLC and anion exchange. Structures of the hybrids were confirmed
using HRESI-MS, where a peak at m/z 948.4423 corresponding to the C52H63N6O10S
[M]+ ion for 48 was observed, as was a peak at m/z 961.4199 corresponding to the
C52H61N6O10S [M]+ ion for 50. Poor 1H NMR spectra lacking phenothiazine peaks were
observed with these hybrids.
Synthesis of pterostilbene-containing hybrids 52 and 54 carrying N,N’dimethylethylenediamine linkers involved Boc-deprotection of 79 and 81, followed by
coupling of the crude amine TFA salts to 63. Both reactions were stirred at room
temperature for 96 h in the presence of K2CO3 (0.4 and 0.2 eq, respectively) to give 52
and 54 in 14% yields. Structures of the hybrids were confirmed using HRESI-MS,
which showed peaks at m/z 609.2901, corresponding to the C36H41N4O3S [M]+ ion for
52, and at m/z 623.2703, corresponding to the C36H41N4O3S [M]+ ion for 54. 1H NMR
spectra with broadened phenothiazine peaks were observed with these hybrids.
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The Boc-group was quantitatively removed from INF55-containing intermediates
85 and 87 as above before reacting each resulting amine TFA salt with 63. The coupling
reactions were carried out by stirring for 76 h at room temperature in dry CH2Cl2,
giving hybrids 56 and 58 in identical 18% yields. The structures were confirmed using
HRESI-MS, which showed peaks at m/z 577.2400, corresponding to the C33H33N6O2S
[M]+ ion for 56 and m/z 591.2183, corresponding to the C33H31N6O3S [M]+ ion for 58.
INF271-containg hybrid 60 was obtained in 25% yield after stirring at room
temperature in dry CH2Cl2 for 48 h with Boc-deprotected amine 93. A peak at m/z
645.2993 observed in HRESI-MS corresponding to the molecular formula C38H41N6O2S
[M]+ supported formation of 60.
Intermediate 95 carrying an amide linkage was deprotected in the usual way and
then coupled to the C-7 position of 63. Hybrid 62 was obtained in 15% after preparative
TLC and anion exchange and its structure was confirmed using HRESI-MS, where a
peak was observed at m/z 645.2663 corresponding to the C37H37N6O3S [M]+ ion for 62.
A total of 16 MB-EPI hybrids were synthesized in this work. All compounds were
purified by preparative TLC and converted to chloride salts using a Cl- anion exchange
resin. All coupling reactions were carried out in the absence of light to minimize
photodegradation. Hybrids with N,N’-dimethylethylenediamine linkers tended to be
more polar than those with piperazine linkers and more difficult to isolate. More than 35
mg of each hybrid was obtained in pure form for characterization and biological testing.
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Chapter 3
Photophysical Characterization and
In Vitro Photodynamic Activity of
Hybrids against S. aureus
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3.1 UV/Vis Spectrophotometry
The efficiency of aPDT with phenothiazinium PSs is influenced by their UV/Vis
absorption properties across the range of wavelengths applied. In general,
phenothiazinium PSs must exhibit significant light absorption at wavelengths > 630 nm
and show high chemical stability in the presence of visible light. MB shows strong
absorbance in the range 550-700 nm, with an intense maximum at λmax1 = 668 nm and a
shoulder at λmax2 = 609 nm.171
To be an effective photosensitiser a phenothiazinium must be able to reside for a
significant amount of time in the excited triplet state following excitation and
intersystem crossing from the exited singlet state. For MB, the triplet excited state is
sufficiently populated via conversion both radiatively (fluorescence) and non-radiatively
from its relatively long-lived excited singlet state.172 Relaxation is promoted by
structural flexibility in donor-acceptor chromophoric system (i.e. the acceptor being the
cationic nucleus and the donors the auxochromic amino groups), while formation of
twisted intramolecular charge transfer (TICT) complexes between the phenothiazinium
core and amino auxochromes has also been proposed as a relaxation route.173 This
complex allows charge separation and non-radiative relaxation and is particularly strong
with N-aryl and N,N-dialkyl auxochromes.174 For phenothiazinium PSs, benzannelation
and the presence of heavy atoms increase the maximum absorption wavelength, while
modifications at the phenothiazinium side chains tend to have lesser effects.173
When designing hybrids it was considered important to maintain as much of the
structural features of MB as possible, making only minimal changes to one of the
auxochromes. In this way the hybrids would be expected to maintain the photosensitizer
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properties of MB. As discussed in Chapter 1.14, substitution of one of the C-7 N-Me
groups of MB with N-alkyl or piperazinyl linkages was considered the best way to
introduce the linker groups without significantly modifying MB’s core structure and
photophysical properties.
The effects of the structural changes introduced to MB on its absorption
properties were examined by comparing the λmax1 and λmax2 values of hybrids to those of
MB. These two maxima arise from the phenothiazinium chromophore, so it was
predicted that these would be excellent indicators of whether the structural changes
introduced in the hybrids were affecting the absorption properties of the MB portion.
UV/Vis spectra of hybrids 47-62 and MB were recorded at the same
concentration (10 µM) and at the same temperature (23 oC) in methanol. The spectra are
presented in Figure 3.1. For ease of comparison, the spectra were clustered according to
the attached EPI and referred to as, for example, reserpine-containing hybrids (Figure
3.1 (a), compounds 47-50). To facilitate further comparisons between the four different
types of linkages, the following colour scheme has been applied in Figure 3.1:
 red = N-alkyl piperazine (compounds 47, 51, 55, 59)
 pink = N-acyl piperazine (compounds 49, 53, 57, 61)
 light blue = N-alkyl-N,N’-dimethylethylenediamine (compounds 48, 52, 56,
60)
 dark blue = N-acyl-N,N’-dimethylethylenediamine (compounds 50, 54, 58, 62)
This same colour coding system has also been applied in subsequent figures in the
chapter.
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Figure 3.1 UV/Visible absorption spectra of MB 33 and: (a) reserpine-containing
hybrids 47-50, (b) pterostilbene-containing hybrids 51-54, (c) INF55-containing hybrids
55-58 and (d) INF271-containing hybrids 59-62. All spectra were recorded using 10 µM
solutions in MeOH at 23 oC.
74

As shown in Figure 3.1, expected changes in lower wavelength bands (250-400
nm) were observed with the different hybrids. These arise from the different EPIs and
linker groups attached to MB. The key finding was that the λmax1 and λmax2 bands arising
from the MB portion of the hybrids varied only slightly from MB in wavelength and
extinction coefficients across the series. This provided a clear indication that the
absorption properties of the MB chromophore had not been drastically changed by
introduction of the appended linker-EPI structures. A summary of the λmax1, λmax2 and
extinction coefficient (log ε) data for MB and hybrids 47-62 is provided in Table 3.1.
Under the conditions used, MB showed λmax1 = 653 nm and λmax2 = 612 nm. The
respective extinction coefficients for the two maxima were log ε1 = 4.04 and log ε2 =
3.73. To better visualise the results, the λmax data are presented graphically in Figure 3.2
and the log ε data in Figure 3.3.
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Table 3.1 Summary of λmax1, λmax2 and extinction coefficient (log ε) data for MB 33 and
hybrids 47-62.
Compound

λmax1 [nm](log ε)

λmax2 [nm](log ε)

MB

653 (4.04)

612 (3.73)

47

651 (4.05)

609 (3.79)

48

656 (4.02)

616 (3.74)

49

653 (3.97)

610 (3.68)

50

656 (4.00)

614 (3.72)

51

653 (3.84)

615 (3.65)

52

661 (3.93)

613 (3.61)

53

653 (3.91)

612 (3.68)

54

661 (3.95)

610 (3.64)

55

656 (3.91)

613 (3.68)

56

651 (3.91)

611 (3.69)

57

650 (3.86)

609 (3.66)

58

659 (3.82)

613 (3.48)

59

655 (3.88)

611 (3.62)

60

659 (3.97)

614 (3.63)

61

652 (3.96)

610 (3.68)

62

656 (4.05)

611 (3.74)
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In Figure 3.2, the λmax1 and λmax2 values for MB were subtracted from the
corresponding values in the hybrids and the differences plotted. All hybrids except 53
showed varying bathochromic (red) or hypsochromic (blue) shifts at both λmax1 and
λmax2, but the changes were all only small (< 7 nm) and the overall appearance of the
bands remained unchanged. No obvious trends were observed with respect to the
different EPI-linker groups attached. For instance, hybrids with piperazine-based linkers
(red/pink bars) showed no clear trends that distinguish them from N,N’dimethylethylenediamine-based linkers (light blue/dark blue bars).

10

Δλmax (nm)

5
Δλmax1
Δλmax2
0

-5
47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62

Figure 3.2 λmax1 and λmax2 data for hybrids 47-62 relative to MB. λmax1 and λmax2 values
for MB were subtracted from the corresponding values for hybrids. Colour coding: red
= N-alkyl piperazine linker, pink = N-acyl piperazine linker, light blue = N-alkyl-N,
N’-dimethylethylenediamine linker, dark blue = N-acyl-N,N’-dimethylethylenediamine
linker.
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The extinction coefficients at λmax1 and λmax2 for 47-62 were compared to the
equivalent values for MB by subtracting the log ε values for MB from the log ε values
for hybrids at the respective maxima and plotting the differences (Figure 3.3).
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Figure 3.3 Extinction coefficient data for hybrids 47-62 at λmax1 (i.e. log ε1) and λmax2
(i.e. log ε2). Log ε values for MB (i.e. log ε1 = 4.04, log ε2 = 3.73) were subtracted
from the log ε values at the respective maxima of hybrids. Colour coding: red = N-alkyl
piperazine linker,
pink = N-acyl piperazine linker, light blue = N-alkyl-N,N’dimethylethylenediamine linker, dark blue = N-acyl-N,N’-dimethylethylenediamine
linker.
Extinction coefficient of the hybrids were mostly lower than MB at both λmax1
and λmax2, although the differences were all small (Δlog ε < ± 0.25). The highest Δlog ε
values were observed with INF55-containing hybrid 58 (Δlog ε1 = 0.24, Δlog ε2 = 0.21).
INF271-containing hybrid 62 closely matched MB showing a Δlog ε1 deviation of
almost zero. Minimal Δlog ε changes were also observed in two of the reserpinecontaining hybrids 48 and 50.
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In summary, the λmax and log ε data confirmed that introduction of the various
linker groups and EPIs to the C7-position of MB to create hybrids 47-62 had only a
minor impact on the UV/Vis absorbtion properties of the MB chromophore.
3.2 Measurement of 1O2 and •OH Production by Hybrids
As described in Chapter 1.9, when PSs are illuminated with appropriate
wavelengths of light they can produce various types of ROS, including singlet oxygen
(1O2), superoxide radical anion, hydrogen peroxide and hydroxyl radical (•OH).
Production of these ROS by PSs can be probed experimentally by monitoring the
fluorescence emitted by fluorescence-based ROS scavengers. Two such probes, singlet
oxygen sensor green (SOSG) and 3’-p-(hydroxyphenyl) fluorescein (HPF), can be used
for the selective detection of 1O2 and •OH, respectively. Both probes are cell-permeable,
relatively insensitive to superoxide and nitric oxide and they are resistant to autooxidation processes.175
The SOSG probe shows high selectivity for singlet oxygen and is water soluble
at mM concentrations. The structure of the probe has not been released by the
commercial supplier (Invitrogen) but it is believed to be a bichromophoric molecule
incorporating a photoinduced electron transfer (PET) design, comprising a dimethyl
anthracene moiety attached to fluorescein (Figure 3.4).
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Figure 3.4 SOSG fluorescence only in the presence of 1O2 after forming SOSG - EP.
Photoelectron transfer processes normally quench the fluorescein emission from
the SOSG molecule. In the presence of singlet oxygen, the anthracene moiety forms an
endoperoxide (SOSG-EP) that disrupts the p-dimethylaryl conjugated system, allowing
the photoexcited fluorescein derivative to relax via fluorescence. The reaction is
irreversible and the fluorescence signal proportional to the singlet oxygen concentration
in solution.176
The HPF probe was developed by Setsukinai et al as a tool for stable and
selective detection of •OH.177 Although a related 3′-p-(aminophenyl) fluorescein (APF)
probe produces ~ 5-fold more fluorescence than HPF in the presence of •OH, HPF is
substantially less sensitive to 1O2, thus making it more selective for •OH and better
suited for use in our experiments.175 In the presence of •OH, the non-fluorescent HPF
molecule is oxidized to produce a bright green fluorescent product, with a molecule of
p-benzoquinone being lost in the process. This chemistry is summarized in Figure 3.5.
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Figure 3.5 Reaction of HPF with •OH produces a green fluorescent molecule.
Cell-free measurements of 1O2 and •OH were performed with the hybrids and
probes in 96-well plates, as summarized in Figure 3.6. Solutions containing hybrids 4762 and the SOSG (1 µM) and HPF (1 µM) probes were prepared in phosphate-buffered
saline (PBS, pH 11). D2O was added to increase the life-time and stability of the
generated •OH and 1O2.178 It is known that the relative lifetime of 1O2 in the presence of
D2O is 35 times longer than in H2O.179 It is also known that the SOSG and HPF probes
are stable in the presence of cells and that there are no significant differences between
the amounts of ROS generated by phenothiazinium PSs in the presence or absence of
cells.175 Thus, the 1O2 and •OH measurements obtained here were directly transferable
to the cell-based aPDT experiments described later in this Chapter.
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Step 1:

Hybrids and MB added to wells
to a concentration of 50 µM
in PBS. Well volume = 85 µL

Step 2:

40 µL probe (5 µM), 40 µL
D2O and 35 µL MeOH
added to each well

Red light source

Step 3:

10 µM hybrid and MB solutions
illuminated with red light (652 nm)
2
at 0, 2, 4, 6, 8, 10 and 12 J/cm
before transfer to plate reader

Figure 3.6 Schematic representation of cell-free experiments for the measurement of
1
O2 and •OH from hybrids upon illumination with red light.

The final assay solutions containing 10 µM hybrids in a total volume of 200 µL
were illuminated with red light (652 nm) at fluences of 0 to 12 J/cm2. A microplate
spectrophotometer was employed for detecting fluorescence from SOSG using the
“slow kinetic” mode, with fluorescence emission at 505 nm measured following
excitation at 525 nm (2 nm monochromator band pass). For HPF, fluorescence emission
was measured at 525 nm after excitation at 492 nm (2 nm monochromator band pass).
The effectiveness of hybrids in aPDT was expected to be influenced by the
efficiency of 1O2 and/or •OH production following illumination. The experiments
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described were not able to quantitative 1O2 and •OH production but they allowed direct
comparison of the ROS-producing efficiencies of the hybrids to MB.
3.2.1 Reserpine-Containing Hybrids
Figure 3.7 shows the relative fluorescence produced by MB and reserpinecontaining hybrids 47-50 in the presence of SOSG and HPF. In these experiments, a
noncoherent light source with 30 nm-band-pass filters at ranges of 652 ± 15 nm were
used for illumination. The total power output provided from the fibre bundle was 300
mW. The plates were arranged to give an irradiance of 100 mW/cm2. The power (P) in
watts was equal to the energy (E) in joules, divided by the time period (t) in seconds:

P(W) = E(J) / t(s)

So
Watt/cm2 = joule/cm2 per second
Therefore a 30 second illumination with irradiance of 100 mW/cm2 over a 3 cm2 area
gave a fluence of 1000 mJ/cm2 or 1 J/cm2. Fluences were increased by extending the
period of illumination.
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Figure 3.7 Comparison of (A) 1O2 and (B) •OH production by reserpine-containing
hybrids 47-50 to MB upon illumination with red light (652 nm). Light with power
output 300 mW was applied 0.5-5.0 min for (1O2) and 0.5-6.0 min for (•OH),
respectively.

In all cases the reserpine-containing hybrids showed significantly lower levels of
1

O2 and •OH production than MB. Indeed, all hybrids except 48 showed very little •OH

production. Although much less than MB, the four compounds did produce significant
1

O2, with 47 producing the highest levels.
Figure 3.7(A) shows data point for 1O2 production from MB after being

formulated in cremophore EL® (CrEL). For later cell-based in vitro and in vivo
experiments it was necessary to identify a suitable aqueous formulation for the hybrids
as they were not sufficiently water soluble and organic solvents suitable for the hybrids
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(MeOH and CH2Cl2) are unsuitable for biological experiments. Identifying a
formulation that did not suppress ROS production was therefore considered crucial. As
shown in Figure 3.7(A), the data for 1O2 production by MB in CrEL tracked closely
with the data for MB in the PBS/MeOH mixture, confirming that CrEL was an excellent
formulation for the later in vitro and in vivo experiments.
Photobleaching is the process whereby photosensitizers decompose during exposure to
light. The degree of decomposition usually depends on the light intensity and period of
illumination. As the release of 1O2 was measured over a period of 0.5-5.0 min, the 1O2
experiments were able to provide information about photobleaching of hybrids. As
shown in Figure 3.7, at fluences of more than 6 J/cm2 MB showed signs of
photobleaching, as evidenced by the flattening of the curve. The reserpine-containing
hybrids on the other hand showed no evidence of photobleaching at fluences up to 10
J/cm2.
3.2.2 Pterostilbene-Containing Hybrids
1

O2 and •OH production by pterostilbene-containing hybrids 51-54 is shown in

Figure 3.8. As observed with the reserpine-containing compounds, the pterostilbenebased hybrids all showed very little •OH production but they also showed very little 1O2
production. Only hybrid 52 produced significant 1O2 but it was markedly less than MB.
No photobleaching effects were evident with 52.
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Figure 3.8 Comparison of (A) 1O2 and (B) •OH production by pterostilbene-containing
hybrids 51-54 to MB.

3.2.3 INF55-Containing Hybrids
1

O2 and •OH production by INF55-containing hybrids 55-58 compared to MB is

shown in Figure 3.9. Once again, these hybrids all showed very little •OH production
under the experimental conditions. Importantly, while still less than MB, all INF55containing hybrids showed robust 1O2 production. For example, at 10 J/cm2 55
produced 83% of the 1O2 produced by MB at the same fluence.
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Figure 3.9 Comparison of (A) 1O2 and (B) •OH production by INF55-containing
hybrids 55-58 to MB.
3.2.4 INF271-Containing Hybrids
1

O2 and •OH production by INF271-containing hybrids compared to MB is

shown in Figure 3.10. As observed with the other three classes, these hybrids produced
essentially no •OH, although 60 showed evidence of slight •OH production at high
fluence. Hybrids 59 and 61 showed minimal 1O2 production relative to MB even at high
fluence. At 4 J/cm2 60 showed strong 1O2 production, however, the 1O2 did not increase
with application of higher fluence, suggesting that photobleaching was occurring. 1O2
production from 62, on the other hand, steadily increased with higher fluence, indicating
the compound is more photostable than 60. At 10 J/cm2 62 produced 86% of the 1O2
produced by MB at the same fluence.
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Figure 3.10 Comparison of (A) 1O2 and (B) •OH production by INF271-containing
hybrids 59-62 to MB.

3.2.5 Quantum Yields of 1O2 and •OH Production by Hybrids 47-62
While the above analysis provided qualitative comparisons between 1O2 and
•OH production by hybrids 47-62 relative to MB a more quantitative treatment was
possible based on fluorescence quantum yields. Fluorescence quantum yield is defined
as the ratio of the number of photons emitted from a fluorophore to the number of
photons absorbed. Relative fluorescence quantum yields in the SOG and HPF assays
can be determined by comparing the observed fluorescence for hybrids to MB, which
produces a known quantum yield (ΦΔ (SOG) = 0.52, ΦΔ (HPF) = 0.46) under the
experimental conditions. The quantum yields for hybrids in each assay relative to MB
are then calculated using the equation:

88

Int
ΦΔ = ΦΔMB X

IntMB

-AMB

X

1-10

X
-A

1-10

n
nMB

2

2

Where Int is the area under the emission curve (on a wavelength scale), A is
optical density at the excitation wavelength and n is the refractive index of the solvent.
The subscript MB refers to the respective values for methylene blue. Since the same
energies of light and the same solvent etc. were used for MB and the hybrids the relative
quantum yields could be obtained by measuring the area under the fluorescence curves
(Figures 3.7-3.10) and dividing by the area under the MB curve. For each fluorescence
curve a best-fit trendline was obtained using polynomial regression and the relative
integration calculated over the appropriate fluence range (0-10 J/cm2 for SOG and 0-12
J/cm2 for HPF). The fluorescence quantum yields for hybrids 47-62 relative to MB in
the SOG and HPF assays are provided in tabular form in Appendix 3.1. The data are
presented in graphical form in Figure 3.11 where % ΦΔ relative to MB is presented for
hybrids in both assays. The data are colour-coded as described earlier (Chapter 3.1)
based on the different linker types.
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Figure 3.11 Changes in SOG and HPF % quantum yields for hybrids 47-62 relative to
MB.

Reserpine-containing hybrids 47-50 showed 1O2 and •OH quantum yields at
around 20-55% of MB. Hybrid 48 showed the highest •OH production at around 55%,
while 47 produced the most 1O2 (46%). Pterostilbene-containing hybrids 51-54 all
showed very low 1O2 and •OH quantum yields (less than 20% relative to MB).
INF55-containing hybrids 55-58 showed much higher 1O2 quantum yields than
•OH. 1O2 production for 55 at 65% relative to MB was the highest of all the compounds
tested. Hybrid 58 also showed strong 1O2 production at about 60% of MB and showed
the strongest •OH production in this series at ~ 30 of MB.
INF271-containing hybrid 62 produced the third highest amount of 1O2 relative
to MB. Hybrid 60 produced reasonable •OH and 1O2 quantum yields, although the 1O2
generation of this hybrid reduced after 6 J/cm2 (Figure 3.11), suggesting photobleaching
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was occurring with this compound. The significantly higher 1O2 quantum yields relative
to •OH quantum yields in the INF55 and INF271-containing hybrid series suggested
that these compounds would likely undergo Type II processes when applied in PDT
(See Chapter 1.9).
3.3 In Vitro Antibacterial Photodynamic Activity
3.3.1 Formulation Vehicle for Hybrids
In the above cell free experiments the hybrids were all significantly soluble in
the aqueous PBS/MeOH solutions. For cell-based in vitro and in vivo aPDT
experiments, MeOH was unsuitable as a co-solvent due to its toxicity. It was therefore
necessary to identify a formulation vehicle that was both non-toxic and capable of
solubilizing the hybrids. Other than MeOH, the best solvents for dissolving the hybrids
were found to be CH2Cl2 and CHCl3, but these are not miscible with water and were
thus unsuitable. A range of commercially available detergents were explored as
formulation vehicles for the hybrids.
Encapsulation of reserpine-containing hybrid 49 into micelles was examined,
using the detergents tween 60 (T60), cremophor EL (CrEL), triblock copolymers F127
(PL-F127) and poloxamer 388 (POL388). Hybrid 49 was chosen as a representative
hybrid for solubility examinations because it was observed to be particularly insoluble
in aqueous solution. Micellar solutions of 49 were prepared by initially dissolving the
compound in CH2Cl2 at 2-3 mM. This solution was added to a 100 mg/mL solution of
each detergent in CH2Cl2 and the combined mixtures were sonicated until a
homogenous solution was obtained. The organic solvent was then removed under
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reduced pressure and the remaining thin film of 49 was redissolved in PBS to create a
homogenous 500 µM aqueous micellar solution of the compound.
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Figure 3.12 Fluorescence emission spectra of hybrid 49 formulated in micelles
generated with tween 60 (T60), cremophor EL (CrEL), triblock copolymers F127 (PLF127) and poloxamer 388 (POL388). Spectra recorded in PBS and MeOH are shown
for comparison.

Figure 3.12 shows the fluorescence emission spectra of hybrid 49 in 10 µM
micellar solutions. The equivalent spectrum of 49 in PBS and MeOH is shown for
comparison. A large increase in the emission intensity at 680 nm was observed for 49
when encapsulated in CrEL and T60 (excitation at 600 nm) compared to the other
micelles, PBS and MeOH.
The increased fluorescence observed with CrEL and T60 suggests that these
detergents minimise aggregation and are excellent solubilisers for 49. CrEL is widely
used as a formulation or drug delivery vehicle for many poorly water-soluble drugs180
and is generally considered to be nontoxic.181 As described on 3.2.1, CrEL was also
found to have no effect on 1O2 production from MB. Based on this, CrEL was chosen as
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the vehicle for formulating the hybrids in all cell-based experiments (Chapter 3) and in
vivo studies (Chapter 4).
3.3.2 Preliminary aPDT Screening of Hybrids against MRSA USA300
MRSA USA300 was chosen as a model Gram-positive organism for preliminary
screening of hybrids for aPDT activity. USA300 is a major source of communityacquired MRSA infections in the USA, Canada, and Europe182 and is responsible for
major skin and soft-tissue infections,183 community-acquired pneumonia and catheterrelated bloodstream infections.184 The strain is isogenic with wild-type MRSA making it
a good test organism for preliminary screening.
Increasing concentrations of CrEL-formulated hybrids (1-20 µM in PBS) were
incubated for 30 min in the dark at room temperature with suspensions of USA300 cells
(108 CFU/mL). Aliquots were transferred to 96-well plates and illuminated with red
light (652 nm) at a fluence of 6 J/cm2. Remaining colonies were counted after overnight
growth and the results plotted as survival fractions at the different concentrations. Dark
controls (same procedure without application of red light) were included in all
experiments. No significant dark toxicity was observed with any of the hybrids or MB
over the concentration range and fluences tested. No differences in dark toxicity of MB
were observed when formulated in CrEL compared to PBS/MeOH (Appendix 3.2).
Figure 3.13 shows the photodynamic killing of MRSA USA300 by hybrids 4762, grouped according to the attached EPI (e.g. reserpine-containing hybrids etc.). Also
shown for comparison is the photodynamic killing by MB under identical conditions.
MB showed a dose dependent effect over the concentration range 0-20 µM, producing a
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~ 2-log reduction in cell viability at the highest concentration. When MB was
formulated in CrEL an additional 1-log killing of cells was observed at the highest
concentration (Figure 3.13(A)), suggesting that CrEL potentiates the photodynamic
activity of MB. This funding further supported for its use as a formulation vehicle for
exploring the aPDT effects of hybrids.
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Figure 3.13 Photodynamic inactivation of MRSA USA300 by hybrids 47-62. Cells (108
CFU) were incubated for 30 min with CrEL-formulated hybrids at 0-20 µM in PBS and
illuminated with 652 nm light (100 mW/cm2, fluence = 6 J/cm2). Aliquots were
removed from the suspensions after light delivery and CFUs determined after overnight
growth in a 37 oC incubator. The remaining cells were plotted as survival fractions.
Data represent the mean of 3-5 independent experiments ± SEM.

Reserpine-containing

hybrids

47-50

showed

very

little

photodynamic

inactivation, except for hybrid 50, which produced a 2-log reduction in cells at the
highest concentration (20 µM, Figure 3.13(B)). Similarly, none of the pterostilbenecontaining hybrids 51-54 showed significant photodynamic activity (Figure 3.13(C)).
More encouraging results were obtained with INF55-containing hybrids, where
compound 58 showed a very strong dose-dependent effect and produced a 6-log
reduction in cells at 20 µM. This represented a 3-log increase in killing relative to MB
(formulated in CrEL) at the same concentration. Hybrid 56 also showed good dose-
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dependency and a 3-log reduction in cells at 20 µM. Hybrids 55 and 57 showed only
slight activity (Figure 3.13(D)).
INF271-containing hybrids 59, 60 and 62 all showed dose-dependent killing,
whereas no activity was observed with 61 (Figure 3.13(E)). At 20 µM, 60 produced a 4log reduction in cells, or 1-log greater than MB (in CrEL). Hybrid 59 showed killing
equivalent to MB (in CrEL) while a 2-log kill was observed with 62.
To facilitate comparisons between the compounds, the data presented in Figure
3.13 were combined into a single figure (Figure 3.14). In this analysis, the 20 µM data
points for each compound were expressed as the log reduction in survival. Hybrids 5658 carrying INF55-based EPIs were clearly active compounds, especially 58, which
showed 3-log greater activity than MB in CrEL. INF271-containing hybrids 59 and 60
were clearly active and 62 also showed some effect. The only other active hybrid 50
(containing an appended reserpine) produced an equivalent effect to MB (in CrEL).
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Figure 3.14 Summary of photodynamic inactivation of MRSA USA300 by MB (in PBS
and CrEL) and hybrids 47-62.

Examples from each of the four different linker classes were found to show
activity, suggesting that the structure of the linker may not be crucial. It was noted,
however, that except for 59, which contained a piperazine-based linker, hybrids that
showed the greatest photodynamic inactivation carried N,N’-dimethylethylenediaminebased linkers. As might be expected, active compounds 56, 58, 60 and 62 were strong
producers of 1O2 (Figure 3.11) but, surprisingly, hybrid 55, which was the strongest 1O2
producer (Figure 3.9), showed no photodynamic activity. This observation suggests that
strong 1O2 production is not on its own sufficient to create hybrids with potent aPDT
activity.
3.3.3 Photodynamic Activity of Hybrids against S. aureus Mutants
The above experiments indicated that four hybrids, including two from the
INF55-containing series (56 and 58) and two from the INF271-containing series (59 and
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60), showed the strongest photodynamic inactivation of MRSA USA300. Based on this,
these compounds were advanced to further study of their photodynamic effects against a
panel of S. aureus strains. To examine whether the photodynamic effects of the chosen
hybrids were being influenced by the NorA pump, their aPDT activities were examined
in NorA knockout (NorA-), wild-type (WT) and NorA-overexpressing (NorA++) S.
aureus cells. These strains respectively contain none (or reduced), basal and elevated
levels of the NorA pump. MB was included in the experiments for comparison. Tegos et
al showed that the aPDT activity of MB varies against NorA knockout (K1758), wildtype (8325-4) and NorA-overexpressing (K2361) S. aureus cells, where higher NorA
expression reduced activity.154 As explained in Chapter 1.12, this is consistent with MB
being a NorA substrate.
In the current experiments, the same three S. aureus strains were incubated with
the four hybrids (formulated in CrEL) or MB at 20 µM for 30 min before centrifuging
and washing to remove compound not taken up into or bound to cells. The cells were
then re-suspended in sterile PBS and transferred to 96-well plates and illuminated with
652 nm red light of increasing fluence (0-16 J/cm2). These solutions were serially
diluted from 10-1-10-6 to facilitate final CFU counts. Cells were then incubated
overnight before performing and determining survival fractions. A summary of the
assay is provided in Figure 3.15. The phototoxicity results are shown in Figure 3.16.
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Figure 3.15 Schematic summary of aPDT assay using NorA-, WT and NorA++
S. aureus cells.

If our hypothesis was correct and the attached NorA inhibitors (INF55 for 56
and 58 and INF271 for 59 and 60) in the hybrids were blocking the NorA pump, thereby
increasing intracellular concentrations of the attached MB PS and producing increased
phototoxicity (Chapter 1.14), the following observations would be expected from these
experiments: (1) hybrids should show higher relative phototoxicity compared to MB in
the wild-type and NorA++ strains due to the presence of the NorA pump and (2) no
change in phototoxicity relative to MB in the NorA- strain.
In agreement with the Tegos study,154 the NorA- strain showed more than 4-log
units of killing in the presence of MB at the maximum fluence 16 J/cm2, while the wildtype and NorA++ strains showed ~ 2 log lower killing (Figure 3.16 (A)). Phototoxicity
against the NorA- strain for the four hybrids was very similar to MB, where they all
produced cell kills within 1 log unit of MB at 16 J/cm2. For the wild-type strain, where
MB produced a 2 log kill at 16 J/cm2, hybrids 56, 58 and 59 all showed more than 1 log
greater killing than MB, while 60 showed equivalent killing to MB. Excitingly, all four
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hybrids showed greater killing at 16 J/cm2 than MB against the NorA++ strain.
Collectively these results were in agreement with the proposed hypothesis. A graphical
summary of the results is provided in Figure 3.17.
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Figure 3.16 Photodynamic inactivation of NorA knockout (NorA-), wild-type (WT),
and NorA-overexpressing (NorA++) S. aureus strains by: (A) MB, (B) 56, (C) 58, (D)
59 and (E) 60. All compounds were present at 20 µM. Data represent the mean ± SEM
from three independent experiments.
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Figure 3.17 Summary of photodynamic inactivation of NorA knockout (NorA-), wildtype (WT) and NorA-overexpressing (NorA++) S. aureus strains by MB and hybrids
56, 58, 59 and 60.
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3.3.4 Concentration-Dependence of Hybrid Phototoxicity
Three hybrids from the S. aureus mutant aPDT experiments, two INF55containing hybrids 56 and 58 and one INF271-containing hybrid 60, were advanced to
dose-response studies. In these experiments, photodynamic inactivation by each
compound was measured at increasing concentrations (0-160 µM) against the S. aureus
panel (i.e. K1758 NorA-, 8325-4 WT and K2361 NorA++) at a constant fluence of 10
J/cm2. MB was also included in the experiments for comparison.
Solutions of CrEL/PBS-formulated hybrids (0-160 µM) were incubated for 30
min in the dark with S. aureus cells (108/mL) at room temperature. The cells were
centrifuged and washed before being resuspended in PBS and illuminated with 10 J/cm2
red light. The centrifuge/washing step served to remove hybrid molecules not contained
within the cells or adhered to their surfaces. CFUs were counted after overnight growth
and the survival fractions determined. Plots of survival fractions versus concentration as
shown in figure 3.18. Dark control experiments were also performed where an identical
procedure was followed without application of light. These dark toxicity data are
provided in Appendix 3.3.
Surprisingly, MB showed evidence of dark toxicity, especially against the
NorA- and NorA++ strains, where it reduced the survival fractions in a dose-dependent
manner up to a maximum of 3-4 logs at 160 µM. The three hybrids 56, 58 and 60 all
showed lower dark toxicity than MB, reducing the survival fractions by a maximum of
2 log units at 160 µM. In most instances, however, only 1 log reductions were observed
in the dark with the hybrids at this high concentration.
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When the light was applied, MB at 80 µM provided a 7 log kill against the
NorA- strain that did not increase as the concentration was raised to 160 µM. MB
produce similar results against the WT and NorA++ strains, where ~ 5-7 log kills were
observed at 80 µM.
INF271-containing hybrid 60 produced more than 3 log units of killing at 40 µM
against the NorA- strain and 4 logs at 80 µM. Increased killing was not observed as the
concentration was raised to 160 µM. Similar results were obtained against the WT strain
but the NorA++ strain showed higher sensitivity, experiencing a 5 log kill at 80 µM and
7 log at 160 µM.
INF55-containing hybrids 56 and 58 showed very strong and dose-dependent
phototoxicity against all three S. aureus strains (Figure 18(C) and 18(D), respectively).
At 20 µM 56, a 5-log kill was observed against the NorA- strain essentially complete
eradication was observed at 80 µM. The WT strain showed a 5-log kill at 80 µM and 6log kill at 160 µM. The NorA++ strain showed an impressive 4-log kill at 20 µM and
total eradication at 40 µM. Hybrid 58 produced similar results to 56 but with almost
complete eradication of the NorA- strain occurring at 40 µM.
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Figure 3.18 Concentration-dependent phototoxicity of (A) MB and hybrids (B) 60, (C)
56 and (D) 58 against S. aureus NorA knockout (NorA-), wild-type (WT) and NorAoverexpressing (NorA++) strains. Data represent the mean ± SEM from 3-4
independent experiments.
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3.4 Cell Uptake Studies with Hybrids 56, 58 and 60
Hybrids 56 and 58 showed significantly enhanced cell-killing potency against
the NorA- and NorA++ S. aureus strains relative to MB, but similar killing to MB
against the WT strain. These results conflicted with our design hypothesis, where
hybrids would have been expected to produce stronger activity against the WT strain
(rather than the NorA- strain) relative to MB.
The role of the NorA pump in the observed activity of hybrids was further
probed by measuring the uptake of 56, 58, 60 and MB into the NorA-, WT and NorA++
S. aureus cells.
Fluorescence versus concentration calibration curves were obtained by
measuring the fluorescence of the hybrids and MB across a concentration range (0-3
µM) in the presence of sodium dodecyl sulfate (SDS). To measure compound uptake
into cells, 108 CFUs were incubated for 30 min with 20 µM hybrids or MB. The cells
were centrifuged and washed to remove compound not bound to or taken up into cells
and then redissolved in PBS and digested in SDS overnight. The fluorescence of digest
solutions was measured and the concentrations of hybrids and MB determined from the
calibration curves. The uptake results for hybrids 56, 58 and 60 are summarized in
Figure 3.19, with MB included for comparison.
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Figure 3.19 Uptake of MB and hybrids 56, 58 and 60 (molecules per cell) by S. aureus
NorA knockout (NorA-), wild-type (WT) and NorA-overexpressing (NorA++) strains.
Data represent the mean ± SEM from 3-4 independent experiments.

Figure 3.19 shows that uptake of hybrids 56, 58 and 60 by all three S. aureus
strains was significantly higher than MB. As expected, MB uptake was greatest in the
NorA- strain and least in the NorA++ strain, in alignment with it being a NorA
substrate.154 Approximately 4.7 ± 0.3 x 109 molecules of INF55-containing hybrid 56
were taken up per cell by the NorA- strain, or 1.3 times more than MB. Uptake of 56
into the other two strains did not differ appreciably (4.6 ± 0.2 x 109 and 4.3 ± 0.2 x 109
molecules/cell for WT and NorA++ strains, respectively). The other two hybrids 58 and
60 showed uptake levels essentially identical to those of 56 across the three strains.
Observing that 56, 58 and 60 show identical uptake across the three S. aureus strains,
despite their differences in NorA expression, suggested that unlike MB, these hybrids
are not substrates for the NorA pump. The question of whether the hybrids were also
serving to block was addressed next.
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3.5 EPI Activity of Hybrids
The NorA pump inhibitory activity of INF55 and INF271 is well characterized 98
but it was unknown whether they retained this activity when part of the hybrids. The
effects of the structural changes introduced through incorporation within hybrids on
NorA activity were explored by measuring the photodynamic inactivation of S. aureus
by MB in the presence of INF55, INF271 and various INF55-containing (84-87) and
INF271-containing (92-95) synthetic intermediates that contained just the attached
linker groups and no MB moiety. It was reasoned that if the modified EPIs in the
synthetic intermediates produced equivalent activity to their parent EPIs then it could be
inferred that the structural changes introduced had not significantly impacted their NorA
inhibitory effects. NorA++ cells were used for these experiments to maximise the
observed differences in photodynamic cell killing by the various MB/EPI treatments.
NorA++ S. aureus cells were treated with 10 µM INF55/INF271 or 84-87/92-95
and 20 µM solutions of MB added before incubation for 30 min. Cells were then
illuminated with increasing fluences of red light (0-16 J/cm2) and survival fractions
determined (as described in Chapter 3.3.2).
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Figure 3.20 Photodynamic inactivation of NorA++ S. aureus cells by MB alone and in
combination with INF55, INF271, INF55-containing synthetic intermediates 84-87 and
INF271-containing intermediates 92-95. Data represent the mean ± SEM from 3-4
independent experiments.
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Figure 3.20 shows that MB produced approximately 2-log units of killing in the
absence of EPIs at the maximum fluence of 16 J/cm2. As expected, introduction of
INF55 and INF271 greatly increased cell killing. At 16 J/cm2 an additional 4 log units
of killing were observed with both EPIs. Similar cell kills were observed with the EPI
derivatives compared to their parent EPIs, suggesting that the derivatives all retained
their ability to block the NorA pump. These results imply that at least some of the
increased uptake of 56, 58 and 60 relative to MB (Figure 3.19) arises from the ability of
the appended EPI structures in the hybrids to inhibit the NorA pump, rather than simply
because the hybrids are not substrates from the pump.
To support these findings, the pump inhibitory activities of hybrids 56, 58 and
60 were examined in experiments where they were co-administrated with the antibiotic
ciprofloxacin, a well-known NorA substrate.31c,185 In these experiments, the
antibacterial activity of ciprofloxacin was measured (in the dark) and compared to its
activity in the presence of MB or the hybrids. A bioluminescent S. aureus strain126b was
used in these experiments, with the level of bioluminescence observed being
proportional to the number of surviving cells after treatment. Use of the bioluminescent
strain eliminated problems that arise from the deep blue colour of the hybrids and MB
interfering with UV/Vis microplate readings.
Bioluminescence of S. aureus (100 µL of 106 CFU/mL MRSA USA300) was
measured after overnight incubation of the cells in the dark with the increasing
concentrations of ciprofloxacin, either alone or in the presence of MB (20 µM) or
hybrids (10 µM). Bioluminescence versus [ciprofloxacin] curves are shown in Figure
3.21. Ciprofloxacin alone showed dose-dependent cell killing above 0.004 µg/mL and
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essentially full eradication at around 0.128 µg/mL. Surprisingly, MB showed some
synergic killing with ciprofloxacin in the absence of light. The reasons for this synergy
are unknown but one possibility is that MB acts as a competitive substrate for NorA,
thus lowering the rate of NorA-mediated ciprofloxacin efflux. The three hybrids 56, 58
and 60 all strongly potentiated the cell-killing effects of ciprofloxacin.
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Figure 3.21 Effects of MB and hybrids 56, 58 and 60 on survival of bioluminescent S.
aureus cells when coadministered with increasing concentrations of ciprofloxacin. MB
was present at 20 µM and the hybrids at 10 µM. Data represent the mean ± SEM from
3-4 independent experiments.

The synergistic effects provided further evidence that these hybrids serve to
block the NorA pump and not simply evade its action. Blocking of the pump in these
experiments led to increased intracellular concentrations of the antibiotic to potentiating
its cell killing effects.
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3.6 Summary and Conclusions
In this Chapter the photophysical properties of hybrids were measured and
compared with MB. The UV/Visible absorption spectra of MB and all hybrids (Figure
3.1) showed that the λmax1 and λmax2 bands arising from the MB moiety in the hybrids
and their extinction coefficients changed only slightly relative to MB, indicating that the
absorption properties of the MB chromophore had not been markedly changed by
addition of the appended EPI-linker structures.
SOSG and HPF probes were used to measure production of 1O2 and •OH,
respectively, from the hybrids relative to MB. Of the four different classes of hybrids,
the reserpine-containing compounds 47-50 produced the most •OH, although the level
were quite low (Figure 3.11). The same hybrids showed significant production of 1O2.
In contrast, pterostilbene-containing hybrids 51-54 showed virtually no •OH production
and very little 1O2 relative to MB. Examination of the aPDT activity of 47-50 and 51-54
against the model organism MRSA USA300 revealed that neither the reserpinecontaining nor pterostilbene-containing hybrid classes showed any significant activity.
Observing •OH and 1O2 production by reserpine-containing hybrids 47-50 but no aPDT
activity against MRSA USA300 demonstrates that production of ROS is not in itself
sufficient to create hybrids with robust aPDT activity.
INF55-containing hybrids 55-58 showed only slight •OH production but they all
showed stronger production of 1O2. INF271-containing hybrids 59-62 also showed very
little •OH production and only 60 and 62 showed good 1O2 production. In the MRSA
USA300 aPDT assays, INF55-containing hybrids 56 and 58 and INF271-containing
hybrids 60 and 62 showed the strongest cell killing effects.
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Lack of •OH production while at the same time producing significant amounts
of 1O2 is evidence that the aPDT activity observed with 56, 58, 60 and 62 was probably
arising mostly through Type II mechanisms (See Chapter 1.9). Poor •OH production by
all of the hybrids 47-62 was probably a result of the many additional hydrogen atoms in
the molecules relative to MB. MB contains only strong aryl C-H bonds, whereas the
hybrids contain many SP3 C-Hs, which might be abstracted by •OH to quench the
radical.
The two INF55-containing hybrids 56 and 58 and one of the INF271-containing
compounds 60 were advanced to experiments examining the dose-dependency of their
aPDT effects against the NorA-, WT and NorA++ S. aureus strains. Compounds 56 and
58 showed similar effects, with the slightly more potent 58 completely eradicating the
NorA- and NorA++ strains at 40 µM and producing a 5-log kill at this concentration
against the WT strain. Compound 60 showed similar potency to MB against the
NorA++ strain but was less effective than MB against the NorA- and WT strains.
Uptake of 56, 58 and 60 was explored next with the S. aureus panel. The key
observation here was that the three compounds showed significantly greater uptake than
MB in all strains and showed identical uptake to each other in all three strains. It was
concluded that 56, 58 and 60 were either evading the NorA pump and/or inhibiting the
NorA pump.
The question of whether the compounds were blocking and/or evading the NorA
pump was addressed by aPDT experiments with combinations of MB and various
INF55- and INF271-containing synthetic intermediates. These substituted INF55 and
INF271 analogues all strongly potentiated the aPDT activity of MB, confirming that the
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structural changes that were introduced into the EPIs did not suppress their EPI activity.
These results supported that the increased aPDT activity of 56, 58 and 60 relative to MB
was arising, at least in part, because their EPI portions were serving to block the NorA
pump, and the resulting increases in intracellular MB were responsible for increase cell
killing.
Further confirmation of the NorA pump-blocking activity of the hybrids was
obtained from experiments with bioluminescent S. aureus strain and the
fluoroquinolone antibiotic ciprofloxacin. Each of the compounds 56, 58 and 60 showed
strong potentiation of ciprofloxacin’s antibiotic effects at 10 µM. As ciprofloxacin is a
known substrate for the S. aureus NorA pump,31c,185 its potentiation in the presence of
the hybrids was further evidence that the compounds block this pump.
In summary, experiments in this Chapter validated the principal around which
MB-EPI hybrids were designed for use in aPDT. Hybrid 58, carrying INF55 as the EPI
and an N-acyl-N,N’-dimethylethylenediamine linker to MB, was identified as the most
active compound from these studies and advanced to an in vivo aPDT MRSA infection
model (Chapter 4).
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Chapter 4
In Vivo Antimicrobial
Photodynamic Activity of Lead
Hybrid 58 in a Murine MRSA
Wound Infection Model
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4.1 Staphylococcus aureus and Humans
S. aureus is a facultative aerobic Gram-positive coccus belonging to the
Staphylococcaceae family. It is frequently found as a commensal organism in the
human respiratory tract and on the skin,186 but has also been a well-known human
pathogen since it was first described by Sir Alexander Ogston in 1880.187 Production of
coagulase and the ability to ferment mannitol are two of the main characteristics that
distinguish S. aureus from other staphylococci. Mean carriage rates in the general
population are around 40% and it is estimated that ~ 20% of the population are carriers
and that 60% are occasionally colonised.188
S. aureus can cause a spectrum of infections ranging from superficial skin
infections to severe, invasive diseases, including bacteraemias.189 Other organs can also
be infected, such as the eye, skin, connective tissues, bones, joints, heart, lungs and
gastrointestinal and urinary tracts.190 S. aureus is known to degrade a number of host
proteins and tissues through production of a range of enzymes and toxins in its quest for
nutrients.191 These enzymes include haemolysins, proteases, lipases and hyaluronidase.
S. aureus proteases are able to modulate numerous host immune responses and can
interfere with the kallikrein-kinin pathway. This leads to increased vascular
permeability, which ensures a plentiful supply of nutrients for the bacteria at the site of
infection.192 S. aureus proteases have been implicated in the pathogenesis of skin
disorders, such as atopic dermatitis.193
In addition to obtaining nutrients, S. aureus must also be able to repel constant
attacks from the innate and acquired immune systems of its human host. S. aureus
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produces an extensive array of virulence factors for this purpose. It can produce a
variety of toxins and factors that kill leukocytes, inhibit neutrophil chemotaxis, resist
phagocytosis, inactivate complement and neutralise host antimicrobial peptides.194
Many of these virulence factors are multifunctional, for example protein A. This cell
wall-associated protein causes release of pro-inflammatory cytokines from monocytes
and fibroblasts195 and also binds to the Fc region of human IgG to disturb antibody
opsonisation.196
While numerous antibiotics have been used effectively against S. aureus
infections over many decades, the frequency of these infections has increased gradually
with time and has been accompanied by increases in mortality rates.197 Today, S. aureus
is the most frequent cause of hospital-acquired infections, including surgical site
infections,198 and is the most common causative agent of skin and soft tissue infections
in the North and Latin Americas and Europe.199 An analysis of the burden of skin and
skin-structure infections in the USA caused by S. aureus found that these infections are
associated with high treatment costs, estimated at ~ $11,000 per patient per episode.200
4.2 Methicillin-Resistant S. aureus (MRSA)
MRSA was first reported in 1961201 and has since undergone significant
evolutionary changes and epidemiologic expansion.202 It was so-named because it
expresses penicillin-binding proteins (PBPs) that show reduced affinity for penicillins
(e.g. methicillin) and other common 𝛽-lactam antibiotics.202 Currently, more than half
of nosocomial S. aureus infections in many countries are caused by MRSA.203 In the
United States, MRSA accounts for almost 60% of clinical S. aureus strains isolated
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from intensive care units.204 Isolates from blood cultures taken from bacteraemia
patients in England revealed that the proportion of MRSA infections has increased
dramatically there from 5% in 1990 to 40% in 2000.205 As well as being a major cause
of hospital-acquired infections all over the world, MRSA is now widespread in the
community, especially in nursing and residential homes.200b,206 Indeed some MRSA
strains are becoming the dominant pathogen in the community (i.e. community-acquired
MRSA).207
Vancomycin, from the glycopeptide family of antibiotics, has been used
extensively in clinical practice for complicated S. aureus and other Gram-positive
infections over several decades. In the last 20 years, however, concerns have been
growing over the increasing minimum inhibitory concentration (MIC) of vancomycin
against MRSA.208 As it is expected that vancomycin resistance will continue to increase
in the coming years, it seems only a matter of time before MRSA becomes resistant to
this antibiotic. There is thus an urgent need to develop new antibiotics and approaches
to replace vancomycin as its effectiveness wanes.
4.3 Skin and Soft Tissue S. aureus Infections and their Treatment
S. aureus is the most frequently isolated pathogen from skin and skin-structure
infections.209 Optimal treatment regimes for staphylococcal skin and soft tissue
infections are constantly being modified.210 Due to the high incidence of resistance, βlactams are no longer an effective treatment choice. Although clindamycin can be
effective, its use has been connected with increasing rates of Clostridium difficileassociated diarrhoea, leading to concerns about its use in skin infections.131 Linezolid is
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also active against the majority of MRSA strains but it is costly and can be associated
with haematological side effects.211 Doxycycline and minocycline need to be used with
caution due to photosensitivity side effects and cannot be used in children under nine
due to deposition in teeth and bones. There is also a lack of data to support their efficacy
against community-acquired MRSA. Rifampin is another antibiotic that has been shown
to be effective against MRSA, but its high frequency generation of resistant mutants
requires that it not be used alone.212 Fluoroquinolones are no longer indicated for the
treatment of skin and soft tissue S. aureus infections due to resistance.213
Vancomycin remains as the antibiotic of choice for invasive staphylococcal
infections. In more severe skin and soft tissue infections, tigecycline and daptomycin
may also be used,213 although tigecycline is expensive and both drugs can only be
administered intravenously.214 While several effective therapies have been developed
for staphylococcal infections their use is primarily reserved for severe, complicated
infections.215 Because of this and the other problems noted above, especially resistance,
there is a continuing need to develop new therapeutics and strategies for treating MRSA
and other staphylococcal skin infections.
aPDT presents an attractive alternative due to the ease of applying light to the
infected skin surface and because of its effectiveness against resistant organisms
(Chapter 1.8). For example, in wound infection operations, which are often complicated
by antibiotic-resistant strains of bacteria and account for 25% of all nosocomial
infections,216 aPDT could present a very practical and effective treatment.217 However,
it is unlikely that aPDT could be the only treatment modality employed due to the
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severe nature of some of these infections. Nevertheless, it could be useful for lowering
the bacterial burden and thus the amount of surgical debridement required.216

4.4 aPDT as a Potential Treatment for MRSA Skin Infections
As alluded to above, aPDT is particularly suited to superficial staphylococcal
infections due to the accessibility of the infection site and ease of topical application of
a photosensitiser and its subsequent illumination.218 Additionally, the vulnerability of S.
aureus to toxic photosensitisation is well recognized.219 Effects of photosensitisation on
the activities of virulence factors produced by the pathogen has generated some resent
interest.220
One of the advantages of aPDT for skin infections is that the treatment can be
focussed directly on the infection site using laser light from an optical fibre that
produces a beam diameter of only millimetres. This ensures that inadvertent exposure of
host tissues to photosensitisation can be minimised. It has been suggested that the
specificity of aPDT might be further increased by conjugating antibodies to
photosensitizers that target specific antigens on organisms of interest. This approach has
been explored, for example, with an IgG-tin(IV) chlorin e6 conjugate.221 In practice,
however, such a strategy would be costly to implement clinically and would require the
infecting organism to be properly identified before treatment. While such selectively is
very attractive from a scientific perspective, if aPDT does not cause considerable
damage to human cells in clinical practice then the need for targeting methods may not
be necessary. In support of these simpler and cheaper approaches, treatment of
keratinocytes with MB and visible light has been shown not to cause DNA damage,
indicating that the treatment is unlikely to be accompanied by genotoxicity.222
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A number of in vitro studies have reported the use of aPDT for inactivating
MRSA223 but there have been relatively few in vivo studies. One in vivo study explored
the effects of aPDT in a skin abrasion wound infection mouse model that made use of a
bioluminescent MRSA (Xen31) strain.126b This strain allowed real-time monitoring of
the infection using a bioluminescence camera. Treatment with a polyethylenimine(PEI-)ce6 photosensitizing agent (Figure 4.1) and a range of noncoherent red light
fluences applied 30 minutes after bacterial inoculation produced up to 2.7 log reductions
in MRSA, as measured by loss of bioluminescence from the wounds. Application of
aPDT also accelerated wound healing by 8.6 days compared to untreated wound
infections.126b
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photosensitizer and shown to inactivate MRSA, inhibit regrowth and accelerate wound
healing.224 In this study, full-thickness wounds of 0.8 cm diameter were established in
the subcutaneous back tissue of BALB/c mice and inoculated with 5 × 107 CFU
MRSA.225 Strong bacterial inactivation (> 3 log kill) was observed after two days when
mice were treated with the agent and illuminated with visible light. For this in vivo
study, Complete re-epithelialization was observed in aPDT-treated mice 9 days after
therapy.225
In a third mouse skin wound EMRSA-16 (epidemic MRSA) infection study,
treatment of infected mice with 100 𝜇g/mL MB followed by illumination with 670 nm
laser light (total fluence 360 J/cm2) resulted in a 25-fold reduction in the number of
EMRSA-16.226
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Figure 4.1 Structures of polyethylenimine-ce6 (PEI-ce6) and tetracationic Zn(II)
phthalocyanine chloride (RLP068/Cl) photosensitizers used in mouse skin abrasion
infection studies.126b,224

The effectiveness of aPDT against MRSA arthritis has been tested in vivo in a
mouse model. MRSA arthritis is a disease affecting joints, where bacteria from the skin
are introduced into the joint synovial fluid, usually via percutaneous instrumentation.
This study revealed that ~ 30% of intra-articular leukocytes, mainly neutrophils, died
immediately after aPDT with photofrin.227 After 24 h aPDT treatment an additional
reduction in the number of intra-articular leukocytes and atrophy of the synovial tissue
were observed. Isolated peripheral neutrophils were shown to have significant affinity
for photofrin and displayed substantial morphological damage after aPDT.227 These
results suggest that aPDT would probably not be useful in MRSA arthritis because of
the damage to intra-articular neutrophils and synovial tissues.
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In an attempt to increase bacterial inactivation and reduce damage to host
neutrophils, the same group later studied the effects of intra-articular injection of
photofrin rather than intravenous administration.228 Each animal received a knee
injection of MRSA (5 × 107 CFU) and after 3 days Photofrin (1 mg) was applied and
illuminated 635 nm light as a range of fluences. The maximum reduction of MRSA was
achieved at a 20 J/cm2. Lesser effects were observed at lower fluences.228 The authors
concluded that aPDT for murine MRSA arthritis would require optimised light
dosimetry to rapidly inactivate bacteria without affecting neutrophils at the infected site.
aPDT with too low a fluence might inactivate insufficient bacteria, whereas too much
light could inactivate neutrophils and damage host tissues, allowing bacteria to regrow
in an environment where the immune response had been compromised.
An artificial skin construct has been developed for simulating MRSA skin
infections.229 The artificial skin is constructed from human-derived epidermal
keratinocytes and dermal fibroblasts, cultured at a media interface to form a stratified
model of full-thickness, epithelialized human skin. aPDT with MB in this model
produced a strong reduction (> 5 log kill) compared to controls and the effect was
sustained over multiple days. Application of MB without light resulted in only a small
reduction in MRSA viability.229

4.5 aPDT Activity of Lead Hybrid 58 in a Murine MRSA Wound Infection Model
The final part of this thesis work involved examining the aPDT activity of lead
hybrid 58 in an in vivo murine MRSA wound infection model. Compound 58 was
chosen for the study due to its potent in vitro aPDT activities, as detailed in Chapter 3,
where its superior effects relative to MB were clearly evident. The primary goal of this
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in vivo study was to demonstrate that the superior in vitro activities of 58 relative to MB
translated to a real MRSA infection. The needle scratch model, developed by Dai et
al,126b was chosen for the study. This model reflects the initial colonisation stage of the
wound infection process and uses a bioluminescent variant of a strain of MRSA (MRSA
Xen 30)230 that is known to cause wound infections of significant clinical relevance,
sometimes with fatal outcomes.231

4.5.1 Experiment Protocol and Results
Female BALB/c mice were divided into 5 cohorts (Table 4.1). Group A animals
(n = 6) were absolute controls that received no treatment, Group B (n = 6) were dark
controls for MB (no light), Group C (n = 6) received aPDT treatment with MB. Group
D (n = 6) were dark controls for hybrid 58 (no light) and Group E (n = 6) received
aPDT treatment with hybrid 58.
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Table 4.1 Animal cohorts for murine MRSA wound infection study.
Group

Animals

Treatment

A - Absolute control

6

No treatment

B - Dark control for MB

6

MB (40 µL of 200 µM)

C - aPDT with MB

6

MB + light (12, 36, 84, 120 J/cm2; 652 nm)

D - Dark control for 58

6

58 (40 µL of 200 µM)

E - aPDT with 58

6

58 + light (12, 36, 84, 108, 120 J/cm2; 652 nm)

Inoculation of 108 CFU MRSA Xen 30 into scratch wounds (using a needle) on
the shaved backs of immunosuppressed female BALB/c mice, led to a stable infection,
as confirmed by bioluminescence imaging (Figure 4.2, Group A). Pictures were
captured using a bioluminescence camera immediately after MRSA inoculation and 30
mins post-inoculation. Light was then applied to the aPDT cohorts (Groups C and E;
Time 0) and images were captured for all cohorts after 2, 6, 14, 18 and 20 min.
Application of 652 nm light in the aPDT cohorts for these periods corresponded to
fluences of 12, 36, 84, 108 and 120 J/cm2, respectively. Images obtained from a
representative animal in Groups A, C and E are shown in Figure 4.2.
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Group A
Group C
(Absolute Control) (aPDT with MB)

Group E
(aPDT with 58)

Immediately
after MRSA
inoculation
30 min
post-inoculation
Time = 0
Time = 2 min
E = 12 J/cm2
Time = 6 min
E = 36 J/cm2
Time = 14 min
E = 84 J/cm2
Time = 18 min
E = 108 J/cm2
Time = 20 min
E = 120 J/cm2
Figure 4.2 Bioluminescence images obtained from a representative animal in Groups A
C and E in the murine MRSA wound infection model. Images were captured postinoculation and at the times indicated. Application of 652 nm light for these periods in
the aPDT Groups C and E corresponded to the fluences indicated. MB in Group C and
compound 58 in Group E were applied by delivering 40 µL of 200 µM solutions
(formulated in CrEL, see Section 3.3.1) via micropipette directly to the infection site.

The bioluminescence image data from Figure 4.2 is presented graphically in
Figure 4.3. These data represent the mean ± SEM of normalized bioluminescence
emanating from the wounds of the 6 mice in each cohort. In the absence of
photosensitizers (Absolute control – Group A), the relative bioluminescence units
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(RLU) decreased only marginally, indicating that infection was stable over the course of
the experiment and relatively unaffected by application of light alone.
In the MB dark control (Group B), there was no significant reduction in
bioluminescence after 6 min, and after 18 min bioluminescence reduction was less than
0.6 RLU (Appendix 4.1(A)). A clear light dose-dependent response was observed in the
aPDT cohort treated with MB (Group C). After 2 min of light application (E = 12 J/cm2)
luminescence was reduced by 45%, which increased to 70% after 6 min (E = 36 J/cm2).
Disappearance of the luminescence signal was observed after 18 min (E = 108 J/cm2).
In Group D, where hybrid 58 was applied without light only a small (0.1 RLU)
reduction in luminescence was observed at the highest incubation (Time = 20 min)
(Appendix 4.1(B)). In Group E, where aPDT with 58 was applied, a remarkable 98%
reduction in luminescence was observed after applying light for only 2 min (E = 12
J/cm2), and total loss of the luminescence signal was observed after 6 mins (E = 36
J/cm2).
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Normalized RLU

8.00E-01
Group A control
Group C MB

6.00E-01

Group E 58
4.00E-01
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0.00E+00
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fluence (J/cm2)

Figure 4.3 Light-dose response (mean ± SEM) for Groups A, C and E in the
bioluminescence MRSA wound infection model. Data are presented as normalized
relative luminescence units (RLU). Dark control Groups B and D showed only small
reductions in RLU at 120 J/cm2 (Appendix 4.1).

4.5.2 Post-Treatment Monitoring of Infections
Post-treatment monitoring of the bioluminescence signal was carried out daily
from the treatment day (Day 0) until to Day 10. As shown in Figure 4.4, a rebound in
the bacterial load (as indicated by a 1.6 fold increase in luminescence) was observed in
each of the non-aPDT control groups (Group A, B and D) after 1 day. These infections
resolved naturally over the course of the following 10 days. For the MB-aPDT cohort
(Group C) a smaller (1.3 fold) rebound was observed after 1 day and the infection was
completely resolved after 7 days. For the 58-aPDT cohort (Group E), essentially no
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rebound in bacterial load was observed after 1 day and the infection completely resolve
after 4 days.

1.60E+00
Group A Control
1.40E+00
Group B MB-dark

normalized RLU

1.20E+00

Group C MB-aPDT
Group D 58-dark

1.00E+00

Group E 58-aPDT
8.00E-01
6.00E-01
4.00E-01
2.00E-01
0.00E+00
0

1

2

3

4

5

6

7

8

9

10

11

Days post-infection

Figure 4.4 Ten day post-treatment monitoring of bacterial loads for Group A-E in the
MRSA wound infection study. Luminescence (normalized) emanating from animal
infection sites was measured using a luminescence camera. Data represent mean ± SEM
obtained from 4-6 animals in each cohort. The luminescence images from which the
data were derived (from representative animals in each cohort) are provided in
Appendix 4.2.

4.5.4 Wound Healing
During experiments all mice were monitored visually for signs of poor health,
suggesting that they might have developed a systemic infection. Weights of animals
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were monitored as a proxy for general health. Slight reduction on body weights of
animals was included in the formulae used for calculation of total RLU.
Wounds of all animals were also inspected visually for signs of healing. As
shown in Figure 4.5, cohorts that received no aPDT treatments (Group A, B and D)
showed few signs of wound healing on days 4-6 of the post-treatment monitoring
period. In contrast, the MB-aPDT cohort (Group C) showed considerable healing by
day 6 and had formed a visible scab by day 7 (not shown). Animals treated with aPDT
and 58 (Group E) showed much faster wound healing, with a visible scab formed after
only 4 days and the wound visibly healed by Day 6.

Day 4

Day 5

Day 6

Group A
control

Group B
MB-dark

Group C
MB-aPDT

Group D
58-dark

Group E
58-PDT

Figure 4.5 Images showing wound healing in representative animals from Groups A-E
on Days 4-6 post-treatment.
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4.6 Summary and Conclusions
In this Chapter, a mouse skin abrasion wound infection was established by the
topical application of an MRSA suspension to superficial scratch wounds on the shaved
dorsal surfaces of BALB/c female mice. Use of bioluminescent bacteria allowed realtime monitoring of the extent of the infection in the mice wounds following treatment
with MB and lead hybrid 58. The images captured after aPDT treatments using a 200
μM solution (40 µL) of 58 showed a very strong light-dose response effect, where all
bacterial luminescence had disappeared after application of only 36 J/cm2 of 652 nm
light. 3-Fold higher light doses (108 J/cm2) were required to effect total loss of
luminescence using MB at the same concentration.
In the days post-aPDT treatment with 58, minimal bacterial re-growth was
observed and total disappearance of the bioluminescence signal occurred by day 4.
Complete loss of bacterial luminescence in dark controls with 58 was not observed until
Day 9. For MB, significant bacterial regrowth was observed in the day following aPDT
treatment and total disappearance of the bioluminescence signal was not observed until
Day 7. The wound healing process after aPDT treatment with 58 occurred earlier (Day
4) than with MB (Day 7), as observed by scab formation in the treated area. Wound
healing in Groups treated with MB and 58 alone (i.e. no light) or with no compound
treatment did not heal until Days 12-14. These results demonstrated that aPDT with
hybrid 58 enhances bacterial inactivation and improves wound healing compared to the
parent photosensitizer MB in this infection model. This finding strongly supported our
original hypothesis that attachment of an EPI to MB can enhance its aPDT activity.
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Chapter 5
Conclusions and Future Directions
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This thesis explored novel light-activated antimicrobial photosensitizers as
potential new agents for inactivating MDR bacteria using aPDT. The overall goal was
to identify an MB-EPI hybrid that showed improved efficacy relative to MB as a
potential treatment for superficial, localised infections, such as S. aureus skin infections.
Evidence has revealed that MDR pumps contribute to antibiotic resistance by
transporting a wide variety of structurally diverse compounds, including the
phenothiazinium dye MB.19 Pharmacological inhibition of pumps, where small
molecule inhibitors are used to block pump activity, is one of the strategies that have
been investigated to date.62a Potentiation of the aPDT effects of MB upon co-incubation
of MDR bacterial strains with MB and EPIs had previously been reported.99a As
discussed in Chapter 1, EPIs can raise the concentration of MB within bacterial cells.
Upon irradiation with visible light, MB generates toxic ROS via Type I and II
photosensitization processes to kill bacterial cells.
Chapter 1 summarized several issues with using combinations of MB with EPIs
and proposed that MB-EPI hybrids could potentially be used to address efflux pumpmediated resistance in aPDT.154 The concept of MB-EPI hybrids evolved from the
reported “dual antimicrobial action” observed with berberine-EPI hybrids (i.e. SS14)
that target the NorA pump in S. aureus.162 The physicochemical similarities between
berberine and MB and evidence that they are overlapping substrates for various efflux
pumps, including NorA, suggested that an analogous MB-EPI hybrids strategy might be
successfully applied in aPDT.99a,154
In Chapter 2, a convergent synthetic strategy was described for the synthesis of
16 hybrids that conjugated MB to the EPIs reserpine, pterostilbene, INF55 and INF271.
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Piperazine and N,N’-dimethylethylenediamine-based linkers were used to attach the
EPIs to MB. Requisite EPI-alkyl/acyl-piperazine and EPI-alkyl/acyl-ethylenediaminebased precursors were prepared and then reacted according to Strekowski’s method with
a key phenothiazinium common intermediate 63 to form the target hybrids. It was
observed that the Strekowski reactions were best carried out in the absence of light to
minimise photodegradation. All compounds were purified by preparative TLC, eluting
with a very uncommon solvent system (3% NH4OAc(aq):MeOH 15:85) and subsequently
converted to chloride salts using Cl- anion exchange resin (Chapter 6). Sufficient
quantities (25-95 mg) of the final hybrids were obtained for the photophysical and
photobiological studies. High resolution mass spectroscopy, NMR and UV/Vis
spectroscopy of these hybrids were used to characterize their structures.
As discussed in Chapter 1.14, when designing the hybrids, it was considered
crucial that the photosensitization properties of MB be maintained and that this might be
achieved by substituting the C-7 N-Me groups of MB with N-alkyl and piperazinyl
linkages. To measure the effects of the structural changes we compared the absorption
properties of MB to hybrids by examining the λmax1 and λmax2 values and extinction
coefficients. The λmax and log ε data confirmed that introduction of the various linker
groups and EPIs did not significantly impact the absorption properties of the MB
chromophore. An interesting observation from these experiments was that the highest
Δlog ε1 value (0.22), meaning that the compound had the greatest reduction in
chromophore absorptivity of all the hybrids relative to MB, was observed with 58, the
compound that was ultimately shown to produce the best activity. It was concluded that
absorptivity of the chromophore was not a critical parameter in these hybrids for
showing good aPDT activity.
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We hypothesized that these light-activated antimicrobial hybrids would show
increased effectiveness over the parent PS MB against S. aureus in aPDT by generating
increased intracellular ROS through inactivation of MDR pumps, namely NorA. Two
important assays were performed to explore whether hybrids maintained the PS and EPI
properties:
1- Measurement of 1O2 and •OH phototoxic species.
2- Assays to demonstrate retention of efflux pump inhibitory activities.
Production of ROS by PSs can be probed experimentally by fluorescence-based
ROS scavengers. SOSG and HPF probes were used to measure production of 1O2 and
•OH, respectively, from the hybrids. All hybrids were found to produce less 1O2 and
•OH than MB. Reserpine-containing hybrids 47-50 showed 1O2 and •OH quantum
yields at around 20-55% of MB, with 48 showing the highest •OH production (55%) of
all hybrids. Pterostilbene-containing hybrids 51-54 all showed 1O2 and •OH quantum
yields less than 20% relative to MB. INF55-containing hybrids 55-58 and INF271containing hybrid 59-62 generally showed higher 1O2 and •OH quantum yields. 1O2
production for 55, 56, 58 and 62 were at 65%, 50%, 60% and 55% relative to MB. It
was observed that production of 1O2 was in general stronger than production of •OH,
indicating that any observed phototoxicity effects would probably occur via Type II
mechanisms.
Aqueous solubilisation of hybrids was achieved by encapsulation in cremophor
EL (CrEL). This was determined to be the best detergent out of tween 60 (T60), triblock
copolymers F127 (PL-F127) and poloxamer 388 (POL388) for solubilising reserpinecontaining hybrid 49, a particularly insoluble hybrid in aqueous solutions. Due to its
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powerful solubilizing effect on 49 and its widespread use as a vehicle for many poorly
water-soluble compounds, as well as its low toxicity properties,180-181 CrEL was chosen
as the vehicle for formulating all hybrids in this study.
Preliminary in vitro aPDT screening against S. aureus USA300 revealed that
hybrids 56, 58, 59 and 60 showed a better killing than MB at equivalent concentrations
and fluence. MB was found to reduce the viability of S. aureus USA300 by 2 log units,
whereas hybrids 56, 58, 59 and 60 showed killing effects of 3-6 logs (Figure 3.14). This
result provided the first evidence that some of the hybrids could function as designed;
i.e. with the EPI serving to block MDRs and generate higher intracellular concentrations
of the attached MB PS and better aPDT cell killing. To support this, MICs were
measured with the antibiotic ciprofloxacin, a known MDR substrate for NorA pump in
the presence of hybrids and MB in the dark. The MIC of ciprofloxacin was greatly
potentiated in the presence of hybrids, leading us to conclude that they are able block
MDR pumps in S. aureus, specified NorA.
In Chapters 3.3.3, the aPDT activities of the four lead hybrids were explored
against NorA knockout (NorA-), wild-type (WT) and NorA-overexpressing (NorA++)
mutant S. aureus strains. These experiments aimed to obtain further evidence that
hybrids show photodynamic effects that were influenced by their action on the NorA
pump. aPDT with MB against these strains displayed the hallmarks of it being a
substrate for the NorA pump. MB produced a 2 log kill against the NorA++ strain upon
irradiation with 16 J/cm2 of light, and a 4 log reduction was obtained under the same
conditions in the NorA- strain. In contrast, phototoxicity of the three hybrids 56, 58 and
60 remained unchanged (3 log killing) against all three strains, consistent with these
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compounds not being substrates for the NorA pumps, and possibly serving to block this
pump.
Of the three best hybrids identified from the in vitro aPDT experiments, two contained INF55 (56 and 58) and one contained INF271 (i.e. 60). Hybrids incorporating
the natural product EPIs reserpine and pterostilbene showed no aPDT activity,
demonstrating the crucial role that molecular structure plays in the activity. The study
also demonstrated the importance of linker groups in the structures, where hybrids with
piperazine-based linkers (indicated as red/pink data in the Chapter 3 figures) generally
showed poorer aPDT activities in comparison to equivalent compounds with N,N’dimethylethylenediamine-based linkers (indicated as light blue/dark blue data in the
Chapter 3 figures). This was highlighted with INF55-containing hybrids 55-58, where
hybrid 58 containing an N,N’-dimethylethylenediamine linker was found to be the best
performing hybrid overall, whereas the equivalent hybrid 55 with a piperazine-based
linker showed very little in vitro aPDT activity. The better performance of the N,N’dimethylethylenediamine linker may arise from its increased flexibity compared to the
rigid piperazine linker.
The efflux pump inhibitory activity of 56, 58 and 60 was explored by measuring
uptake of these compounds into WT, NorA- and NorA++ S. aureus cells. The hybrids
showed identical uptake in all three strains, consistent with them not being NorA
substrates.
aPDT concentration response experiments with NorA++ S. aureus cells
identified hybrid 58 as a highly potent lead. At 40 µM this hybrid showed complete
eradication of cells at 10 J/cm2 fluence (Figure 3.18). Under the same conditions, MB
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produced a 5 log kill. It was also noted that, increasing the concentration of MB to 160
µM did not lead to complete eradication, as was observed with 58. On the basis of all of
the photophysical an in vitro aPDT experiments hybrid 58 was advanced to an in vivo
aPDT infection model.
A murine MRSA wound infection model was used to study the in vivo activity
of lead hybrid 58.232 This model reflects the early stages of an infectious process, i.e.
initial colonisation of a wound by a potential pathogen. Infections were established by
inoculating scratch wounds on the dorsal surfaces of mice with bioluminescence
MRSA. MRSA was found to be highly susceptible to photodynamic killing by 58,
where irradiation with 36 J/cm2 of 652 nm light in the presence of 200 μM 58 resulted
in complete disappearance of luminescent MRSA. A 3-fold higher light dose (108
J/cm2) was required for the same effects using MB at the same concentration. Posttreatment monitoring of the bacterial loads showed that total disappearance of the
bioluminescence signal had occurred by Day 4 with 58, which was not observed until
Day 7 with MB. Significant bacterial regrowth had occurred one day after treatment
with MB but this rebound growth was not observed with 58.
This study has demonstrated that Gram-positive bacteria are susceptible to
hybrid-photosensitization and low light energies were found to kill the bacteria. It has
been reported that higher light energies are often necessary to kill the Gram-negative
species.233 It would be of interest to explore the activity of 58 against Gram-negative,
e.g. P. aeruginosa, in future experiments, and it would be worthwhile using higher light
fluences in these studies.
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MB has been used clinically and is known to show low toxicity towards normal
cells.234 In this thesis it was shown that the effects of 58 occur at lower concentration
than MB, suggesting it would likely show little toxicity in humans. The low irradiation
times required for the successful killing of bacteria and reduction of their virulence
potential are attractive features for the clinical setting, where short treatment durations
would cause less discomfort to patients and minimise damage to host tissues. Further
investigations are needed to fully understand the toxicity of these hybrids.
As shown in chapter 2, a library of four compounds using four different linker
groups were synthesized for each EPI used in this study. The importance of linker group
as well as EPIs was revealed by this study. Hybrids 55 and 58 have the same EPI but
different linker group and the result shows that hybrid

58 with N,N’-

dimethylethylenediamine linker showed 4 logs killing of S. aureus NorAoverexpressing whilst the hybrids 55 with piperazine linker group did not reveal any
activity. Further pharmacophore study need to perform to find the best non-cleavable or
any possibility of using cleavable linker groups for these hybrids.

138

Chapter 6
Experimental
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6.1 Experimental Procedure - Chemistry
6.1.1 Chemistry - General
All reactions were performed under an argon atmosphere in flame or oven-dried
glassware with magnetic stirring unless otherwise stated. Pterostilbene was purchased
from ChromaDex (NV, USA). Reserpine, IRA-904 quaternary ammonium Cl- anion
exchange resin and all other commercial reagents were purchased from Sigma-Aldrich
(St. Louis, MO) and used without further purification, unless otherwise noted.
Anhydrous acetonitrile and toluene were obtained using a PureSolv system. N,Ndimethylformamide (DMF) was dried over barium oxide and distilled under reduced
pressure onto 4Å molecular sieves. Anhydrous tetrahydrofuran (THF) and diethyl ether
(Et2O) were freshly distilled from sodium benzophenone ketyl. All other solvents were
of analytical reagent (AR) grade and used as received. The term petroleum spirit refers
to petroleum spirit within the boiling range 40-60 oC.
Reaction monitoring was performed using thin layer chromatography (TLC)
analysis on Merck Silica Gel 60 F254 (0.2 mm) aluminium plates. Purification by flash
column chromatography used silica gel 60 (230-400 mesh, Merck) with the indicated
eluents. Purification of hybrids 47-62 was performed using Merck 60 F254 preparative
TLC plates (1000 µm).
Melting points were determined on a Buchi digital M-560 melting point
apparatus and are uncorrected. 1H and 13C NMR spectra were recorded on either Varian
Unity-300 MHz or Varian-Inova-500 MHz spectrometers in deuterated solvents.
Spectra were referenced internally using the chemical shifts of solvent resonances
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relative to TMS. UV/Vis spectra were recorded on a Shimadzu UV-1700 PharmaSpec
UV/Vis spectrophotometer. Infrared spectra were obtained as neat samples using an
Avator ESP spectrometer. Low resolution electrospray ionisation mass spectra (EILCMS) were measured using a Shimadzu LC-MS (2010) spectrophotometer. High
resolution electrospray ionisation mass spectroscopy (HRESI-MS) were recorded using
a factory modified Waters QToF UltimaTM Spectrometer (Wyntheshawe, UK).
6.1.2 Synthesis of 3-(Dimethylamino)phenothiazin-5-ium triiodide 63
Dimethylamine in methanol (6.2 g, 11.9 mmol) was added
dropwise to a solution of phenothiazin-5-ium tetraiodide
hydrate 65 (5.0 g, 6.90 mmol) in 80 mL chloroform at room
temperature. The reaction was stirred for 5 h while monitoring by TLC (3% NH4OAc
(aq)/MeOH,

15:85). The resulting precipitate was filtered, washed with chloroform and

air dried to give 63 (205 mg, 60%) as a dark blue solid. TLC Rf (3% NH4OAc
(aq)/MeOH,

15:85) = 0.28; Mp 144 -145 ºC. 1H NMR (500 MHz, (CD3)2SO) δ 8.18 (dd,

J = 8.0, 1.6 Hz, 1H, H9), 8.13 (dd, J = 8.0, 1.6 Hz, 1H, H6), 8.06 (d, J = 10.0 Hz, 1H,
H1), 7.98 (dd, J = 10.0, 2.4 Hz, 1H, H2), 7.94 (d, J = 2.4 Hz, 1H, H4), 7.82 (m, 2H, H7,
H8), 3.64 and 3.60 (2s, 6H, N(CH3)2); 13C NMR (125 MHz, (CD3)2SO) δ 156.1, 144.1,
139.8, 139.6, 138.0, 134.6, 133.2, 129.8, 126.3, 126.1, 125.8, 109.7, 43.4, 42.9; IR
(neat) ν 2800, 1617, 1559, 1489, 1429, 1411, 1252, 1118, 1078, 887, 835, 772 cm-1;
HRESI-MS: m/z calcd for [C14H13N2S] 241.2051, found 241.2067.
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6.1.3 Synthesis of Piperazine and N,N’-Dimethylethylenediamine Linkers
Tert-butyl 4-(2-bromoacetyl)piperazine-1-carboxylate 76
Bromoacetylchloride (500 g, 3.2 mmol) was added dropwise
during 30 min to a solution of tert-butyl piperazine-1carboxylate (500 mg, 2.7 mmol) and K2CO3 (2.0 g, 14.6
mmol) in 50 mL anhydrous THF. The reaction was stirred for 12 h while monitoring by
TLC (Pet. spirit:EtOAc, 50:50). The reaction mixture was concentrated and the residue
re-dissolved in CH2Cl2. The organic layer was washed with water and brine, dried over
anhydrous Na2SO4 and concentrated. The crude residue was purified by silica gel
column chromatography (30% EtOAc/Pet, Spirit) to afford 77 (250 mg, 35%) as an offwhite solid. TLC Rf (Pet. spirit:EtOAc, 50:50) = 0.48; Mp 114 -115 ºC. 1H NMR (500
MHz, CDCl3) δ 3.85 (s, 2H, H9), 3.62-3.42 (m, 8H, H3, H4, H6, H7), 1.45 (s, 9H, H13,
H14, H15);

13

C NMR (125 MHz, CDCl3) δ 165.1, 154.3, 80.4, 46.5 (2C), 41.9 (2C),

28.3 (3C), 25.6; IR (neat) ν 1762, 1723, 1560, 1498, 1429, 1413, 1250, 1120 cm-1;
HRESI-MS: m/z calcd for C11H19 79BrN2O3) 306.0581, found 306.0590.
Tert-butyl (2-(2-bromo-N-methylacetamido)ethyl)(methyl) carbamate 77
Bromoacetylchloride (500 g, 3.2 mmol) was added dropwise
during 30 min to a solution of tert-butyl methyl(2(methylamino)ethyl)carbamate (500 mg, 2.7 mmol) and
K2CO3 (1.2 g, 8.7 mmol) in 30 mL anhydrous CH2Cl2. The reaction was stirred for 16 h
while monitoring by TLC (Pet. spirit:EtOAc, 50:50). The reaction mixture was
concentrated and the residue re-dissolved in CH2Cl2. The organic layer was washed
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with water and brine, dried over anhydrous Na2SO4 and concentrated. The crude residue
was purified by silica gel column chromatography (30% EtOAc/Pet, Spirit) to afford 77
(330 mg, 40%) as an off-white solid. TLC Rf (Pet. spirit:EtOAc, 50:50) = 0.46; Mp 129
-131 ºC. 1H NMR (500 MHz, CDCl3) δ 4.26 (s, 2H, H9), 3.46 (t, 2H, H7), 3.28 (t, 2H,
H6), 3.25 (s, 3H, H3), 2.89 (s, 3H, H4), 1.45 (s, 9H, H13, H14, H15);

13

C NMR (125

MHz, CDCl3) δ 165.3, 153.9, 79.6, 51.8, 47.5, 35.3, 34.9, 28.2 (3C), 27.6; IR (neat) ν
1752, 1717, 1559, 1489, 1429, 1411, 1252, 1118 cm-1; HRESI-MS: m/z calcd for C11H21
79

BrN2O3) 308.0535, found 308.0552.

6.1.4 Synthesis of Reserpine-Containing Intermediates
Methyl (1S,2R,3R,4aS,13bR,14aS)-3-((4-hydroxy-3,5-dimethoxy benzoyl)oxy)-2,11dimethoxy-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydroindolo [2',3':3,4]pyrido[1,2b]isoquinoline-1-carboxylate 70165
Aluminium chloride (1.0 g, 7.63 mmol) was
added in one portion to a stirring solution of
reserpine 8 (100 mg, 0.16 mmol) in dry
CH2Cl2 (20 mL) at room temperature. The
reaction was stirred for 2 h while monitoring
by TLC (EtOAc). The reaction was quenched by addition of 5% aqueous HCl (15 mL)
and the mixture diluted with CH2Cl2 (30 mL) and the layers separated. The aqueous
layer was extracted twice more with CH2Cl2 and the combined organic fractions were
washed with water and brine, dried over anhydrous MgSO4 and concentrated to yield 70
(90 mg, 95%) as a yellowish solid. TLC Rf (EtOAc) = 0.45; Mp 154-156 ºC; 1H NMR
(500 MHz, CDCl3) δ 7.54 (br s, 1H, H7), 7.33 (s, 2H, H25, H29),7.31 (d, J = 10.0 Hz,
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1H, H1), 6.88 (s, 1H, H4), 6.78 (d, J = 10.0 Hz, 1H, H2), 4.97 (sextet, J = 4.5 Hz, 1H,
H20), 4.74 (app s, 1H, H19), 3.98 (t, J = 10.0 Hz, 1H, H38), 3.92 (s, 6H, H31, H33),
3.86 (s, 3H, H30), 3.81 (s, 3H, H37), 3.50 (s, 3H, H34), 3.28 (d, J = 7.1 Hz, 2H, H17),
3.21 (d, J = 7.1 Hz, 1H, H18), 2.95 (sextet, J = 7.1 Hz, 1H, H36) 2.77-2.45 (m, 5H,
H14, H21, H35), 2.15-1.95 (m, 4H, H12, H13);

13

C NMR (125 MHz, CDCl3) δ 172.4

(C39), 165.6 (C23), 156.7 (C3), 146.8 (C26, C28), 139.7 (C5, C8), 137.1 (C27), 121.2
(C24), 120.87 (C6, C9), 118.6 (C1), 109.7 (C2), 106.8 (C25, C29), 95.3 (C4), 60.7
(C19, C20), 56.9 (C30, C31, C33), 55.9 (C34), 54.5 (C0), 52.2 (C37), 51.4 (C18), 50.9
(C17), 48.5 (C12), 33.2 (C36), 31.3 (C35), 29.4 (C36), 23.7 (C21), 16.3 (C13); IR
(neat) ν 3736, 2921, 1732, 1691, 1550, 1436, 1181, 1118 cm-1; HRESI-MS: m/z calcd
for [C32H38N2O9] 595.2656, found 595.2671.
Methyl (1S,2R,3R,4aS,13bR,14aS)-3-((4-(2-hydroxyethoxy)-3,5-dimethoxy
benzoyl) oxy)-2,11-dimethoxy-1,2,3,4,4a,5,7,8,13,13b,14,14adodecahydroindolo[2',3':3,4] pyrido[1,2-b]isoquinoline-1-carboxylate 71
The phenolic reserpine 70 (100 mg, 17
mmol) was dissolved in dry DMF (5 mL)
in a 25 mL flame-dried round bottom
flask under Ar and K2CO3 (1.00 g, 17.8
mmol) was added. The mixture was
stirred at room temperature for 30 min before adding 2-bromoethanol (50 mg, 40 mmol)
and warming to 80 oC. After overnight stirring and monitoring by TLC (EtOAc) the
reaction mixture was concentrated and the residue re-dissolved in CH2Cl2. The organic
layer was washed with water and brine, dried over anhydrous Na2SO4 and concentrated.
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The crude residue was purified by silica gel column chromatography (60% EtOAc/Pet,
Spirit) to afford 71 (100 mg, 96%) as a yellow solid. TLC Rf (EtOAc) = 0.38; Mp 121123 ºC; 1H NMR (500 MHz, CDCl3) δ 7.58 (br s, 1H, H7), 7.33 (m, 3H, H25, H29, H1),
6.84 (app d, J = 2 Hz, 1H, H4), 6.78 (d, J = 10.0 Hz, 2.0 Hz, 1H, H2), 5.05 (sextet, J =
4.5 Hz, 1H, H20), 4.47 (app s, 1H, H19), 4.25 (t, J = 10.0 Hz, 2H, H40), 3.92 (s, 6H,
H31, H33), 3.89 (t, J = 10.0 Hz, 1H, H38), 3.84 (s, 3H, H30), 3.82 (s, 3H, H37), 3.73 (t,
J = 10.0 Hz, 2H, H41), 3.50 (s, 3H, H34), 3.18 (d, J = 7.1 Hz, 2H, H17), 3.05 (d, J = 7.1
Hz, 1H, H18), 2.96 (sextet, J = 7.1 Hz, 1H, H36) 2.70 (dd, J = 10.0 Hz, 5.0 Hz, 2H,
H14), 2.52-2.27 (m, 3H, H21, H35), 2.15-1.95 (m, 4H, H12, H13) ;

13

C NMR (125

MHz, CDCl3) δ 171.8 (C39), 165.8 (C23), 156.4 (C3), 149.2 (C26, C28), 140.1 (C5,
C8), 137.5 (C27), 121.5 (C24), 120.84 (C6, C9), 118.3 (C1), 109.2 (C2), 106.5 (C25,
C29), 94.9 (C4), 69.8 (C40), 60.7 (C19, C20), 59.5 (C41), 56.9 (C30, C31, C33), 55.9
(C34), 54.5 (C0), 52.2 (C37), 51.4 (C18), 50.9 (C17), 48.5 (C12), 33.2 (C36), 31.3
(C35), 29.4 (C36), 23.7 (C21), 16.3 (C13) ; IR (neat) ν 3741, 2918, 1731, 1688, 1553,
1437, 1182, 1121 cm-1; HRESI-MS: m/z calcd for [C34H42N2O10] 639.2839, found
639.2844.
Methyl (1S,2R,3R,4aS,13bR,14aS)-3-((4-(2-bromoethoxy)-3,5-dimethoxybenzoyl)
oxy)-2,11-dimethoxy-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodeca-hydroindolo[2',3': 3,4]
pyrido[1,2-b]isoquinoline-1-carboxylate 72
O-alkylated reserpine alcohol 71 (100 mg,
0.16 mmol) was dissolved in dry THF (20
mL) in a 50 mL flame-dried round bottom
flask under Ar. CBr4 (200 mg, 0.60 mmol)
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was added and the mixture stirred at room temperature for 10 min before adding PPh 3
(100 mg, 0.38 mmol) in one portion. Stirring was continued at room temperature for a
further 3 h while monitoring by TLC (Pet. spirit:EtOAc, 70:30). The solvent was
evaporated and the residue purified by silica gel column chromatography using a
gradient (Pet. spirit:EtOAc, 60:40 → 100% EtOAc) to give 72 (98 mg, 91%) as a
yellow-brown solid. TLC Rf (Pet. spirit:EtOAc, 60:40) = 0.55; Mp 140-143 ºC; 1H
NMR (500 MHz, CDCl3) δ 7.58 (br s, 1H, H7), 7.32 (m, 3H, H25, H29, H1), 6.85 (app
d, J = 2.0 Hz, 1H, H4), 6.78 (d, J = 10.0 Hz , 2.0 Hz, 1H, H2), 5.10 (sextet, J = 4.5 Hz,
1H, H20), 4.75 (t, J = 10.0 Hz, 2H, H40), 3.91 (s, 7H, H31, H33, H19), 3.77 (app t, 7H,
H30, H37, H38), 3.63 (t, J = 10.0 Hz, 2H, H41), 3.52 (s, 3H, H34), 3.18 (d, J = 7.1 Hz,
2H, H17), 3.05 (d, J = 7.1 Hz, 1H, H18), 2.97 (sextet, J = 7.1 Hz, 1H, H36) 2.73 (dd, J
= 10.0 Hz, 5.0 Hz, 2H, H14), 2.54-2.22 (m, 3H, H21, H35), 2.12-1.88 (m, 4H, H12,
H13);

13

C NMR (125 MHz, CDCl3) δ 172.1 (C39), 165.4 (C23), 156.6 (C3), 149.0

(C26, C28), 140.5 (C5, C8), 137.0 (C27), 122.0 (C24), 120.2 (C6, C9), 118.8 (C1),
109.0 (C2), 106.0 (C25, C29), 94.7 (C4), 69.3 (C40), 60.2 (C19, C20), 57.2 (C30, C31,
C33), 56.1 (C34), 54.5 (C0), 52.0 (C37), 51.1 (C18), 51.2 (C17), 48.2 (C12), 33.0
(C36), 31.6 (C41), 31.1 (C35), 29.6 (C36), 23.9 (C21), 18.1 (C13); IR (neat) ν 3744,
2916, 1734, 1683, 1558, 1437, 1183, 1119 cm-1; HRESI-MS: m/z calcd for
[C34H41BrN2O9] 701.2633, found 701.2645.
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Methyl (1S,2R,3R,4aS,13bR,14aS)-3-((4-(2-(4-(tert-butoxy carbonyl) piperazin-1yl)ethoxy)-3,5-dimethoxybenzoyl)oxy)-2,11-dimethoxy-1,2,3,4,4a,5,7,8,13,13b,14,
14a-dodecahydroindolo[2',3':3,4]pyrido[1,2-b]isoquin- oline-1-carboxylate 66
Bromide 72 (200 mg, 0.28 mmol)
was dissolved in dry THF (25 mL)
in a 50 mL flame-dried round
bottom flask under Ar and N-Bocpiperazine (150 mg, 0.78 mmol) and
triethylamine (500 mg, 5.0 mmol) were successively added. A reflux condenser was
attached and the mixture heated at 100 oC with stirring 16 h while monitoring by TLC
(60% EtOAc/Pet. spirit). The solvent was evaporated and the residue purified by silica
gel column chromatography (Pet. spirit:EtOAc, 50:50) to provide 66 (184 mg, 80%) as
a yellow-brown solid. TLC Rf (Pet. spirit:EtOAc, 60:40) = 0.25; Mp 170-172 ºC; 1H
NMR (500 MHz, CDCl3) δ 7.55 (br s, 1H, H7), 7.31 (m, 3H, H25, H29, H1), 6.78 (app
d, J = 2.0 Hz, 1H, H4), 6.69 (d, J = 10.0 Hz, 2.0 Hz, 1H, H2), 5.03 (sextet, J = 4.5 Hz,
1H, H20), 4.46 (app s, 1H, H19), 4.27 (t, J = 10.0, 2H, H40), 3.90 (s, 6H, H31, H33),
3.87 (t, J = 10.0 Hz, 1H, H38), 3.83 (s, 3H, H30), 3.80 (s, 3H, H37), 3.71 (t, J = 10.0
Hz, 2H, H41), 3.50 (s, 3H, H34), 3.41 (app dd, J = 8.5 Hz, 4H, H43, H45), 3.18 (d, J =
7.1 Hz, 2H, H17), 3.08 (d, J = 7.1 Hz, 1H, H18), 2.94 (sextet, J = 7.1 Hz, 1H, H36) 2.68
(dd, J = 10.0 Hz, 5.0 Hz, 2H, H14), 2.56 (app dd, J = 8.5 Hz, 4H, H42, H44), 2.50-2.24
(m, 3H, H21, H35), 2.18-1.92 (m, 4H, H12, H13), 1.45 (s, 9H, H46);

13

C NMR (125

MHz, CDCl3) δ 172.1 (C32), 166.0 (C23), 158.8 (C46), 156.2 (C3), 148.9 (C26, C28),
138.8 (C5, C8), 137.3 (C27), 121.2 (C24), 120.82 (C6, C9), 118.1 (C1), 109.0 (C2),
106.3 (C25, C29), 94.5 (C4), 79.4 (C46), 69.8 (C40), 68.5 (C10), 60.6 (C19, C20), 59.1
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(C41), 57.2 (C30, C31, C33), 56.1(C42, C44), 56.1 (C34), 52.0 (C37), 51.6 (C18), 51.1
(C17), 48.8 (C12), 45.8 (C43, C45), 33.0 (C15), 32.0 (C14), 31.5 (C14), 29.2 (C36),
27.9 (C46), 23.7 (C21), 16.3 (C13); IR (neat) ν 3741, 2935, 2794, 1700, 1695, 1457,
1418, 1248, 1152 cm-1; HRESI-MS: m/z calcd for [C43H58N4O11] 807.4180, found
807.4188.
Methyl (1S,2R,3R,4aS,13bR,14aS)-3-((4-(2-(4-(tert-butoxy carbonyl)piperazin-1yl)-2-oxoethoxy)-3,5-dimethoxybenzoyl)oxy)-2,11-dimethoxy-1,2,3,4,4a,5,7,8,13,13b
,14,14a-dodecahydroindolo[2',3':3,4]pyrido[1,2-b]isoquin-oline-1-carboxylate 68
Phenolic reserpine 70 (50 mg, 0.08
mmol) was dissolved in DMF (7
mL) in a 25 mL flame-dried round
bottom flask under Ar and K2CO3
(250 mg, 1.79 mmol) was added.
The mixture was stirred for 20 min before N-bromoacetyl-N’-Boc-piperazine 76 (40 mg,
0.13 mmol) was added in one portion. The mixture was stirred at 80 oC for 48 h while
monitoring by TLC (EtOAc:MeOH, 95:5). The solvent was evaporated and the residue
purified by silica gel column chromatography to yield 68 (43 mg, 64%) as a brown
solid. TLC Rf (EtOAc:MeOH, 95:5) = 0.25; Mp 138-141 ºC; 1H NMR (500 MHz,
CDCl3) δ 7.64 (br s, 1H, H7), 7.35 (m, 3H, H25, H29, H1), 6.82 (s, 1H, H4), 6.77 (d, J
= 15.0 Hz, 1H, H2), 5.05 (sextet, J = 4.5 Hz, 1H, H20), 4.68 (s, 2H, H40), 4.44 (app s,
1H, H19), 3.88 (s, 6H, H31, H33), 3.86 (t, J = 10.0 Hz, 1H, H38), 3.85 (s, 3H, H30),
3.81 (s, 3H, H37), 3.76 (app dd, J = 8.5 Hz, 4H, H42, H44), 3.63 (app dd, J = 8.5 Hz,
4H, H43, H45), 3.48 (s, 3H, H34), 3.19 (d, J = 7.1 Hz, 2H, H17), 3.07 (d, J = 7.1 Hz,
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1H, H18), 2.94 (sextet, J = 7.1 Hz, 1H, H36) 2.69 (dd, J = 10.0 Hz, 5.0 Hz, 2H, H14),
2.56-2.24 (m, 3H, H21, H35), 2.13-1.85 (m, 4H, H12, H13), 1.48 (s, 9H, H46);

13

C

NMR (125 MHz, CDCl3) δ 172.0 (C32), 168.2 (41), 165.6 (C23), 158.5 (C46), 156.0
(C3), 148.8 (C26, C28), 138.9 (C5, C8), 137.2 (C27), 121.1 (C24), 120.8 (C6, C9),
118.2 (C1), 109.1 (C2), 106.1 (C25, C29), 94.3 (C4), 79.2 (C46), 68.4 (C10), 65.7
(C40), 60.5 (C19, C20), 57.1 (C30, C31, C33), 56.0 (C34), 52.4 (C37), 51.9 (C43, C45),
51.5 (C18), 51.0 (C17), 50.6 (C42, C44), 48.6 (C12), 33.1 (C15), 31.8 (C14), 31.4
(C14), 29.1 (C36), 27.8 (C46), 23.8 (C21), 16.1 (C13); IR (neat) ν 3340, 2931, 2844,
1707, 1694, 1458, 1415, 1211, 1125 cm-1; HRESI-MS: m/z calcd for [C43H56N4O12]
821.3973, found 821.3987.
Methyl (1S,2R,3R,4aS,13bR,14aS)-3-((4-(2-((2-((tert-butoxy carbonyl) (methyl)
amino)ethyl)(methyl)amino)ethoxy)-3,5-dimethoxybenzoyl) oxy)-2,11-dimethoxy1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydroindolo[2',3':3,4] pyrido[1,2-b]isoquinol
one-1-carboxylate 67
Bromide 72 (200 mg, 0.28 mmol)
was dissolved in dry THF (20
mL) in a 50 mL flame-dried
round bottom flask under Ar and
N-Boc-N,N’-dimethylethylenedi
amine 75 (150 mg, 0.78 mmol) was added followed by triethylamine (500 mg, 5.0
mmol). A reflux condenser was attached and the mixture warmed to 100 oC and stirred
for 16 h while monitoring by TLC (Pet. spirit:EtOAc 60:40). The mixture was
concentrated and the residue purified by a silica gel column chromatography using 30%
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EtOAc/Pet. spirit to provide 67 (172 mg, 75%) as a brown solid. TLC Rf (Pet.
spirit:EtOAc 60:40) = 0.23; Mp 188-191 ºC; 1H NMR (500 MHz, CDCl3) δ 7.60 (br s,
1H, H7), 7.24 (m, 3H, H25, H29, H1), 6.91 (app d, J = 2.0 Hz, 1H, H4), 6.78 (d, J =
10.0 Hz, 2.0 Hz, 1H, H2), 5.04 (sextet, J = 4.5 Hz, 1H, H20), 4.54 (app s, 1H, H19),
4.21 (t, J = 10.0, 2H, H40), 3.89 (s, 6H, H31, H33), 3.86 (t, J = 10.0 Hz, 1H, H38), 3.81
(s, 3H, H30), 3.79 (s, 3H, H37), 3.71 (t, J = 10.0 Hz, 2H, H41), 3.48 (s, 3H, H34), 3.22
(t, J = 10.0 Hz, 2H, H43), 3.16 (d, J = 7.1 Hz, 2H, H17), 3.03 (d, J = 7.1, 1H, H18),
2.96 (sextet, J = 7.1 Hz, 1H, H36) 2.94 (s, 3H, H45), 2.92 (S, 3H, H44), 2.68 (dd, J =
10.0 Hz, 5.0 Hz, 2H, H14), 2.55 (t, J = 10.0 Hz, 2H, H42), 2.49-2.22 (m, 3H, H21,
H35), 2.16-1.90 (m, 4H, H12, H13), 1.44 (s, 9H, H46); 13C NMR (125 MHz, CDCl3) δ
171.6 (C32), 165.8 (C23), 158.5 (C46), 156.0 (C3), 149.1 (C26, C28), 139.0 (C5, C8),
137.1 (C27), 121.0 (C24), 120.4 (C6, C9), 117.6 (C1), 108.7 (C2), 105.9 (C25, C29),
94.1 (C4), 79.2 (C46), 69.5 (C40), 68.1 (C10), 60.4 (C19, C20), 59.0 (C41), 57.0 (C30,
C31, C33), 56.1 (C34), 55.3 (C42), 52.6(C43), 51.8 (C37), 51.4 (C18), 50.8 (C17), 48.6
(C12), 46.7 (C44), 36.8 (C45), 32.6 (C15), 31.6 (C14), 29.1 (C36), 28.4 (C46), 23.6
(C21), 16.1 (C13); IR (neat) ν 3419, 2941, 1709, 1684, 1458, 1330, 1216, 1158 cm-1;
HRESI-MS: m/z calcd for [C43H60N4O11] 809.4337, found 809.4369.
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Methyl

(1S,2R,3R,4aS,13bR,14aS)-3-((4-(2-((2-((tert-butoxycarbonyl)(methyl)

amino)ethyl)(methyl)amino)-2-oxoethoxy)-3,5-dimethoxyben-zoyl)oxy)-2,11dimethoxy-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydroindolo[2' ,3':3,4]pyrido[1,2b]isoquinoline-1-carboxylate 69
The phenolic reserpine derivative
70 (50 mg, 0.08 mmol) was
dissolved in dry DMF (7 mL) in a
50 mL oven-dried round bottom
flask under Ar and K2CO3 (250
mg, 1.79 mmol) was added. The mixture was stirred at room temperature for 30 min
before adding N-bromoacetyl-N’-Boc-N,N’-dimethylethylenediamine 77 (40 mg, 0.13
mmol) in one portion. The reaction mixture was heated to 80 oC and stirred for 48 h
while monitoring by TLC (EtOAc:MeOH, 95:5). The solvent was evaporated and the
residue purified by silica gel column chromatography using a gradient (100% EtOAc →
5% MeOH/EtOAc) to give 69 (47 mg, 70%) as a brown solid. TLC Rf (EtOAc:MeOH,
95:5) = 0.20; Mp 103-105 ºC; 1H NMR (500 MHz, CDCl3) δ 7.63 (br s, 1H, H7), 7.367.28 (m, 3H, H25, H29, H1), 6.91 (app d, J = 1.0 Hz, 1H, H4), 6.78 (d, J = 10.0 Hz, 1.0
Hz, 1H, H2), 5.04 (sextet, J = 4.5 Hz, 1H, H20), 4.68 (s, 2H, H40), 4.51 (app s, 1H,
H19), 3.89 (s, 6H, H31, H33), 3.84 (s, 3H, H30), 3.81 (s, 3H, H37), 3. 68 (app s, 1H,
H38), 3.49 (s, 3H, H34), 3.40 (t, J = 10.0 Hz, 2H, H43), 3.17 (d, J = 7.1 Hz, 2H, H17),
3.03 (d, J = 7.1 Hz, 1H, H18), 2.94 (s, 3H, H45), 2.92 (S, 3H, H44), 2.88 (sextet, J = 7.1
Hz, 1H, H36), 2.70 (dd, J = 10.0 Hz, 5.0 Hz, 2H, H14), 2.55 (t, J = 10.0 Hz, 2H, H42),
2.49-2.22 (m, 3H, H21, H35), 2.16-1.90 (m, 4H, H12, H13), 1.44 (s, 9H, H46);

13

C

NMR (125 MHz, CDCl3) δ 171.4 (C32), 166.4 (C41), 165.3 (C23), 158.2 (C46), 156.1
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(C3), 149.3 (C26, C28), 139.0 (C5, C8), 136.0 (C27), 121.5 (C24), 119.3 (C6, C9),
117.4 (C1), 108.4 (C2), 104.7 (C25, C29), 93.0 (C4), 79.5 (C46), 69.0 (C40), 67.4
(C10), 60.2 (C19, C20), 56.8 (C30, C31, C33), 56.0 (C34), 53.3 (C43), 52.4 (C42), 51.6
(C37), 51.3 (C18), 50.7 (C17), 48.5 (C12), 43.7 (C45), 36.6 (C44), 32.5 (C15), 31.8
(C14), 29.1 (C36), 28.3 (C46), 23.3 (C21), 16.3 (C13); IR (neat) ν 3291, 2935, 2828,
2162, 1704, 1696, 1458, 1415, 1213, 1126 cm-1; HRESI-MS: m/z calcd for
[C43H58N4O12] 823.4129, found 823.4135.
6.1.5 Synthesis of Pterostilbene-Containing Intermediates
(E)-2-(4-(3,5-Dimethoxystyryl)phenoxy)ethan-1-ol 82
To a solution of pterostilbene 9 (300 mg, 1.1 mmol) in
anhydrous DMF (10 mL) in a 25 mL flame-dried
round bottom flask under Ar was added K2CO3 (260
mg, 1.1 mmol) and the mixture was stirred at room
temperature for 20 min. 2-Bromoethanol (300 mg, 2.5 mmol) was added dropwise over
10 min and the reaction mixture warmed to 80 oC and stirred for 16 h while monitoring
by TLC (Pet. spirit:EtOAc, 50:50). The solvent was evaporated under reduce pressure
and the residue re-dissolved in CH2Cl2. The organic layer was washed successively with
water and brine, dried over anhydrous Na2SO4 and concentrated. The crude residue was
purified by silica gel column chromatography using 10% EtOAc/Pet. spirit to afford 82
(280 mg, 90%) as an off-white powder. TLC Rf (Pet. spirit:EtOAc, 50:50) = 0.45; Mp
83-84 ºC; 1H NMR (500 MHz, CD3OD) δ 7.46 (d, J = 10.0 Hz, 2H, H6, H2), 7.05 (d, J
= 15.8 Hz, 1H, H9), 6.93 (m, 3H, H3, H5, H8), 6.67 (s, 2H, H12, H14), 6.38 (s, 1H,
H16), 4.31 (t, J = 12.0 Hz, 2H, H18), 3.78 (s, 6H, H10, H11), 3.65 (t, J = 14.0 Hz, 2H,
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H19);

13

C NMR (125 MHz, CD3OD) δ 162.6 (C4), 161.8 (C15, C17), 141.5 (C13),

130.8 (C2, C6), 128.3 (C9), 127.9 (C8), 114.9 (C3, C5), 105.0 (C12, C14), 100.4 (C16),
69.7 (C18), 60.9 (C19), 54.8 (C10, C11); IR (neat) ν 3671, 2927, 2348, 1586, 1146,
1129, 1110 cm-1; HRESI-MS: m/z calcd for [C18H19NaO4] 322.1181, found 322.1189.
(E)-1-(4-(2-Bromoethoxy)styryl)-3,5-dimethoxybenzene 83
To a solution of alcohol 82 (200 mg, 0.67 mmol) in
anhydrous THF (25 mL) in a 50 mL flame-dried round
bottom flask under Ar was added CBr4 (850 mg, 2.5
mmol). PPh3 (262 mg, 1.0 mmol) was then added in
one portion and the reaction stirred for 3 h at room temperature while monitoring by
TLC (Pet. spirit:EtOAc, 50:50). The solvent was evaporated and the residue redissolved in EtOAc. The organic layer was washed successively with water and brine,
dried over anhydrous MgSO4 and concentrated. The crude residue was purified by silica
gel column chromatography to afford 83 (225 mg, 94%) as an off-white foam. TLC Rf
(Pet. spirit:EtOAc, 50:50) = 0.69; Mp 76-77 ºC; 1H NMR (500 MHz, CD3OD) δ 7.45 (d,
J = 10.0 Hz, 2H, H6, H2), 7.08 (d, J = 15.8 Hz, 1H, H9), 6.95 (m, 3H, H3, H5, H8),
6.66 (s, 2H, H12, H14), 6.35 (s, 1H, H16), 4.30 (t, J = 12.0 Hz, 2H, H18), 3.76 (s, 6H,
H10, H11), 3.63 (t, J = 14.0 Hz, 2H, H19); 13C NMR (125 MHz, CD3OD) δ 161.9 (C4),
161.5 (C15, C17), 141.0 (C13), 130.8 (C2, C6), 127.8 (C9), 127.9 (C8), 115.2 (C3, C5),
106.1 (C12, C14), 99.8 (C16), 69.5 (C18), 60.8 (C19), 55.01 (C10, C11) ; IR (neat) ν
2928, 2346, 1583, 1145, 1122, 1115 cm-1; HRESI-MS: m/z calcd for [C18H19BrO3]
362.0518, found 362.0524.

153

Tert-butyl (E)-4-(2-(4-(3,5-dimethoxystyryl)phenoxy)ethyl)piperazine-1carboxylate 78
To a solution of bromide 83 (150 mg, 0.41
mmol) in anhydrous THF (30 mL) in a 50 mL
oven-dried round bottom flask under Ar was
added KI (300 mg, 1.80 mmol). N-Bocpiperazine (120 mg, 0.63 mol) was then added in one portion, a reflux condenser
attached and the reaction heated at 100 oC with stirring for 48 h while monitoring by
TLC (Pet. spirit:EtOAc, 50:50). The solvent was evaporated and the residue redissolved in EtOAc (50 mL). The organic layer was washed successively with water
and brine, dried over anhydrous Na2SO4 and concentrated. The crude residue was
purified by silica gel column chromatography using a gradient (10 → 15% EtOAc/Pet.
Spirit) to give 78 (166 mg, 87%) as an off-white solid. TLC Rf (Pet. spirit:EtOAc,
50:50) = 0.30; Mp 103-105 ºC; 1H NMR (500 MHz, CDCl3) δ 7.40 (d, J = 10.0 Hz, 2H,
H6, H2), 7.12 (d, J = 15.8 Hz, 1H, H9), 6.90 (m, 3H, H3, H5, H8), 6.70 (s, 2H, H12,
H14), 6.38 (s, 1H, H16), 4.31 (t, J = 12.0 Hz, 2H, H18), 3.75 (s, 6H, H10, H11), 3.43
(dd, J = 7.5 Hz, 4H, H22, H24), 3.65 (t, J = 14.0 Hz, 2H, H19), 2.65 (dd, J = 7.5 Hz,
4H, H21, H25), 1.46 (s, 9H, H23) ;

13

C NMR (125 MHz, CDCl3) δ 161.4 (C23), 160.8

(C15, C17), 159.9 (C4), 141.5 (C13), 131.6 (C2, C6), 128.1 (C9), 127.6 (C8), 115.0
(C3, C5), 106.0 (C12, C14), 100.4 (C16), 76.8 (C23), 69.4 (C18), 58.9 (C19), 57.6
(C21, C25), 54.5 (C10, C11), 47.4 (C22, C24), 28.9 (C23); IR (neat) ν 2934, 2836,
1685, 1584, 1513, 1425, 1248, 1145 cm-1; HRESI-MS: m/z calcd for [C27H36N2O5]
491.4463, found 491.4487.
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Tert-butyl (E)-4-(2-(4-(3,5-dimethoxystyryl)phenoxy)acetyl) piperazine-1-carboxy
late 80
To a solution of phenolic pterostilbene 9 (256
mg, 1.0 mmol) in anhydrous DMF (10 mL) in a
25 mL oven-dried round bottom flask under Ar
was added K2CO3 (552 mg, 4.0 mmol). Nbromoacetyl-N’-Boc-piperazine 76 (460 mg, 1.5 mmol) was then added in one portion
and a reflux condenser attached and the reaction stirred at 100 oC for 48 h while
monitoring by TLC (pet. Spirit:EtOAc, 50:50). The solvent was evaporated and the
residue redissolved in CH2Cl2 (50 mL). The organic layer was washed successively with
water and brine, dried over anhydrous NaSO4 and concentrated. The crude residue was
purified by silica gel column chromatography using 15% EtOAc/Pet. spirit to afford 80
(371 mg, 77%) as an off-white solid. TLC Rf (Pet. spirit:EtOAc, 55:45) = 0.42; Mp 5253 ºC; 1H NMR (500 MHz, CDCl3) δ 7.44 (d, J = 10.0 Hz, 2H, H6, H2), 7.11 (d, J =
15.8 Hz, 1H, H9), 7.05-6.86 (m, 3H, H3, H5, H8), 6.63 (app d, J = 1.5 Hz, 2H, H12,
H14), 6.37 (s, 1H, H16), 4.71 (s, 2H, H18), 3.81 (s, 6H, H10, H11), 3.57 (dd, J = 7.5
Hz, 4H, H21, H25), 3.42 (dd, J = 7.5 Hz, 4H, H22, H24), 1.46 (s, 9H, H23); 13C NMR
(125 MHz, CDCl3) δ 166.8 (C19), 161.2 (C15, C17), 157.6 (C4), 154.7 (C23), 139.7
(C13), 131.1 (C7), 128.6 (C9), 128.1 (C2, C6), 127.5 (C8), 115.0 (C3, C5), 104.5 (C12,
C14), 100.0 (C16), 80.6 (C23), 68.2 (C18), 55.6 (C10, C11), 45.6 (C22, C24), 42.2
(C21, C25), 28.6 (C23); IR (neat) ν 2930, 2886, 1684, 1651, 1589, 1510, 1436, 1232,
1219 cm-1; HRESI-MS: m/z calcd for [C27H34N2O6] 505.2315, found 505.2331.
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Tert-butyl (E)-(2-((2-(4-(3,5-dimethoxystyryl)phenoxy)ethyl) (methyl)amino)ethyl)
(methyl)carbamate 79
To a stirring solution of pterostilbene alkyl
bromide 83 (150 mg, 0.41 mol) in anhydrous
CH2Cl2 (30 mL) in a 50 mL oven-dried round
bottom flask under Ar was added K2CO3 (250
mg, 1.80 mmol). N-Boc-N,N’-dimethylethylenediamine 75 (120 mg, 0.63 mol) was then
added in one portion, a reflux condenser attached and the reaction heated at 60 oC for 48
h while monitoring by TLC (Pet. spirit:EtOAc, 50:50). The cooled reaction mixture was
diluted with CH2Cl2 (30 mL) and the organic layer washed successively with water and
brine, dried over anhydrous Na2CO3 and concentrated. The crude residue was purified
by silica gel column chromatography using a gradient (15% EtOAc/Pet. spirit to 100%
EtOAc) to provide 79 (154 mg, 81%) as a pale yellow solid. TLC Rf (Pet. spirit:EtOAc,
50:50) = 0.27; Mp 131-135 ºC; 1H NMR (500 MHz, CDCl3) δ 7.44 (d, J = 10.0 Hz, 2H,
H6, H2), 7.14 (d, J = 15.8 Hz, 1H, H9), 7.06-6.90 (m, 3H, H3, H5, H8), 6.65 (s, 2H,
H12, H14), 6.37 (s, 1H, H16), 4.29 (t, J = 12.0 Hz, 2H, H18), 3.75 (s, 6H, H10, H11),
3.13 (t, J = 7.5 Hz, 2H, H24), 2.75 (t, J = 7.1 Hz, 2H, H19), 2.57 (s, 3H, H22), 2.43 (3, J
= 7.1 Hz, 2H, H25), 2.19 (s, 3H, H21), 1.45 (s, 9H, H23); 13C NMR (125 MHz, CDCl3)
δ 161.2 (C23), 160.7 (C15, C17), 159.6 (C4), 141.0 (C13), 131.3 (C2, C6), 128.0 (C9),
127.2 (C8), 114.7 (C3, C5), 105.5 (C12, C14), 99.8 (C16), 78.1 (C23), 67.9 (C18), 58.9
(C19), 56.2 (C25), 54.4 (C10, C11), 53.1 (C24), 46.4 (C22), 37.5 (C21), 28.7 (C23); IR
(neat) ν 2944, 2861, 1687, 1585, 1511, 1422, 1247, 1125 cm-1; HRESI-MS: m/z calcd
for [C27H38N2O5] 493.2356, found 493.2364.
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Tert-butyl (E)-(2-(2-(4-(3,5-dimethoxystyryl)phenoxy)-N-methyl acetamido)ethyl)
(methyl)carbamate 81
To a stirring solution of phenolic pterostilbene
9 (256 mg, 1.0 mmol) in anhydrous DMF (10
mL) in a 25 mL oven-dried round bottom flask
under Ar was added K2CO3 (552 mg, 4.0
mmol). N-bromoacetyl-N’-Boc-N,N’-dimethylethylenediamine 77 (460 mg, 1.5 mmol)
was added in one portion, a reflux condenser attached and the reaction heated at 80 oC
for 24 h while monitoring by TLC (Pet. spirit:EtOAc, 50:50). The reaction mixture was
concentrated and the residue redissolved in CH2Cl2 (30 mL). The organic layer was
washed successively with water and brine, dried over anhydrous MgSO4 and
concentrated. The residue was purified by silica gel column chromatography using a
gradient (Pet. spirit:EtOAc, 85:15 to 100% EtOAc) to afford 81 (255 mg, 77%) as a
pale yellow solid. TLC Rf (Pet. spirit:EtOAc, 50:50) = 0.27; Mp 118-120 ºC; 1H NMR
(500 MHz, CDCl3) δ 7.41 (d, J = 18.0 Hz, 2H, H6, H2), 7.07-6.86 (m, 4H, H3, H5, H8,
H9), 6.64 (s, 2H, H12, H14), 6.38 (s, 1H, H16), 4.69 (d, J = 18.0 Hz, 2H, H18), 3.82 (s,
6H, H10, H11), 3.54 (t, J = 8.5 Hz, 2H, H25), 3.39 (t, J = 8.5 Hz, 2H, H24), 3.10 (s, 3H,
H21), 2.86 (s, 3H, H22), 1.45 (s, 9H, H23); 13C NMR (125 MHz, CDCl3) δ 167.8 (C19),
160.9 (C15, C17), 157.7 (C4), 155.9 (C23), 139.6 (C13), 130.8 (C7), 128.5 (C9), 127.8
(C2, C6), 127.0 (C8), 114.9 (C3, C5), 104.4 (C12, C14), 97.7 (C16), 79.8 (C23), 67.1
(C18), 55.3 (C10, C11), 47.4 (C24), 45.5 (C25), 34.8 (C21, C22), 28.4 (C23); IR (neat)
ν 2935, 2831, 1684, 1659, 1590, 1509, 1457, 1204, 1173, 1148 cm-1; HRESI-MS: m/z
calcd for [C27H36N2O6] 507.2471, found 507.2486.
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6.1.6 Synthesis of INF55-Containing Intermediates
2-(4-(Bromomethyl)phenyl)-5-nitro-1H-indole 90
To a solution of the methyl ester 88 (80 mg, 0.27 mmol) in
dry THF (5.0 mL) under Ar was added NaBH4 (50 mg, 1.3
mmol) and the reaction stirred at room temperature while
monitoring by TLC (pet. Spirit:EtOAc, 50:50). After 24 h the reaction was quenched by
slow addition of sat. NH4Cl (aq) until bubbling ceased. The mixture was diluted with
water (50 mL) and extracted with EtOAc (4 x 50 mL). The combined organic layers
were dried over anhydrous MgSO4 and concentrated to give benzylic alcohol 89 (85%)
as a bright yellow powder. TLC Rf (Pet. spirit:EtOAc, 50:50) = 0.42; Mp 215-218 oC;
1

H NMR (500 MHz, (CD3)2CO) δ 11.37 (br.s, 1H, H9), 8.53 (s, 1H, H2), 8.04 (d, J =

8.5 Hz, 1H, H5), 7.89 (d, J = 8.5 Hz, 2H, H13, H17), 7.59 (d, J = 8.5 Hz, 1H, H4), 7.51
(d, 2H, J = 8.5 Hz, H14, H16), 7.17 (s, 1H, H7), 4.72 (s, 2H, H18);

13

C NMR (125

MHz, (CD3)2CO) δ 146.3 (C6), 143.1 (C15), 141.2 (C8), 140.1 (C12), 131.5 (C3), 130.9
(C14, C16), 130.0 (C1), 125.8 (C13, C17), 119.1 (C4), 118.4 (C5), 110.6 (C2), 101.7
(C7), 64.3 (C18). The alcohol 89 (30 mg, 0.10 mmol) and CBr4 (100 mg, 0.30 mmol)
were added to a flame-dried 25 mL round bottom flask followed by anhydrous
Et2O/THF (1:1, 5 mL). The mixture was stirred at room temperature for 30 min before
PPh3 (80 mg, 0.31 mmol) was added in one portion. The reaction was stirred at room
temperature for 3 h while monitoring by TLC (Pet. spirit:EtOAc, 70:30). The solvent
was evaporated and the residue purified by silica gel column chromatography using Pet.
spirit:EtOAc 90:10 to yield 90 (30 mg, 94%) as a yellow powder. TLC Rf (Pet.
spirit:EtOAc, 50:50) = 0.91; Mp 198-199 oC; 1H NMR (500 MHz, (CD3)2CO) δ 10.14
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(br.s, 1H, H9), 9.27 (s, 1H, H2), 8.05 (d, 1H, J = 8.5 Hz, H5), 7.91 (d, 2H, J = 7.5 Hz,
H4), 7.61-7.57 (m, 4H, H13, H14, H16, H17), 6.92 (s, 1H, H7), 4.51 (s, 2H, H18);

13

C

NMR (125 MHz, (CD3)2CO) δ 143.0 (C6), 142.1 (C8), 138.3 (C15), 137.6 (C10), 135.8
(C12), 132.5 (C3), 129.5 (C14, C16), 129.2 (C7), 125.8 (C13, C17), 113.7 (C4), 112.2
(C5), 98.6 (C11), 33.3 (C2). HRESI-MS: m/z calcd for [C15H11BrN2O2] 330.0018,
found 330.0023.
Tert-butyl 4-(4-(5-nitro-1H-indol-2-yl)benzyl)piperazine-1-carboxylate 84
Bromide 90 (70 mg, 0.21 mmol) was dissolved in
anhydrous THF (25 mL) under Ar and KI (175 mg, 1.1
mmol) added. The mixture was stirred at room
temperature for 30 min before adding N-Boc-piperazine (100 mg, 0.53 mmol) in one
portion. The reaction was then heated at reflux for 48 h while monitoring by TLC (Pet.
spirit:EtOAc, 70:30). The mixture was concentrated and the residue purified by silica
gel column chromatography using Pet. spirit:EtOAc 85:15 to afford 84 (89 mg, 96%) as
a yellow solid. TLC Rf (Pet. spirit:EtOAc, 70:30) = 0.43; Mp 208-210 ºC; 1H NMR (500
MHz, (CD3)2SO) δ 12.25 (br.s, 1H, H9), 8.53 (s, 1H, H2), 7.89 (d, J = 7.5 Hz, 2H, H5),
7.84 (d, J = 8.5 Hz, 2H, H13, H17), 7.53 (d, J = 7.5 Hz,1H, H4), 7.42 (d, J = 8.5, 2H,
H14, H16), 7.15 (s, 1H, H7), 3.51 (s, 2H, H18), 3.30 (m, 4H, H20, H22), 2.33 (m, 4H,
H19, H23), 1.37 (s, 9H, H21) ;

13

C NMR (125 MHz, (CD3)2SO) δ 155.0 (C21), 142.4

(C6), 141.2 (C15), 139.9 (C8), 139.0 (C12), 130.2 (C3), 130.0 (C14, C16), 128.7 (C1),
125.5 (C13, C17), 118.0 (C4), 117.7 (C5), 110.9 (C2), 101.6 (C7), 70.9 (C21), 62.7
(C18), 53.0 (C19, C23, C20, C22), 28.6 (C21) ; IR (neat) ν 3272, 2969, 2811, 2769,
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1663, 1520, 1476, 1330, 1318, 1216, 1158 cm-1; HRESI-MS: m/z calcd for
[C24H28N4O4] 435.2032, found 435.2043.
4-(5-nitro-1H-indol-2-yl)benzoic acid 91
To a solution of methyl ester 88 (250 mg, 0.84 mmol) in
MeOH/CH2Cl2 (10:90 v/v, 40 mL) was added methanolic
NaOH (3 N, 2.5 mL). The mixture was stirred at room
temperature for 30 min before attaching a reflux condenser and heating the reaction
overnight at reflux while monitoring by TLC (CH2Cl2:MeOH, 90:10). The solvent was
removed under reduced pressure and the residue redissolved in water (100 mL). The
aqueous layer was washed with CH2Cl2 (2 x 60 mL) and the pH reduced to 2-3 by
dropwise addition of 5% HCl. The aqueous layer was extracted with CH 2Cl2 (3 x 50
mL). The combined organic layers were washed with water and brine, dried over
anhydrous MgSO4 and concentrated to give 91 (230 mg, 96%) as a yellow powder. TLC
Rf (CH2Cl2:MeOH, 90:10) = 0.21; Mp 138-139 ºC; 1H NMR (500 MHz, (CD3)2SO) δ
12.41 (s, 1H, H9), 8.56 (s, 1H, H2), 8.02 (m, 5H, H5, H13, H14, H16, H17), 7.57 (d, J =
10.0 Hz, 1H, H4),7.31 (s, 1H, H7);

13

C NMR (125 MHz, (CD3)2CO) δ 174.2 (C18),

148.3 (C6), 143.1 (C15), 141.2 (C8), 140.1 (C12), 131.5 (C3), 130.9 (C14, C16), 130.0
(C1), 125.8 (C13, C17), 119.1 (C4), 118.4 (C5), 110.6 (C2), 101.7 (C7); IR (neat) ν
3420, 3233, 2891, 2787, 2771, 1793, 1518, 1473, 1321, 1317, 1210, 1151 cm-1; HRESIMS: m/z calcd for [C15H10N2O4] 281.0689, found 281.0680.
Tert-butyl 4-(4-(5-nitro-1H-indol-2-yl)benzoyl)piperazine-1-carboxylate 86
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The acid 91 (20 mg, 0.07 mmol) was dissolved in
anhydrous THF (10 mL) under Ar and DIEA (9.0 mg,
0.07 mmol) added. N-Boc-piperazine (16 mg, 0.08
mmol) and HATU (35 mg, 0.09 mmol) were then successively added and the reaction
stirred at room temperature for 5 h while monitoring by TLC (Pet. spirit:EtOAc, 30:70).
The solvent was removed under reduced pressure and the residue redissolved in CH2Cl2.
The organic layer was washed with 5% aqueous HCl, water and brine and then dried
over anhydrous Na2SO4 and concentrated. The crude residue was purified by silica gel
column chromatography using Pet. spirit:EtOAc 60:40 to afford 86 (26 mg, 85%) as a
yellow solid. TLC Rf (Pet. spirit:EtOAc, 30:70) = 0.50; Mp 210-12 ºC; 1H NMR (500
MHz, (CD3)2CO) δ 11. 05 (br.s, 1H, H9), 8.58 (s, 1H, H2), 8.06 (d, J = 7.5 Hz, 1H, H5),
7.99 (d, J = 8.5 Hz, 2H, H13, H17), 7.74 (d, J = 8.5, 2H, H14, H16), 7.60 (d, J = 8.5
Hz,1H, H4), 7.27 (s, 1H, H7), 3.35 (m, 4H, H19, H22), 2.13 (m, 4H, H20, H23), 1.43 (s,
9H, H21);

13

C NMR (125 MHz, (CD3)2CO) δ 171.1 (C18), 151.8 (C21), 147.5 (C6),

142.5 (C15), 140.6 (C8), 139.0 (C12), 131.4 (C3), 130.8 (C14, C16), 129.5 (C1), 125.9
(C13, C17), 119.1 (C4), 118.3 (C5), 110.5 (C2), 101.8 (C7), 68.2 (C21), 46.0 (C20,
C23), 40.4 (C19, C22), 29.3 (C21); IR (neat) ν 3267, 2957, 2795, 2768, 1701, 1663,
1521, 1475, 1322, 1312, 1215, 1119 cm-1; HRESI-MS: m/z calcd for [C24H26N4O5]
449.1825, found 449.1826.
Tert-butyl methyl(2-(methyl(4-(5-nitro-1H-indol-2-yl)benzyl)amino)ethyl)
carbamate 85
Bromide 90 (80 mg, 0.24 mmol) was dissolved in
anhydrous THF (25 mL) under Ar in a 50 mL oven-
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dried round bottom flask. KI (200 mg, 1.12 mmol) was added and the mixture stirred at
room temperature for 30 min before adding N-Boc-N,N’-dimethylethylenediamine 75
(100 mg, 0.53 mmol) in one portion. A reflux condenser was attached and the reaction
heated to reflux for 48 h while monitoring by TLC (Pet. spirit:EtOAc, 70:30). The
solvent was evaporated and the residue purified by silica gel column chromatography
using a gradient from Pet. spirit:EtOAc 60:40 to 100% EtOAc to yield 85 (63 mg,
78%) as a yellow solid. TLC Rf (Pet. spirit:EtOAc, 70:30) = 0.23; Mp 118-120 ºC; 1H
NMR (500 MHz, (CD3)2SO) δ 12.26 (br.s, 1H, H9), 8.55 (s, 1H, H2), 8.00-7.82 (m, 3H,
H5, H13, H17), 7.60-7.38 (m, 3H, H4, H14, H16), 7.21 (s, 1H, H7), 4.00 (s, 2H, H18),
3.37 (m, 4H, H23, H22), 2.66 (s, 3H, H20), 1.96 (s, 3H, H19), 1.36 (s, 9H, H21);

13

C

NMR (125 MHz, (CD3)2SO) δ 158.8 (C21), 142.1 (C6), 141.2 (C15), 140.0 (C8), 139.7
(C12), 129.9 (C3), 129.6 (C14, C16), 128.6 (C1), 125.3 (C13, C17), 117.8 (C4), 117.5
(C5), 110.7 (C2), 101.2 (C7), 79.4 (C21), 62.0 (C23), 47.1 (C22), 42.7 (C19), 35.0
(C20), 28.4 (C21); IR (neat) ν 3268, 2961, 2810, 2776, 1668, 1523, 1475, 1396, 1330,
1317, 1211, 1153 cm-1; HRESI-MS: m/z calcd for [C24H30N4O4] 437.2189, found
437.2180.
Tert-butyl methyl(2-(N-methyl-4-(5-nitro-1H-indol-2 yl)benzamido)ethyl)
carbamate 87
The acid 91 (20 mg, 0.07 mmol) was dissolved in
anhydrous THF (9 mL) under Ar in a 25 mL flamedried round bottom flask. DIEA (9.0 mg, 0.07
mmol), N-Boc-piperazine (16 mg, 0.088 mmol) and
HATU (35 mg, 0.09 mmol) were successively added and the reaction stirred at room
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temperature for 7 h while monitoring by TLC (pet. Spirit:EtOAc, 70:30). The solvent
was evaporated and the residue redissolved in CH2Cl2 (30 mL). The organic layer was
washed with 5% aqueous HCl, water and brine, dried over anhydrous Na2SO4 and
concentrated. The crude residue was purified by silica gel column chromatography
using a gradient from Pet. spirit:EtOAc 60:40 to 100% EtOAc to provide 87 (23 mg,
78%) as a yellow solid. TLC Rf (Pet. spirit:EtOAc, 70:30) = 0.45; Mp 162-164 ºC; 1H
NMR (500 MHz, CDCl3) δ 12.20 (br.s, 1H, H9), 8.57 (s, 1H, H2), 7.61 (d, J = 11.5 Hz,
2H, H13, H17), 7.49 (d, 1H, H5), 7.43-7.27 (m, 3H, H4, H14, H16), 6.91 (d, J = 11.4
Hz,1H, H7), 3.76-3.32 (m, 4H, H23, H22), 2.76 (s, 3H, H20), 1.68 (s, 3H, H19), 1.46 (s,
9H, H21); 13C NMR (125 MHz, CDCl3) δ 174.0 (C18), 157.0 (C21), 142.0 (C6), 140.4
(C15), 139.8 (C8), 139.1 (C12), 129.1 (C3), 128.1 (C14, C16), 127.5 (C1), 125.2 (C13,
C17), 116.9 (C4), 116.3 (C5), 110.3 (C2), 101.2 (C7), 79.8 (C21), 61.9 (C23), 47.1
(C22), 43.1 (C19), 36.8 (C20), 28.5 (C21); IR (neat) ν 3233, 2981, 2790, 1697, 1675,
1598, 1472, 1398, 1332, 1317, 1166, 1028 cm-1; HRESI-MS: m/z calcd for
[C24H28N4O5] 451.1981, found 451.1988.
6.1.7 Synthesis of INF271-Containing Intermediates
1-(2-hydroxyphenyl)-3-(naphthalen-2-yl)urea 98
O-Aminophenol (4.0 g, 36.7 mmol) was added to a solution of
2-naphthaleneisocyanate 97 (4.00 g, 23.6 mmol) in dry CH2Cl2
(100 mL) in one portion. The reaction was stirred at room
temperature for 48 h while monitored by TLC (Pet. spirit:EtOAc, 50:50). The white
precipitate was filtered, washed with dry CH2Cl2:Et2O, 50:50 (2 x 100 mL) and dried in
vacuo. The residue was additionally washed with 1M aqueous HCl in cases where O163

aminophenol was observed in the 1H NMR spectrum of the product. Compound 98
(5.20 g, 80%) was obtained as an off-white powder. TLC Rf (Pet. spirit:EtOAc, 50:50) =
0.48; Mp 163-165 ºC; 1H NMR (500 MHz, (CD3)2SO) δ 9.98 (s, 1H, H20), 9.50 (s, 1H,
H11), 8.24 (s, 1H, H13), 8.12 (s, 1H, H10), 8.08 (d, 1H, J = 9.8 Hz, H3), 7.82 (d, J =
10.0 Hz, 1H, H6), 7.80 (d, J = 10.0 Hz, 1H, H19), 7.78 (d, J = 10.0 Hz, 1H, H8), 7.45,
7.40 (dd, J = 10.0 Hz, 2H, H1, H2 ), 7.33 (d, J = 9.8 Hz, 1H, H17), 6.86 (d, J = 10.0
Hz,1H, H7), 6.96, 6.98 (dd, J = 10.0 Hz, 2H, H16, H18);

13

C NMR (125 MHz,

(CD3)2SO) δ 153.3 (C12), 146.3 (C15), 138.3 (C9), 134.5 (C5), 129.7 (C4), 129.1 (C3),
128.5 (C14), 128.1 (C17), 127.6 (C1), 127.0 (C6), 122.5 (C2), 120.1 (C19), 119.3 (C8),
115.1 (C10), 113.6 (C16); IR (neat) ν 3669, 3316, 2978, 2923, 1701, 1654, 1602, 1534,
1460, 1250, 1220 cm-1; HRESI-MS: m/z calcd for [C17H14N2O2] 277.0977, found
277.0973.
1-(2-(3-Hydroxypropoxy)phenyl)-3-(naphthalen-2-yl)urea 99
Phenolic urea 98 (1.0 g, 3.6 mmol) and KOH (1.20 g, 8.63
mmol) were added to a 50 mL oven-dried round bottom flask
under argon. Anhydrous DMF (7 mL) was added and the
mixture cooled to 0 oC before adding 3-bromopropanol (600
mg, 4.3 mmol) over 20 min. The reaction was stirred at room
temperature for 16 h while monitoring by TLC (Pet. spirit:EtOAc, 50:50). The DMF
was evaporated and the residue purified by silica gel column chromatography using a
gradient of EtOAc:Pet. spirit 30:70 to 100% EtOAc. The product isolated was
redissolved in EtOAc (250 mL) and washed with 1 M KOH and brine. The organic
layer was dried over anhydrous MgSO4 and concentrated to yield 99 (904 mg, 75%) as
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an off-white powder. TLC Rf (Pet. spirit:EtOAc, 50:50) = 0.32; Mp 145-146 ºC; 1H
NMR (500 MHz, (CD3)2SO) δ 9.62 (s, 1H, H11), 8.18 (d, J = 7.5 Hz, 1H, H19), 8.15 (s,
1H, H13), 8.14 (s, 1H, H10), 7.84 (d, J = 7.4 Hz, 1H, H6), 7.80 (dd, J = 7.5 Hz, 2H, H8,
H3), 7.51 (d, J = 7.5 Hz, 1H, H7), 7.43 (t, J = 7.5 Hz, 1H, H2), 7.34 (t, J = 7.5 Hz, 1H,
H1), 7.02 (d, J = 7.5 Hz,1H, H16), 6.92 (dd, J = 7.5 Hz, 2H, H17, H18), 4.70 (s, J = 6.5
Hz, 1H, H24), 4.27 (t, J = 6.5 Hz, 2H, H21), 3.65 (t, J = 6.5 Hz, 2H, H23), 1.97 (q, J =
6.5 Hz, 2H, H22);

13

C NMR (125 MHz, (CD3)2SO) δ 155.4 (C15), 149.9 (C12), 140.3

(C9), 136.6 (C5), 131.9 (C6), 131.6 (C14), 131.3 (C7), 130.3 (C17), 129.85 (C4), 129.2
(C3), 126.8 (C1), 124.8 (C2), 123.3 (C18), 122.4 (C8), 121.7 (C19), 116.2 (C10), 114.6
(C16) 68.4 (C21), 60.3 (C23) 34.9 (C22); IR (neat) ν 3672, 3318, 2977, 2921, 1699,
1653, 1601, 1534, 1461, 1251, 1222 cm-1; HRESI-MS: m/z calcd for [C20H20N2O3]
335.1396, found 335.1402.
1-(2-(3-Bromopropoxy)phenyl)-3-(naphthalen-2-yl)urea 100
CBr4 (3.10 g, 9.0 mmol) was added to a solution of alcohol 99
(800 mg, 2.4 mmol) in dry THF (30mL) in a 50 mL flamedried round bottom flask under Ar. After 30 min stirring at
room temperature PPh3 (2.50 g, 9.5 mmol) was added in one
portion and stirring continued at room temperature for a further 16 h. The solvent was
removed under reduced pressure and the residue redissolved in CH2Cl2 (45 mL). The
organic layer was washed with 1% KOH, water and brine and dried over anhydrous
Na2SO4. The crude residue was purified by silica gel column chromatography using Pet.
spirit:EtOAc 90:10 to afford 100 (800 mg, 85%) as grey crystals. TLC Rf (Pet.
spirit:EtOAc, 50:50) = 0.76; Mp 122-123 ºC; 1H NMR (500 MHz, (CD3)2SO) δ 9.58 (s,
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1H, H11), 8.17 (d, J = 7.5 Hz, 1H, H19), 8.13 (s, 1H, H13), 8.11 (s, 1H, H10), 7.84 (d, J
= 7.5 Hz, 1H, H6), 7.81 (dd, J = 7.4 Hz, 2H, H8, H3), 7.52 (d, J = 7.5 Hz, 1H, H7), 7.45
(t, J = 7.5 Hz, 1H, H2), 7.36 (t, J = 7.5 Hz, 1H, H1), 7.05 (d, J = 7.6 Hz, 1H, H16), 6.94
(dd, J = 7.4 Hz, 2H, H17, H18), 4.18 (t, J = 6.5 Hz, 2H, H21), 3.80 (t, J = 6.5 Hz, 2H,
H23), 2.35 (q, J = 6.5 Hz, 2H, H22);

13

C NMR (125 MHz, (CD3)2SO) δ 156.1 (C15),

149.7 (C12), 139.9 (C9), 136.3 (C5), 132.8 (C6), 131.9 (C14), 131.0 (C7), 129.5 (C17),
129.0 (C4), 128.8 (C3), 126.9 (C1), 124.7 (C2), 123.0 (C18), 121.9 (C8), 120.9 (C19),
115.8 (C10), 114.01 (C16) 64.8 (C21), 34.5 (C23) 29.1 (C22); IR (neat) ν 3317, 2996,
2927, 1696, 1655, 1602, 1534, 1250, 1221 cm-1; HRESI-MS: m/z calcd for
[C20H19BrN2O2] 397.0552, found 397.0566.
1-(Naphthalen-2-yl)-3-(2-(3-(piperazin-1-yl)propoxy)phenyl)urea 92
Bromide 100 (200 mg, 0.5 mmol), N-Boc-piperazine (200
mg, 1.1 mmol), K2CO3 (800 mg, 5.75 mmol) and KI 400
mg, 2.39 mol) were successively added to a 50 mL ovendried round bottom flask under Ar. Dry THF (30 mL) was
then added, a reflux condenser attached and the mixture
stirred at 80 oC for 48 h. The reaction mixture was concentrated in vacuo and the
residue redissolved in EtOAc (200 mL). The organic layer was washed with water and
brine, dried over anhydrous Na2SO4 and concentrated. The crude residue was purified
by silica gel column chromatography using a gradient (Pet. spirit:EtOAc, 50:50 to 100%
EtOAc) to afford 92 (214 mg, 85%) as a brown powder. TLC Rf (Pet. spirit:EtOAc,
50:50) = 0.28; Mp 98-100 ºC; 1H NMR (500 MHz, (CD3)2SO) δ 8.90 (s, 1H, H11), 8.28
(d, J = 7.5, 1H, H19), 8.09 (s, 1H, H13), 7.76 (d, J = 7.5 Hz, 3H, H3, H6, H8), 7.11 (s,
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1H, H10), 7.46 (d, J = 7.6 Hz, 1H, H7), 7.43 (d, J = 7.5 Hz, 2H, H1), 7.36 (d, J = 7.5
Hz, 1H, H2), 7.08 (d, J = 7.4 Hz, 1H, H16), 6.9-6.10 (d, J = 7.6 Hz, 1H, H18), 6.94 (d, J
= 7.5 Hz, 1H, H17), 4.73 (t, J = 7.1 Hz, 2H, H21), 3.63 (t, J = 7.1 Hz, 2H, H27), 3.44
(dd, J = 7.1 Hz, 4H, H26, H29), 3.65 (t, J = 7.1, 2H, H30), 2.17 (t, J = 7.1 Hz, 2H, H23),
1.83 (q, J = 7.1 Hz, 2H, H22), 1.47 (s, 9H, H25);

13

C NMR (125 MHz, (CD3)2SO) δ

155.6 (C15), 154.7 (C40), 152.9 (C12), 135.4 (C9), 133.7 (C5), 129.9 (C7), 127.8
(C17), 126.8 (C4), 126.5 (C3), 125.3 (C1), 124.6 (C6), 124.3 (C14), 121.4 (C2), 120.5
(C18), 119.9 (C8, C19), 116.7 (C10), 112.9 (C16), 79.8 (C36), 73.1 (C21), 58.2 (C23),
56.7 (C26, C30), 46.2 (C27, C29), 28.4 (C37, C38, C39), 27.7 (C25); IR (neat) ν 3327,
2979, 2930, 2741, 1690, 1601, 1528, 1449, 1248, 1233, 1193, 1164, 1117 cm-1; HRESIMS: m/z calcd for [C29H36N4O4] 505.2815, found 505.2834.
Tert-butyl 4-(2-(2-(3-(naphthalen-2-yl)ureido)phenoxy)acetyl)piperazine-1carboxylate 94
To a solution of the phenolic urea 98 (200 mg, 0.72
mmol) in dry DMF (5 mL) in a 50 mL oven-dried
round bottom flask under Ar was added Cs2CO3 (800
mg, 2.5 mmol). The mixture was stirred at 40 oC for
30 min before N-bromoacetyl-N’-Boc-piperazine 76 (200 mg, 0.65 mmol) in dry DMF
(3 mL) was added dropwise over 5 min. The reaction was stirred at 80 oC for 16 h while
monitoring by TLC (Pet. spirit:EtOAc, 50:50). The solvent was removed in vacuo and
the residue redissolved in EtOAc. The organic phase was washed with water and brine,
dried over anhydrous Na2SO4 and concentrated. The crude residue was purified by silica
gel column chromatography using a gradient (Pet. spirit:EtOAc, 50:50 to 100% EtOAc
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followed by EtOAc:MeOH, 95:5) to yield 94 (237 mg, 66%) as an off-white powder. Rf
(pet. Spirit:EtOAc, 50:50) = 0.48; Mp 243-244 ºC; 1H NMR (500 MHz, (CD3)2SO) δ
9.57 (s, 1H, H11), 8.36 (s, 1H, H13), 8.15 (d, J = 7.5 Hz, 1H, H19), 7.78 (d, 1H, J = 7.5
Hz, H3), 7.76 (d, J = 7.5 Hz, 1H, H6), 7.72 (dd, J = 7.5 Hz, 2H, H7, H8), 7.38, 7.43 (dt,
J = 7.4 Hz, 2H, H1,H2 ), 7.32 (d, J = 7.5 Hz, 1H, H17), 6.94-6.98 (m, J = 7.5 Hz, 3H,
H10, H16, H18), 4.51 (s, 2H, H29), 3.68-3.31 (m, J = 7.11, 4H, H23, H24), 3.01 (s, 1H,
H27), 2.93 (s, 1H, H26), 1.41 (s, 9H, H22);

13

C NMR (125 MHz, (CD3)2SO) δ 166.0

(C28), 153.7 (C22, C=O), 152.5 (C12), 146.8 (C15), 138.4 (C9), 137.5 (C5), 133.8
(C4), 129.0 (C14), 128.4 (C7), 127.5 (C17), 127.3 (C3), 126.8 (C1), 126.3 (C6), 123.8
(C2), 121.7 (C18), 121.1 (C19), 119.4 (C8),114.8 (C10), 113.2 (C16), 79.1 (C22), 66.5
(C27), 54.8 (C23), 43.8 (C26), 41.1 (24), 36.2 (C29), 27.9 (C22); IR (neat) ν 3363,
2984, 2925, 1707, 164, 1629, 1601, 1540, 1507, 1430, 1241, 1232, 1193, 1158, 1128,
1119 cm-1; HRESI-MS: m/z calcd for [C28H32N4O5] 505.2833, found 505.2827.
Tert-butyl methyl(2-(methyl(3-(2-(3-(naphthalen-2-yl)ureido)phenoxy)propyl)
amino)ethyl)carbamate 93
Bromide

100

(200

mg,

0.50

mmol),

N-Boc-N,N’-

dimethylethylenediamine 75 (200 mg, 1.0 mmol), K2CO3
(850 mg, 6.11 mmol) and KI (450 mg, 2.69 mmol) were
added to a 50 mL flame-dried round bottom flask under Ar
followed by dry THF (40 mL). The reaction was stirred for
48 h at 80 oC while monitoring by TLC (Pet. spirit:EtOAc,
50:50). The solvent was evaporated and the residue redissolved in EtOAc (50 mL). The
organic layer was washed with 5% aqueous HCl, water and brine before being dried
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over anhydrous Na2SO4 and concentrated. The crude residue was purified by silica gel
column chromatography using a gradient (Pet. spirit:EtOAc, 70:30 to 100% EtoAc
followed by EtOAc:MeOH, 90:10) to yield 93 (215 mg, 85%) as a pale yellow powder.
TLC Rf (Pet. spirit:EtOAc, 50:50) = 0.28; Mp 94-97 ºC; 1H NMR (500 MHz, (CD3)2SO)
δ 9.27 (s, 1H, H11), 8.35 (s, 1H, H13), 7.85 (d, J = 7.5 Hz, 1H, H19), 7.78 (d, J = 7.5
Hz, 1H, H3), 7.71 (d, J = 7.5 Hz, 1H, H6), 7.54 (d, J= 7.5 Hz, 1H, H8), 7.45 (d, J = 7.5
Hz, 2H, H1), 7.42 (d, J = 7.5 Hz, 1H, H7), 7.40 (d, J = 7.5 Hz, 1H, H2), 7.20 (d, J = 7.5
Hz, 1H, H16), 7.16 (s, 1H, H10), 7.10 (d, J = 7.5 Hz, 1H, H18), 7.08 (d, J = 7.5 Hz, 1H,
H17), 4.04 (t, J = 7.1 Hz, 2H, H21), 3.27 (s, 4H, H29), 3.06 (t, J = 7.1 Hz, 3H, H27),
2.53 (t, J = 7.1 Hz, 2H, H26), 2.46 (t, J = 7.1 Hz, 2H, H23), 2.18 (s, 3H, H30), 1.82 (q, J
= 7.1 Hz, 2H, H22), 1.42 (s, 9H, H37, H38, H39);

13

C NMR (125 MHz, (CD3)2SO) δ

155.6 (C15), 154.7 (C40), 152.9 (C12), 135.4 (C9), 133.7 (C5), 129.9 (C7), 127.8
(C17), 126.8 (C4), 126.5 (C3), 125.3 (C1), 124.6 (C6), 124.3 (C14), 121.4 (C2), 120.5
(C18), 119.9 (C8, C19), 116.7 (C10), 112.9 (C16), 79.8 (C36), 73.1 (C21), 55.6 (C26),
55.4 (C23), 52.4 (27), 46.9 (C30), 36 (C29), 28.4 (C37, C38, C39), 27.4 (C22); IR
(neat) ν 3360, 2974, 2931, 2802, 1689, 1654, 1600, 1533, 1449, 1249, 1231, 1193,
1159, 1117 cm-1; HRESI-MS: m/z calcd for [C29H38N4O4] 507.2971, found 507.2964.
Tert-butyl methyl(2-(N-methyl-2-(2-(3-(naphthalen-2-yl)ureido)phenoxy)
acetamido)ethyl)carbamate 95
To a stirring solution of the phenolic urea 98 (200 mg,
0.72 mmol) in dry DMF (5 mL) in a 50 mL oven-dried
round bottom flask under Ar was added Cs2CO3 (1.0 g,
3.06 mmol). The mixture was stirred at 40 oC for 30
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min before adding N-bromoacetyl-N’-Boc-N,N’-dimethylethylenediamine 77 (200 mg,
0.64 mmol) in DMF (3 mL) was added dropwise over 5 min. The reaction was heated to
80 oC and stirred while monitoring by TLC (Pet. spirit:EtOAc, 50:50). The solvent was
removed and the residue redissolved in EtOAc. The organic layer was washed with
water and brine and the aqueous layer back-extracted with EtOAc (50 mL). The pooled
organic fractions were dried over anhydrous MgSO4 and concentrated. The crude
residue was purified by silica gel column chromatography using a gradient (Pet.
spirit:EtOAc, 70:30 to 100% EtoAc followed by EtOAc:MeOH, 95:5) to afford 95 (290
mg, 80%) as an off-white powder. TLC Rf (Pet. spirit:EtOAc, 50:50) = 0.22; Mp 110113 ºC; 1H NMR (500 MHz, (CD3)2SO) δ 8.70 (s, 1H, H11), 8.50 (s, 1H, H13), 8.43 (d,
J = 7.5 Hz, 1H, H19), 8.22 (s, 1H, H10), 7.81-7.72 (m, J = 7.5 Hz, 3H, H3, H6, H2),
7.42 (dd, J = 7.4 Hz, 2H, H7, H8), 7.33 (t, J = 7.4 Hz, 1H, H1), 7.04 (t, J = 7.5 Hz, 1H,
H17), 6.95 (t, J = 7.5 Hz, 1H, H18), 6.81 (d, J = 7.5 Hz, 1H, H16), 4.52 (s, 2H, H29),
3.70-3.30 (m, J = 7.11, 4H, H23, H24), 3.1 (s, 1H, H27), 2.95 (s, 1H, H26), 1.41 (s, 9H,
H22); 13C NMR (125 MHz, (CD3)2SO) δ 168.2 (C28), 160.1 (C22), 157.3 (C12), 153.2
(C15), 146.2 (C9), 137.4 (C5), 134.5 (C7), 132.2 (C4), 130.0 (C14), 128.6 (C17), 127.6
(C3), 126.4 (C1), 124.2 (C6), 122.9 (C2), 121.9 (C18), 119.7 (C19), 119.2 (C8), 114.4
(C10), 111.8 (C16), 79.6 (C36), 73.2 (C21), 55.9 (C26), 55.4 (C23), 52.3 (27), 46.8
(C30), 36.0 (C29), 28.5 (C37, C38, C39), 27.5 (C22); IR (neat) ν 3363, 2977, 2930,
1704, 1648, 1629, 1601, 1533, 1506, 1454, 1249, 1229, 1193, 1155, 1155, 1115 cm-1;
HRESI-MS: m/z calcd for [C28H34N4O5] 507.2607, found 507.2598.
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6.1.8 Synthesis of Reserpine-Containing Hybrids
General Procedure for the Synthesis of Hybrids 47-62. The general procedure is
exemplified using the synthesis of 3-(4-(2-(4-((((1S,2R,3R,4aS,13bR,14aS)-2,11dimethoxy-1-(methoxycarbonyl)-1,2,3, 4 ,4a,5,7,8,13,13b,14,14a-dodecahydroindolo
[2',3':3,4]

pyrido[1,2-b]isoquinolin-3-yl)oxy)carbonyl)-2,6-dimethoxyphenoxy)ethyl)

piperazin-1-yl)-7-(dimethylamino) phenothiazin-5-ium chloride 47

The Boc-protected intermediate 66 (80 mg, 0.07 mmol) was dissolved in CH2Cl2 (25
mL) in a 50 mL round bottom flask under Ar and cooled to 0 oC. TFA (5 mL) was
added in one portion and the reaction allowed to warm to room temperature with
stirring while monitoring by TLC (Pet. spirit:EtOAc, 40:60). Upon consumption of the
starting material the reaction was quenched with water and extracted with CH2Cl2 (3 x
30 mL). The pooled organic fractions were dried over anhydrous MgSO4 and
concentrated under reduced pressure. The crude amine TFA salt was redissolved in dry
CH2Cl2 (15 mL) in a 25 mL oven-dried round bottom flask under Ar and 3dimethylaminophenothiazin-5-ium triiodide 63 (120 mg, 0.19 mmol, 0.9 eq) was added
in one portion. The reaction was stirred at room temperature for 72 h while monitoring

171

by TLC (3% NH4OAc(aq):MeOH, 15:85). K2CO3 was added in cases where the reaction
showed little or no progress after overnight stirring. The completed reaction was
concentrated and the residue purified by preparative TLC using 3% NH4OAc(aq)/MeOH
15:85. The dark blue product obtained was dissolved in dry MeOH (25 mL) and stirred
at room temperature with quaternary ammonium chloride-anion exchange resin (350
mg, 10% w/w). After 1 h the mixture was filtered through a plug of cotton and the
filtrate concentrated to give 47 (15.3 mg, 18%) as a dark blue powder. The lightsensitive compound was stored in a vial under Ar wrapped in aluminium foil at -20 oC.
TLC Rf (3% NH4OAc (aq):MeOH 15:85) = 0.03; Mp > 250 ºC; UV (MeOH): 292 (log ε
5.06, λmax), 3.29 (log ε 4.59), 386 (log ε 4,45), 510 (log ε 4.00, λmin), 610 (log ε 4.80),
651 (log ε 5.04, λmax) nm; IR (neat) ν 3419, 2926, 2843, 1708, 1591, 1459, 1387, 1330,
1222, 1126 cm-1; L HRESI-MS: m/z calcd for [C52H61N6O9S] 946.4299, found
946.4276.
3-(4-(2-(4-((((1S,2R,3R,4aS,13bR,14aS)-2,11-dimethoxy-1-(methoxycarbonyl)1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydroindolo[2',3':3,4]pyrido[1,2-b]iso
quinolin-3-yl)oxy)carbonyl)-2,6-dimethoxyphenoxy)acetyl)piperazin-1-yl)-7(dimethylamino)phenothiazin-5-ium chloride 49

The general procedure was used with Boc-protected intermediate 68 (80 mg, 0.01
mmol). Stirring at room temperature for 96 h yielded 49 (13.6 mg, 14%) as a dark blue
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powder after preparative TLC and anion exchange. TLC Rf (3% NH4OAc(aq):MeOH
15:85) = 0.02; Mp > 250 ºC; UV (MeOH): 292 (log ε 4.88, λmax), 3.27 (log ε 4.46), 392
(log ε 4,45), 512 (log ε 3.79, λmin), 609 (log ε 4.67), 653 (log ε 4.97, λmax) nm; IR (neat):
3744, 2933, 2845, 1714, 1700, 1592, 1458, 1384, 1329, 1209, 1179, 1152 cm-1; HRESIMS: m/z calcd for [C52H59N6O10S] 960.4092, found 960.4063.
3-((2-((2-(4-((((1S,2R,3R,4aS,13bR,14aS)-2,11-dimethoxy-1-(methoxycarbonyl)-1,2,
3,4,4a,5,7,8,13,13b,14,14a-dodecahydroindolo[2',3':3,4]pyrido[1,2-b]isoquin olin-3yl )oxy)carbonyl)-2,6-dimethoxyphenoxy)ethyl)(methyl)amino)ethyl)(methyl) amin
o)-7-(dimethylamino)phenothiazin-5-ium chloride 48

The general procedure was used with Boc-protected intermediate 67 (100 mg, 0.12
mmol). Stirring for 72 h at room temperature in the presence of K2CO3 (0.4 eq) afforded
48 (22 mg, 18%) as a dark blue powder after preparative TLC and anion exchange. TLC
Rf (3% NH4OAc(aq):MeOH 15:85) = 0.03; Mp = 212-214 ºC; UV (MeOH): 292 (log ε
4.86, λmax), 327 (log ε 4.31), 392 (log ε 4.17), 512 (log ε 3.75, λmin), 609 (log ε 4.70),
656 (log ε 5.02, λmax) nm; IR (neat) ν 3416, 2931, 2870, 1709, 1594, 1454, 1383, 1327,
1229, 1216 1123 cm-1; HRESI-MS: m/z calcd for [C52H63N6O9S] 948.4456, found
948.4423.
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3-((2-(2-(4-((((1S,2R,3R,4aS,13bR,14aS)-2,11-dimethoxy-1-(methoxycarbonyl)-1,2,
3,4,4a,5,7,8,13,13b,14,14a-dodecahydroindolo[2',3':3,4]pyrido[1,2-b]isoquinolin-3yl)oxy)carbonyl)-2,6-dimethoxyphenoxy)-N-methylacetamido)ethyl)(methyl)amino
)-7-(dimethylamino)phenothiazin-5-ium chloride 50

The general procedure was used with Boc-protected intermediate 69 (90 mg, 0.11
mmol). Stirring for 96 h at room temperature in the presence of K2CO3 (0.4 eq) afforded
50 (12 mg, 11%) as a dark blue powder after preparative TLC and anion exchange. TLC
Rf (3% NH4OAc(aq):MeOH 15:85) = 0.02; Mp > 250 ºC; UV (MeOH): 292 (log ε 4.85,
λmax), 329 (log ε 4.29), 392 (log ε 4.23), 512 (log ε 3.77, λmin), 609 (log ε 4.70), 656 (log
ε 5.00, λmax) nm; IR (neat) ν 3363, 2926, 2848, 1716, 1710, 1594, 1462, 1387, 1330,
1217, 1183, 1124 cm-1; HRESI-MS: m/z calcd for [C52H61N6O10S] 961.4170, found
961.4199.
6.1.9 Synthesis of Pterostilbene-Containing Hybrids
(E)-3-((2-((2-(4-(3,5-dimethoxystyryl)phenoxy)ethyl)(methyl) amino)ethyl)(methyl)
amino)-7-(dimethylamino)phenothiazin-5-ium chloride 51

174

The general procedure was
used

with

Boc-protected

intermediate 78 (100 mg, 0.21
mmol).

Stirring

at

room

temperature for 72 h in the presence of K2CO3 (0.3 eq) afforded 51 (35 mg, 26%) as a
dark blue powder after preparative TLC and anion exchange. TLC Rf (3%
NH4OAc(aq):MeOH 15:85) = 0.03; Mp = 162-163 ºC; 1H NMR (500 MHz, CD2Cl2) δ
7.98 (dd, J = 8.0, 1.6 Hz, 1H, H36), 7.44 (d, J = 10.0 Hz, 2H, H6, H2), 7.42 (dd, J = 8.0,
1.6 Hz, 1H, H33), 7.37 (d, J = 10.0 Hz, 1H, H26), 7.35 (dd, J = 10.0, 2.4 Hz, 1H, H27),
7.08 (d, J = 2.4 Hz, 1H, H29), 6.86 (m, 5H, H35, H9, H3, H5, H8), 6.67 (s, 2H, H12,
H14), 6.38 (s, 1H, H16), 4.31 (t, J = 12.0 Hz, 2H, H18), 3.75 (s, 6H, H10, H11), 3.64
and 3.60 (2s, 6H, N(CH3)2), 2.95 (t, J = 14.0 Hz, 2H, H19), 2.93 (dd, J = 7.5 Hz, 4H,
H22, H24), 2.08 (dd, J = 7.5 Hz, 4H, H21, H25); 13C NMR (125 MHz, (CD3)2SO) δ 13C
NMR (125 MHz, CD2Cl2) δ 161.4, 158.8, 139.9, 139.1, 130.5, 128.8, 128.1, 126.9,
122.2, 119.8, 115.10, 106.7, 106.4, 104.5, 99.9, 66.3, 60.9, 57.0, 55.6, 54.2, 54.0, 48.4,
30.0, 28.9; UV (MeOH): 294 (log ε 4.86, λmax), 323 (log ε 4.70), 415 (log ε 4.10, λmin),
612 (log ε 4.60), 655 (log ε 4.84, λmax) nm; IR (neat) ν 2921, 1589, 1386, 1146, 1129,
1110 cm-1; HRESI-MS: m/z calcd for [C36H39N4O3S] 607.2743, found 607.2764.
(E)-3-(4-(2-(4-(3,5-dimethoxystyryl)phenoxy)acetyl)piperazin-1-yl)-7-(dimethyl
amino)phenothiazin-5-ium chloride 53
The general procedure was used
with Boc-protected intermediate
80 (60 mg, 0.12 mmol). Stirring
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at room temperature for 72 h in the presence of K2CO3 (0.2 eq) yielded 53 (25 mg,
30%) as a dark blue powder after preparative TLC and anion exchange. TLC Rf (3%
NH4OAc(aq):MeOH 15:85) = 0.04; Mp = 85-87 ºC; UV (MeOH): 292 (log ε 5.10, λmax),
320 (log ε 4.91), 412 (log ε 3.37, λmin), 615 (log ε 4.64), 654 (log ε 4.87, λmax) nm; IR
(neat) ν 3261, 2921, 1589, 1386, 1146, 1129, 1110 cm-1; HRESI-MS: m/z calcd for
[C36H37N4O4S] 621.2536, found 607.2546.
(E)-3-((2-((2-(4-(3,5-dimethoxystyryl)phenoxy)ethyl)(methyl) amino)ethyl)(methyl)
amino)-7-(dimethylamino)phenothiazin-5-ium chloride 52
The general procedure was
used

with

Boc-protected

intermediate 79 (70 mg, 0.15
mmol). Stirring for 72 h at
room temperature in the presence of K2CO3 (0.4 eq) provided 52 (27 mg, 28%) as a
dark blue powder after preparative TLC and anion exchange. TLC Rf (3%
NH4OAc(aq):MeOH 15:85) = 0.02; Mp = 178-180 ºC; UV (MeOH): 293 (log ε 5.10,
λmax), 324 (log ε 4.95), 413 (log ε 3.26, λmin), 611 (log ε 4.63), 661 (log ε 4.92, λmax)
nm; IR (neat) ν 2919, 2848, 1589, 1455, 1386, 1174, 1145, 1137 cm-1; HRESI-MS: m/z
calcd for [C36H41N4O3S] 609.2899, found 609.2901.
(E)-3-((2-(2-(4-(3,5-dimethoxystyryl)phenoxy)-N-methylacetamido)ethyl)(methyl)
amino)-7-(dimethylamino)phenothiazin-5-ium chloride 54
The general procedure was
used

with

Boc-protected

176

intermediate 81 (80 mg, 0.16 mmol). Stirring for 48 h at room temperature in the
presence of K2CO3 (0.2 eq) afforded 54 (28 mg, 26%) as a dark blue powder after
preparative TLC and anion exchange. TLC Rf (3% NH4OAc(aq):MeOH 15:85) = 0.02;
Mp = 194-196 ºC; UV (MeOH): 293 (log ε 5.17, λmax), 324 (log ε 4.99), 415 (log ε
3.29, λmin), 613 (log ε 4.67), 661 (log ε 4.95, λmax) nm; IR (neat) ν 2938, 2842, 1664,
1589, 1456, 1203, 1149, 1065, 1055 cm-1; HRESI-MS: m/z calcd for [C36H41N4O3S]
623.2692, found 623.2703.
6.1.10 Synthesis of INF55-Containing Hybrids
3-(Dimethylamino)-7-(4-(4-(5-nitro-1H-indol-2-yl)benzyl)piperazin-1-yl)pheno
thiazine-5-ium chloride 55
The general procedure was used with
Boc-protected intermediate 84 (90
mg, 0.20 mmol). Stirring at room
temperature for 48 h gave 55 (29 mg, 23%) as a dark blue powder after preparative TLC
and anion exchange. TLC Rf (3% NH4OAc(aq):MeOH 15:85) = 0.04; Mp > 250 ºC; UV
(MeOH): 295 (log ε 4.99, λmax), 415 (log ε 3.43, λmin), 610 (log ε 4.62), 656 (log ε 4.91,
λmax) nm; IR (neat) ν 3205, 2924, 1683, 1591, 1517, 1472, 1387, 1329, 1220, 1134,
1045; HRESI-MS: m/z calcd for [C33H31N6O2S] 575.2229, found 575.2236.
3-(Dimethylamino)-7-(methyl(2-(methyl(4-(5-nitro-1H-indol-2-yl)benzyl)amino)
ethyl)amino)phenothiazin-5-ium chloride 57
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The general procedure was used
with Boc-protected intermediate 86
(100 mg, 0.23 mmol). Stirring at
room temperature for 76 h in the
presence of K2CO3 (0.3 eq) provided 57 (25 mg, 18%) as a dark blue powder after
preparative TLC and anion exchange. TLC Rf (3% NH4OAc(aq):MeOH 15:85) = 0.03;
Mp > 250 ºC; UV (MeOH): 297 (log ε 5.06, λmax), 419 (log ε 3.49, λmin), 609 (log ε
4.68), 651 (log ε 4.91, λmax) nm; IR (neat) ν 3305, 2975, 2922, 1695, 1558, 1553, 1549,
1540, 1472, 1409, 1400, 1331, 1220, 1134 cm-1; HRESI-MS: m/z calcd for
[C33H33N6O2S] 577.2386, found 577.2400.
3-(Dimethylamino)-7-(4-(4-(5-nitro-1H-indol-2-yl)benzoyl)piperazin-1-yl)phenol
thiazine-5-ium chloride 56
The general procedure was used
with Boc-protected intermediate 85
(80 mg, 0.18 mmol). Stirring at
room temperature for 48 h yielded
56 (25 mg, 22%) as dark blue powder after preparative TLC and anion exchange. TLC
Rf (3% NH4OAc(aq):MeOH 15:85) = 0.02; Mp > 250 ºC; UV (MeOH): 295 (log ε 5.03,
λmax), 415 (log ε 3.65, λmin), 609 (log ε 4.66), 650 (log ε 4.86, λmax) nm; IR (neat) ν
3245, 2922, 2850, 1663, 1591, 1519, 1458, 1386, 1329, 1230, 1219, 1135 cm-1; HRESIMS: m/z calcd for [C33H29N6O3S] 589.2022, found 589.2048.
3-(Dimethylamino)-7-(methyl(2-(N-methyl-4-(5-nitro-1H-indol-2-yl)benzamido)
ethyl)amino)phenothiazin-5-ium chloride 58
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The general procedure was used
with Boc-protected intermediate 87
(120 mg, 0.26 mmol). Stirring at
room temperature for 76 h in the
presence of K2CO3 (0.4 eq) afforded 58 (30 mg, 18%) as a dark blue powder after
preparative TLC and anion exchange. TLC Rf (3% NH4OAc(aq):MeOH 15:85) = 0.02;
Mp > 250 ºC; UV (MeOH): 294 (log ε 5.02, λmax), 413 (log ε 3.39, λmin), 610 (log ε
4.46), 659 (log ε 4.82, λmax) nm; IR (neat) ν 3240, 2921, 2853, 1665, 1591, 1516, 1456,
1387, 1328, 1226, 1218, 1130 cm-1; HRESI-MS: m/z calcd for [C33H31N6O3S]
591.2175, found 591.2183.
6.1.11 Synthesis of INF271-Containing Hybrids
3-(Dimethylamino)-7-(4-(3-(2-(3-(naphthalen-2-yl)ureido)phenoxy)propyl)
piperazin-1-yl)phenothiazin-5-ium chloride 59
The general procedure was used with
Boc-protected intermediate 92 (100 mg,
0.19 mmol). Stirring at room temperature
for 48 h afforded 59 (34 mg, 25%) as a
dark blue powder after preparative TLC
and anion exchange. TLC Rf (3% NH4OAc(aq):MeOH, 15:85) = 0.04; Mp > 250 ºC; UV
(MeOH): 287 (log ε 4.86), 295 (log ε 4.88, λmax), 323 (log ε 4.14), 368 (log ε 3.37, λmin),
608 (log ε 4.61), 655 (log ε 4.88, λmax) nm; IR (neat) ν 3355, 2972, 2921, 2740, 1704,
1595, 1458, 1353, 1136, 1127, 1118 cm-1; HRESI-MS: m/z calcd for [C38H39N6O2S]
643.2855, found 643.2870.
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3-(Dimethylamino)-7-(4-(2-(2-(3-(naphthalen-2-yl)ureido)phenoxy)acetyl)
piperazin-1-yl)phenothiazin-5-ium chloride 61
The general procedure was used with
Boc-protected intermediate 94 (90 mg,
0.18 mmol). Stirring at room temperature
for 72 h with K2CO3 (0.3 eq) yielded 61
(21 mg, 17%) as a dark blue powder after preparative TLC and anion exchange. TLC Rf
(3% NH4OAc(aq):MeOH 15:85) = 0.03; Mp 228-231 ºC; UV (MeOH): 289 (log ε 4.93),
293 (log ε 4.94, λmax), 324 (log ε 4.10), 410 (log ε 2.04, λmin), 608 (log ε 4.67), 652 (log
ε 4.96, λmax) nm; IR (neat) ν 3324, 2989, 2923, 2738, 1700, 1653, 1593, 1458, 1386,
1215, 1196, 1136, 1127 cm-1; HRESI-MS: m/z calcd for [C37H35N6O3S] 643.2491,
found 643.2508.
3-(Dimethylamino)-7-(methyl(2-(methyl(3-(2-(3-(naphthalen-2yl)ureido)phenoxy)propyl)amino)ethyl)amino)phenothiazin-5-ium chloride 60
The general procedure was used with Bocprotected intermediate 93 (100 mg, 0.19
mmol). Stirring at room temperature for
48 h provided 60 (34 mg, 25%) as a dark
blue powder after preparative TLC and
anion exchange. TLC Rf (3% NH4OAc(aq):MeOH 15:85) = 0.03; Mp = 239-241 ºC; UV
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(MeOH): 290 (log ε 4.86), 327 (log ε 4.06), 415 (log ε 3.03, λmin), 610 (log ε 4.60), 659
(log ε 4.97, λmax) nm; IR (neat) ν 3299, 2968, 2925, 2710, 1700, 1593, 1450, 1386,
1327, 1231, 1195, 1136, 1126, 1117 cm-1; HRESI-MS: m/z calcd for [C38H41N6O2S]
645.3012, found 645.2993.
3-(Dimethylamino)-7-(methyl(2-(N-methyl-2-(2-(3-(naphthalen-2-yl)ureido)
phenoxy)acetamido)ethyl)amino)phenothiazin-5-ium chloride 62
The general procedure was used with
Boc-protected intermediate 95 (80.0
mg, 0.16 mmol). Stirring at room
temperature for 72 h with K2CO3 (0.3
eq) afforded hybrid 62 (15 mg, 15%)
as a dark blue powder after preparative TLC and anion exchange. TLC Rf (3%
NH4OAc(aq):MeOH 15:85) = 0.02; Mp = 246-248 ºC; UV (MeOH): 293 (log ε 4.93,
λmax), 325 (log ε 4.16), 413 (log ε 3.09, λmin), 610 (log ε 4.73), 656 (log ε 5.05, λmax) nm;
IR (neat) ν 3311, 2968, 2923, 2851, 2736, 1706, 1654, 1593, 1457, 1387, 1327, 1231,
1192, 1136, 1126, 1119 cm-1; HRESI-MS: m/z calcd for [C37H37N6O3S] 645.2648,
found 645.2663.
6.2 Experimental Procedures - Photochemical and In Vitro Studies
6.2.1 Microbial Strains and Culture Conditions
The following bacterial strains were used: S. aureus 8325-4 (wild-type), K1902
(8325-4, NorA-), K2378 (NorA++), S. aureus Community Associated (CA)-MRSA
USA300 (Human isolate/Clinical Microbiology, MGH). The NorA-overexpressing
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strain K2378 was obtained from Prof Kim Lewis at Northeastern University, Boston.
All other strains were obtained from Dr George Tegos at The University of New
Mexico.
Bacterial cells were cultured in Mueller-Hinton Broth (MHB) or brain heart
infusion (BHI) medium at 37 °C with shaking at 100 rpm. Cell growth was assessed
using an Evolution 300 UV/Vis Spectrophotometer (Thermo Scientific, Waltham, MA).
Cultures were grown to an optical density (OD600) of 0.6, corresponding to a bacterial
cell density of 108 CFU/mL, and then washed and resuspended in phosphate-buffered
saline (PBS) (Dulbecco) at 2 × 109 CFU/mL. Cell growth was assessed using a
spectrophotometer (Shimadzu, Mini 1240) measuring absorbance at 600 nm (OD600).
6.2.2 Chemicals

Purified H2O was produced in-house (Milli-Q Water Purification System,
Millipore). D2O (99.8%) was obtained from Cambridge Isotope Laboratories
(Apeldoorn, The Netherlands). Ciprofloxacin was obtained from the Massachusetts
General Hospital Pharmacy and MB was obtained from Sigma-Aldrich (St. Louis, MO).

6.2.3 Photosensitizers and Light Source
Stock solutions of MB and the synthesized hybrids were prepared in phosphatebuffered saline (PBS) (2 mM) after encapsulation in Cremophore EL (CrEL) (See
Chapter 6.2.5). For all photodynamic experiments, the stock solutions were stored for a
maximum of 2 weeks at 4°C in the dark. For UV/Vis experiments, stock solutions of PS
(10 µM) in methanol were prepared immediately prior to use.
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A noncoherent light source with interchangeable fiber bundles (LC122;
LumaCare, London, United Kingdom) was employed in all photodynamic experiments.
Thirty nanometre band-pass filters at ranges of 652 ± 15 nm were used for both MB and
hybrids. The total power output provided from the fibre bundle was 300 mW and plates
were positioned to give an irradiance of 100 mW/cm2.
6.2.4 ROS Generation Assay
Cell-free ROS assays were performed in 96-well plates. SOSG and HPF probes
(Molecular Probes InvitrogenTM) were prepared as 5 µM stocks in MeOH before use.
Solutions of hybrids and MB in PBS were added to each well to give 50 µM solutions
in a volume of 85 µL. Probe solutions (40 µL) and deuterium oxide (40 µL) were then
added followed by MeOH (35 µL) to produce a final volume of 200 µL, with
compounds present at 10 µM. Plates were illuminated with light delivered in increasing
doses (1-10 J/cm2 for SOG and 1-12 J/cm2 for HPF). A microplate spectrophotometer
(Spectra Max M5, Molecular Devices) was used to monitor the fluorescence signals in
the “slow kinetic” mode. For HPF, fluorescence emission at 525 nm was measured upon
excitation at 492 nm using a 2 nm monochromator band pass for both excitation and
emission. With SOSG, the corresponding values were 505 nm and 525 nm, respectively.
Data are expressed as mean ± SEM from three independent experiments, each
performed in quadruplicate to sextuplicate.
6.2.5 Preparation of Micellar Solutions of Compounds
Triblock copolymers F127 (PL-F127) and poloxamer 388 (POL388) were
purchased from BASF chemical company. Cremophor EL (CrEL) and Tween 60 (T60)
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were obtained from Sigma-Aldrich. Micellar suspensions were prepared by mixing
solutions containing 2-3 mM hybrids or MB in CH2Cl2 with 500 mL of detergent
solution (100 mg/mL) in dry CH2Cl2. An additional 2 mL of CH2Cl2 was added and the
mixtures stirred and sonicated until a homogenous solution was obtained. The final
detergent /compounds ratios were ~ 250:1. The solvent was then removed in vacuo and
the resulting dry film redissolved in 1 mL of sterile PBS with agitation. The micellar
suspensions were filtered through a 0.22 µm mixed-cellulose-ester (MCE) filter under
sterile conditions.
6.2.6 Photodynamic Studies
Bacterial suspensions in PBS (108 cells/mL) were incubated with CrELformulated hybrids in PBS (1-20 µM) in the dark at room temperature for 30 min. The
suspensions were centrifuged at 12,000 rpm and then washed twice with sterile PBS
before being placed into wells of a 96-well microtiter plate (Fisher Scientific) and
illuminated with light at room temperature. Fluences ranged from 0-20 J/cm2 at 100
mW/cm2. Contents of the wells were mixed before sampling, with aliquots being
serially diluted 10-fold in PBS to give 10-1-10-6-fold dilutions. The diluted samples were
streaked horizontally onto square BHI agar plates, as described by Jett et al.235 Plates
were incubated at 37 °C overnight and CFUs counted. The limit of detection in these
experiments was 8 log units of killing.
6.2.7 Cell Uptake Studies
Bacterial suspensions (108 cells/mL) were incubated in PBS in the dark at room
temperature for 30 min with hybrids at the same final concentrations (20 µM) used for
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the photodynamic experiments. Incubations were carried out in triplicate. The cell
suspensions were centrifuged (9000 rpm) and the supernatants aspirated. The cells were
then washed twice with sterile PBS (1 mL) and centrifuged. Cell pellets were digested
in 3 mL of sodium dodecyl sulfate (SDS) solution (10% in PBS) for at least 24 h or
until homogenous solutions were obtained. Fluorescence of the extracts was measured
using a spectrofluorometer (FluoroMax3; SPEX Industries, Edison, N.J.). The
excitation wavelength for both MB and hybrids was 650 nm and the emission range was
655 to 720 nm. Calibration curves were prepared from samples of the pure hybrids and
MB (dissolved at equivalent concentrations in SDS) and used for determination of
hybrid concentrations in the cell extracts. Uptake values were obtained by dividing the
number of nanomoles of PS in the extract by the number of CFUs obtained by serial
dilution, with the number of PS molecules/cell then being calculated using Avogadro’s
number.
6.2.8 MIC Determinations with Ciprofloxacin
The pump inhibitory activities of hybrids and MB were determined by MIC
measurements in sterile 96-well, black-sided plates using bioluminescence rather than
traditional turbidity measurements. A bioluminescent S. aureus suspension (MRSA
USA300, 100 µL containing 106 CFU/mL) was incubated at 37 °C for 15 h with
vigorous shaking in the dark with 100 µL ciprofloxacin alone (dilution series from
0.001 to 1.024 µg/mL) and ciprofloxacin in the presence of 100 µL MB (20 µM) and
100 µL (10 µM) of hybrids 56, 58 and 60. The luminescence was monitored using a
luminescence plate reader (MicroBeta Trilux 1450; PerkinElmer Life and Analytical
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Sciences Inc., Wellesley, MA). MIC values were plotted from 3-4 independent
experiments.
6.3 Murine MRSA Wound Infection Experiments
6.3.1 Photosensitizers, Light Source and Bacterial Species
Methylene blue (MB) was purchased from Sigma (UK). Stock solutions of MB
and hybrid 58 were freshly prepared as Cremophor EL Micelles in sterile PBS (see
Chapter 6.2.5 for details) to a final concentration of 200 μM. A noncoherent light source
(LC122; LumaCare, London, UK) with interchangeable fibre bundles and 30 nm bandpass filters (652 ± 15 nm) was used for all experiments. Power output from the fibre
bundle was 300 mW. The spot was positioned at a constant distance from the wound to
give an irradiance of 100 mW over the 1 cm2 wound area.
Bioluminescent MRSA (Xen 30)230 was obtained from the Dai Lab (Wellman
Center for Photomedicine). Cultures were prepared by growing overnight in brain heart
infusion (BHI) at 37 °C with 100 rpm orbital shaking. Bacterial growth was assessed
with an Evolution 300 UV/Vis Spectrophotometer (Thermo Scientific, Waltham, MA).
Optical density (OD) at 600 nm of 0.8 corresponded to a bacterial cell density of 108
CFU/mL. Cells were washed and re-suspended in PBS and used at a density of 108
CFU/mL.
6.3.2 Animal Preparation and Infection
Six to eight week old adult female BALB/c mice (Charles River Laboratories,
Wilmington, MA) weighing 17-21 g were used in the study. Animals were housed one
per cage and maintained on a 12-hour light/dark cycle with ad libitum access to food
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and water. All procedures were approved by the Subcommittee on Research Animal
Care (IACUC) (Massachusetts General Hospital) and met guidelines of the US National
Institutes of Health (NIH). Mice were administered cyclophosphamide at 4 days and 1
day prior to MRSA inoculation. The first dose was 150 mg/kg and the second dose 100
mg/kg (both injected i.p.). Cyclophosphamide reduces peripheral blood neutrophils to
<100/μL blood, making mice more vulnerable to infection.224
Mice were anesthetized with i.p. injections of a ketamine/xylazine cocktail and
their dorsal surfaces shaved. Skin abrasion wounds were introduced on the dorsal
surfaces using a 28-gauge needle (Micro-Fine IV, Becton Dickinson, Franklin Lakes,
NJ), creating 6 x 6 crossed scratch lines covering on area of 1 cm2. The scratches were
applied such that they damaged only the stratum corneum and upper-layer of the
epidermis (i.e. not the dermis). Five minutes after wounding, a 40 μL aliquot was taken
from a suspension containing 108 CFU/mL bioluminescent MRSA (Xen 30) in PBS and
inoculated over the scratched areas using a micropipette.
6.3.3 Bioluminescence Imaging
A Hamamatsu Photonics KK (Bridgewater, NJ) bioluminescence imaging
system was used in the study.126b The setup consisted of an intensified charge-coupleddevice (ICCD), camera (C2400-30H; Hamamatsu), camera controller, imaging box,
image processor (C5510-50; Hamamatsu) and a color monitor (PVM 1454Q;
Hamamatsu). Light-emitting diodes were mounted inside the imaging box to supply
light for dimensional imaging of the sample. This setup allowed a grayscale background
image of each mouse to be captured. Using the photo-counting mode, clear images were
obtained at very low-light levels through detection and integration of individual
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photons. Luminescence emanating from bacteria was captured using an integration time
of 2 min with a maximum setting on the image-intensifier control module.
ARGUS software (Hamamatsu) was used to present luminescence images as
false-colour images superimposed on the grayscale background image. The software
calculated total pixel values (relative luminescence units RLU) from the luminescence
images of the infected wound areas. Wounds were observed daily and photographs
captured using a Nikon Coolpix L20 camera until wounds had healed. Wound area
analysis was performed using ImageJ software.

Prior to imaging, mice were anesthetized by i.p. injections of a
ketamine/xylazine cocktail. The mice were placed on an adjustable stage in the
specimen chamber and their infected areas positioned directly under the camera. A
grayscale background image of each wound was taken followed by a photon count of
the same region. This total wound photon count was obtained as relative luminescence
units (RLUs) and displayed in a false-color scale ranging from pink (most intense) to
blue (least intense).

6.3.4 Application of aPDT
Photosensitizers MB and 58 (40 µL of 200 µM stock solutions) were added to
infection sites of animals in Groups B-E 30 minutes after bacterial inoculation. Fifteen
minutes after addition of PS (time to allow compounds to bind/penetrate bacteria) the
mice were again imaged to quantify any dark toxicity of the PS. Mice were illuminated
with light from a non-coherent light source as described above, receiving total light
doses of 120 J/cm2 delivered in aliquots in periods of 2, 4, 8, 4 and 2 min for a total of
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20 min. Bioluminescence imaging were captured after each light dose (12, 36, 84, 108
and 120 J/cm2). Dark controls (animals receiving PS without light treatment) were
assessed at the times corresponding to light delivery in the aPDT treatment groups.
Control Group A received light and no PS, with images capture at the same time
intervals as other groups.
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Appendix 2.1 LRESI-MS of some selected hybrids.
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Appendix 3.1 SOG and HPF quantum yields for MB and hybrids 47-62.
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Appendix 3.2 Dark toxicity of MB and hybrids 47-62 against S. aureus MRSA
USA300. Cells (108 per mL) were incubated for 30 min with CrEL-formulated hybrids
at 0-20 µM in PBS and subsequently illuminated with 652 nm light (fluence 6 J/cm2).
CFUs were determined after overnight growth at 37 oC and survival fractions
calculated. Data represent the mean of 3-5 independent experiments ± SEM.
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Appendix 3.3 Dark toxicity over the concentration range 0-16 µM of (A) MB, (B) 56,
(C) 58 and (D) 60 against NorA knockout (NorA-), wild-type (WT), and NorAoverexpressing (NorA++) S. aureus strains. Data represent the mean ± SEM from 3-4
independent experiments.
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Appendix 4.1 Light-dose responses (mean ± SEM) for dark controls in (A) Groups B
and (B) Group D in the bioluminescence MRSA wound infection model. Data are
presented as normalized relative luminescence units (RLU). Data from Figure 4.3 for
the equivalent aPDT Groups C (MB) and D (58) are included for comparison.
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Appendix 4.2 Daily bioluminescence images obtained from representative animals in
Groups A-E during 10 days of post-treatment monitoring.
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